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Abstract 
Antipsychotic drugs (APDs) are being used increasingly to treat a variety of conditions in 
adolescence. Accordingly there has been a dramatic increase in the prescription of APDs to 
adolescents over the past twenty years. Adolescence is an important postnatal developmental period 
in which major maturation changes occur in both brain structures and multiple neurotransmitter 
systems. Therefore, adolescence may represent a period of sensitivity to environmental 
perturbations including exposure to such pharmacological agents. The specific neurobiological 
consequences of APDs on the adolescent brain are however still poorly understood. The aim of the 
work presented in this thesis is to investigate how APD administration in adolescence can affect the 
immature adolescent brain, using a rodent model of adolescence.    
In this thesis, I examined chronic risperidone treatment (1.3 mg/kg/day for 21-22 days) in 
adolescent rats (postnatal day (PND) 36-PND56/57) with respect to short- and long-term 
neurobiological changes. Short-term alterations were measured either during or proximal to chronic 
treatment. Long-term effects were measured after a lengthy drug-free interval of 36 – 60 days. 
Risperidone-induced neurobiological effects in adolescents were compared with those in adult rats 
(PND80-PND100/101) treated with the same risperidone regimen. Risperidone was chosen for 
detailed examination given this is the atypical APD that is most commonly prescribed to 
adolescents in the clinic. Behavioural effects were assessed using two well-validated tests for APD 
action, namely suppression of the conditioned avoidance response (CAR) and the horizontal bar test 
for catalepsy. Risperidone-induced changes in brain structures and metabolism of the nucleus 
accumbens (NAc) were examined with clinical comparable methods namely magnetic resonance 
imaging (MRI) and proton magnetic resonance spectroscopy (1H MRS), respectively. 
Neurochemical alterations and gene expression in the NAc and the striatum were assessed with high 
performance liquid chromatography (HPLC) and real-time polymerase chain reaction respectively.  
My data reveal that, during chronic risperidone treatment, adolescent rats were less sensitive to 
risperidone-induced increases in catalepsy (when tested in horizontal bar test) and escape failures 
(when tested in CAR paradigm), both of which are striatum-dependent behaviours. By contrast, 
adult rats were observed to develop a progressive increase in these behaviours during chronic 
risperidone treatment. Accompanying these behavioural findings, increased levels of dopamine 
metabolites were observed selectively in the striatum of rats treated with risperidone in adolescence. 
Increased dopamine metabolites represent increased turnover of dopamine and/or increased 
dopamine availability, which both suggest increased dopaminergic signalling. Increased dopamine 
neurotransmission in adolescent-treated rats may overcome the behavioural effects of dopaminergic 
blockade by risperidone. When assessed after an equivalent drug-free interval of 36 days, rats 
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previously treated with risperidone in adolescence were less sensitive to catalepsy induced by a 
challenge dose of risperidone, compared to those previously treated in adulthood. In fact, rats with 
prior adult risperidone exposure developed a sensitization-like catalepsy response to this challenge. 
However, no accompanying neurochemical correlates were identified in the striatum in both age 
groups at this time of assessment.   
Unlike these cataleptic outcomes, rats with prior adolescent risperidone treatment were more 
sensitive to risperidone-induced changes in CAR, a NAc-dependent behaviour, compared to those 
with prior adult risperidone treatment. These behavioural changes in CAR were detected after a 
lengthy drug-free interval of 60 days. A challenge dose of risperidone induced a sensitization-like 
suppression of previously acquired CAR selectively in rats treated with risperidone in adolescence. 
In these same rats, a decreased expression of 5-hydroxytryptamine 2A (5HT2A) receptors and 
catechol-o-methyl transferase (COMT) was observed in the NAc, the major brain region associated 
with APD-induced suppression of avoidance. Blockade of D2 receptors is critical for CAR 
suppression, whereas blockade of 5HT2A receptors potentiates this effect. Given 5HT2A receptors, 
and therefore presumably 5HT2A function, was downregulated in adolescent risperidone-exposed 
animals, this may help to explain why CAR suppression was sensitised in this group.  Acquisition 
of CAR was also assessed in another cohort of previously untrained rats after a lengthy washout 
from chronic risperidone treatment. I found that rats with prior adolescent risperidone exposure had 
a retarded ability to acquire CAR when assessed as adults. However, there were no accompanying 
changes in the levels of monoamines or their metabolites in the NAc. This risperidone treatment 
also did not induce any short-term alterations in NAc metabolites or long-term alterations in brain 
structures in either age group. Whether this CAR learning deficit was specific to adolescent 
risperidone exposure or if it reflects a broader learning impairment remains unknown.  
In summary, through a comparative examination of the same risperidone regimen in adolescent and 
adult rats, I have identified short- and long-term behavioural and gene expression changes selective 
to adolescent exposure. These findings indicate that risperidone treatment can alter maturation 
changes and induce long-term effect on the adolescent brain. The findings of this thesis provide 
supporting evidence that the adolescent brain differs markedly from the adult brain in response to 
risperidone. Furthermore, these findings indicate that adolescent APD prescription practices should 
directly not follow adult findings or guidelines. Given risperidone is the most commonly prescribed 
atypical APD to adolescents, these findings may prove clinically relevant. 
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1.1. Adolescence and brain maturation changes 
 
Adolescence represents a period of major changes in brain and behaviour. According to the 
definition by the World Health Organization (WHO), adolescence spans the period between 10 and 
19 years of age (http://www.who.int/maternal_child_adolescent/topics/adolescence/dev/en/). During 
this period, several major remodelling processes take place in the brain in addition to well-known 
behavioural and hormonal changes (Dahl 2004a). For example, in human subjects, both longitudinal 
and cross-sectional studies have reported adolescence-specific maturation changes in grey matter 
volume and cortical structures (Giedd et al. 1999; Gogtay et al. 2004), volume of subcortical 
structures (Goddings et al. 2014; Raznahan et al. 2014; Wierenga et al. 2014), functional 
connectivity among different brain regions (Tomasi and Volkow 2014), global and regional cerebral 
blood flow (Chiron et al. 1992), local cerebral metabolic rates of glucose utilization (Chugani et al. 
1987), dopamine receptors (Jucaite et al. 2010; Seeman et al. 1987; Weickert et al. 2007) and 
dendritic spines (Petanjek et al. 2011; Peter 1979). Detailed reviews of adolescent maturation 
changes in humans and primates can be found elsewhere (for example, see (Blakemore 2012; Giedd 
and Rapoport 2010; Keshavan et al. 2014)). 
Developmental changes during adolescence are not restricted to humans. Rodents also undergo 
changes in neurobehavioural, physical and sexual characteristics which resemble those 
developmental changes in adolescent humans (Spear 2000; 2007). Based on the timing of these 
‘adolescence-like’ characteristics including puberty and its related changes, the adolescent period in 
experimental rodents (Figure 1-1(a)) is generally considered to span from postnatal day (PND) 28 to 
PND56 while this period can vary with sex and species (Brenhouse and Andersen 2011; 
McCutcheon and Marinelli 2009; Schneider 2013; Spear 2000; 2007; Yetnikoff et al. 2014). Other 
researchers have proposed that it can also be as early as PND21 and as late as PND70 (Burke and 
Miczek 2014; Schneider 2013; Tirelli et al. 2003).  
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Figure 1-1 Adolescence in rodents and neural maturation changes during adolescence(a) The World Health 
Organization (WHO) defines the adolescence in human to be between 10 and 19 years. Timing of puberty 
and the estimated age windows of adolescence in mice and rats of both sexes are shown (Figure adapted 
after (Schneider 2013)). (b) Invasive neurochemical and neurophysiological investigations in adolescent 
rodents have shown important changes principally in dopaminergic systems and also in endocannabinoid 
and gamma-aminobutyric acid (GABA)-ergic systems in major brain regions such as prefrontal cortex 
(PFC), striatum, nucleus accumbens (NAc) and ventral tegmental area (VTA). 
  
(a) 
(b) 
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Studies in adolescent rodents have complemented investigations in humans and enabled further 
identification of multiple neural maturation processes at both structural and functional levels during 
this period (Figure 1-1(b)); in particular, maturation of dopaminergic (DA) (Andersen et al. 2000; 
Matthews et al. 2013; McCutcheon et al. 2012; McCutcheon and Marinelli 2009; Tarazi et al. 1998; 
1999; Teicher et al. 1995; Tseng and O'Donnell 2007; Yetnikoff et al. 2014) and endocannabinnoid 
systems (de Fonseca et al. 1993; Klugmann et al. 2011) in major brain regions such as striatum, 
nucleus accumbens (NAc), ventral tegmental area (VTA) and prefrontal cortex (PFC) have been 
explored. Recently, adolescent maturation of gamma-amino butyric acid (GABA)-secreting 
interneurons of the PFC has also been reported (Caballero et al. 2014). A recent longitudinal 
magnetic resonance imaging (MRI) study in rats has also identified a peak in cortical thickness 
during adolescence and a continued increase in volume of cerebral cortex and striatum and 
myelination from adolescence to adulthood (until PND60) (Mengler et al. 2014). Levels of striatal 
metabolites such as N-acetylaspartate (NAA), glutamate and glutamine have also been observed to 
increase from neonatal period through adolescence to adulthood as examined in a longitudinal 
magnetic resonance spectroscopy (MRS) study in rats (Morgan et al. 2013). Detailed reviews on 
maturation of adolescent neuronal systems can be found elsewhere (Brenhouse and Andersen 2011; 
Lewis 1997; McCutcheon and Marinelli 2009; Spear 2000; Sturman and Moghaddam 2011; 
Wahlstrom et al. 2010). Given these major remodelling changes in the brain, adolescence has been 
regarded as a critical postnatal developmental period.  
Pharmacological exposures, when given at critical windows, have been hypothesized to be 
assimilated into normal brain development altering the developmental trajectory, with a subsequent 
change in mature neuronal function (Andersen and Navalta 2004; Dahl 2004b; Tirelli et al. 2003). 
Adolescent exposure to antipsychotic drugs (APDs) is of particular importance here given a 
dramatic increase in prescription of these drugs to adolescents and children over the recent two 
decades (See Section 2).  
APDs are generally classified into two categories: first generation or typical APDs and second 
generation or atypical APDs although a consensus for this classification has not been achieved [See 
reviews for classifications of APDs and their proposed mechanisms (Lieberman et al. 2008; 
Miyamoto et al. 2005; Miyamoto et al. 2012) and meta-analyses for comparison among different 
APDs (Leucht et al. 2009; Samara et al. 2014)]. In general, typical APDs, for example haloperidol, 
have high affinities for dopamine D2 receptors, a slow dissociation rate from these receptors and a 
low affinity for 5-hydroxytryptamine 2A (5HT2A) receptors. As a result of this receptor binding 
profile, they are associated with an increased likelihood of extrapyramidal side effects (EPS). 
Atypical APDs, for example, clozapine, risperidone and olanzapine, show primary affinities for a 
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wide range of neurotransmitter receptors including dopaminergic, serotoninergic (5-
hydroxytryptamine, 5HT), adrenergic alpha (α), muscarinic and histaminergic receptors; have a 
high ratio of affinity for 5HT2A compared with that for D2 receptors; and fast dissociation from D2 
receptors. In adult patients, atypical APDs are generally considered to have fewer EPS compared to 
typical APDs. However this notion has been challenged by the findings of Clinical Antipsychotic 
Trials of Intervention Effectiveness (CATIE) schizophrenia trial (Miller et al. 2008). Our current 
knowledge of neurobiological effects of APDs is largely limited to clinical and preclinical studies in 
adults. The influence of APDs on the neuronal systems during adolescence is poorly understood. 
For instance, we do not understand which alterations in the adolescent brain induced by APDs are 
irreversible, partially or fully reversible nor which exposure window is critical. The use of animal 
models is crucial here to both complement clinical studies in this age group and permit a detailed 
interrogation of brain circuits and neurotransmitter pathways (Vitiello et al. 2009).  
The neurotransmitters targeted by APDs exist in animals and have a similar maturation profile 
(Spear 2000; 2007). Well-controlled preclinical studies in adolescent animals can deliver results in a 
more timely and cost-effective manner than clinical studies. Both short- and long-term outcomes of 
APDs independent of underlying disease states can also be examined. However, one problem in the 
interpretation of most preclinical APDs studies is the age of exposure. For example, a number of 
studies simply report the body weight of the animals utilized. Body weight is an imprecise indicator 
of age given the large variability of body weights of rats at the same age even from the same colony 
(McCutcheon and Marinelli 2009). Even in preclinical literature, only a limited number of studies 
have investigated the outcomes of adolescent APD administration, especially long-term 
consequences. The majority of studies ignore the age of APD exposure. Here, I critically review 
preclinical studies of adolescent APD treatment in both neurodevelopmentally normal animals and 
rodent models of neuropsychiatric disorders. Next I discuss the translational value of these 
preclinical studies, along with their advantages and disadvantages as well as possible future 
directions.  
1.2. Adolescent APD prescription: A brief overview of the clinical picture 
Given the focus here is on the value of preclinical studies, I provide only a brief overview of the 
clinical pharmacoepidemiology of APD use in adolescence. More comprehensive clinical reviews 
and perspectives on APD prescription in children and adolescents are reported elsewhere (for 
example, see (Ben Amor 2012; Pringsheim et al. 2011; Ronsley et al. 2015; Schneider et al. 2014; 
Seida et al. 2012; Vitiello et al. 2009).  
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An increasing pattern of APD prescription has been observed in patients of all age groups over the 
previous two decades. In particular, there has been a significant increase in atypical APD 
prescription to adolescents and children, compared to adults, mainly due to lower rates of 
extrapyramidal side effects compared to typical APDs (Karanges et al. 2014; Kaye et al. 2003; 
Olfson et al. 2012). The increase in APD prescribing to adolescents and children has been reported 
in the United States (US) (Olfson et al. 2006; Patel et al. 2002; Zito et al. 2003), Australia 
(Hollingworth et al. 2013; Karanges et al. 2014), France (Verdoux et al. 2015), the United Kingdom 
(UK) (Kaye et al. 2003), the Netherlands (Kalverdijk et al. 2008), Canada (Ronsley et al. 2013), 
Israel (Gilat et al. 2011) and China (Song and Guo 2013). Moreover, these studies also report a 
differential gender distribution of APD prescription. In adolescents and children, a higher 
proportion of male patients receive APD prescriptions (Hollingworth et al. 2013; Kalverdijk et al. 
2008; Olfson et al. 2006; Olfson et al. 2012; Ronsley et al. 2013). The duration of APD 
administration in youths is also increasing, again with male patients receiving longer duration of 
APD treatment (Kalverdijk et al. 2008). 
Despite the US Food and Drug Administration’s (FDA) approval of selected atypical APDs such as 
risperidone, olanzapine and aripiprazole for a limited number of disorders, for example, autism, 
bipolar disorder and schizophrenia (Ronsley et al. 2015), the majority of APD prescriptions in 
adolescents and children are for symptom-targeted treatment of behaviour such as aggression, mood 
instability, violent behaviour or irritability associated with non-psychotic neuropsychiatric disorders 
(Cooper et al. 2006; Olfson et al. 2006; Olfson et al. 2012; Rettew et al. 2015). Consequently, off-
label prescribing constitutes a greater proportion of increased use of APDs in these two populations. 
In addition, a significant proportion of clinical APD studies in adolescents to date have only 
investigated short-term tolerability and safety profiles. Very few studies have follow-up periods of 
more than 1 year (Seida et al. 2012). Information about the efficacy and safety of APDs in 
adolescents and the existing guidelines also tend to be extrapolated from adult data (Cooper et al. 
2006; Correll 2008). Systematic reviews of existing clinical trials in children and adolescents have 
identified that hyperprolactinemia and metabolic side effects are prominent with atypical APD 
treatment (Martínez-Ortega et al. 2013; Pringsheim et al. 2011). However, the knowledge and 
understanding of long-term neural outcomes resulting from adolescent APD treatment remains 
limited and several questions remain unanswered (Patel et al. 2005). Consequently the rise in 
atypical APD prescription to children and adolescents has received significant attention and concern 
from health care professionals, care-givers and the general public with wide media coverage.  
As outlined in the Section 1.1., adolescent brain maturation pathways are highly conserved across 
species (Spear 2000; 2007). This enables researchers to model adolescent pharmacological 
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treatment in experimental rodents and investigate the effects of such administration in a strictly-
controlled manner. Preclinical APD studies also allow invasive investigations into brain 
neurochemistry and ultrastructure, which are clearly not possible clinically. Moreover, another 
advantage of preclinical studies is that the issues of drug-drug interaction, residual drug effect in 
polypharmacy or sequential drug exposure often confounds interpretation in clinical studies 
(Andersen and Navalta 2011). Preclinical studies in adolescent rodents can thus allow the 
investigation of short- and long-term effects of APDs on neural maturation processes with high 
translational value (Vitiello et al. 2009) although these preclinical studies clearly have certain 
limitations (See Section 1.4 for discussion on limitations).  
1.3. Adolescent APD administration: Findings of preclinical studies 
In this section, I critically review and discuss the studies that subjected animals to APDs at 
postnatal ages corresponding to adolescent human brain development (Brenhouse and Andersen 
2011; Burke and Miczek 2014; McCutcheon and Marinelli 2009; Schneider 2013; Spear 2007; 
Yetnikoff et al. 2014). Studies that examined APD treatment in prenatal period or in animals older 
than PND60 or that did not clearly describe the age of the animals at the start of treatment were 
excluded from the review. I choose to discuss the literature on APD treatment in adolescent animals 
separated on the basis of ‘healthy’ animals (Table 1 and 2) and rodent models of schizophrenia 
(Table 3) to highlight how the effects of APDs differ, depending on neurobiological status of the 
animal. The effects of APDs on control animals in the studies of rodent models of neuropsychiatric 
disorders are discussed together with the findings in healthy adolescent animals.  
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Table 1-1 Short-term outcomes of adolescent APD administration in neurologically intact animals 
APD Dose Route Duration Age of 
treatment 
Species, 
Strain, 
Sex 
Washout 
period 
Behavioural 
changes 
Neurochemical 
changes 
Metabolic 
changes References 
HAL 0.05-10 
mg/kg 
IP Single 
administration 
Age range 
from PND18 
to PND825 
Male SD 
rats 
None  Catalepsy, 
ptosis and 
motor effects: 
PND18, 25 and 
32 and 540 rats 
> PND56 rats 
Not studied Not 
studied 
(Campbell 
and 
Baldessarini 
1981) 
HAL 0.001-30 
mg/kg 
IP Single 
administration 
PND18, 30 
or 110 
SD rats None  Not studied HAL-induced 
changes in DA 
metabolites in 
NAc: PND30 
rats > PND18 
and PND110 
rats; 
Not 
studied 
(Teicher et 
al. 1993) 
HAL 1 or 2 
mg/kg/day 
IP 3 or 6 weeks PND42 to 
PND62/84 
Male 
C57BL/6 
mice 
2-4 days ↓ spontaneous 
alterations in Y 
maze with both 
regimens; 
↑latency to 
platform in WM 
with 6-week 
exposure 
↑striatal D1 and 
D2 proteins 
with both 
regimens;  
↑hippocampal 
D2 proteins 
only with 6-
week treatment; 
Normal PFC D2 
proteins  
Not 
studied 
(Xu et al. 
2012) 
8 
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RIS 1 
mg/kg/day 
Drinking 
water 
140 days PND28/35 to 
PND168/175 
Male 
Wistar 
rats 
None;  
Tests 
on-drug. 
↑PPI only on 
day 70 of 
treatment; 
normal startle 
response; 
↑grooming;  
Normal 
locomotion 
after day 75 and 
CAR 
acquisition 
atday 85  
Normal 
thickness and 
number of 
cells(+) for 
GFAP, Fos, PV, 
CaBP of PL 
after 140-day 
treatment  
Not 
studied 
(Castellano 
et al. 2009) 
RIS  0.3 mg/kg 
t.i.d. 
Cookie 
dough 
21 days PND23 to 
PND43 
Female 
SD rats 
None ↓motor activity 
on day 12; 
↑histamine 
H1R, NPY and 
AgRP mRNA 
levels in 
mediobasal 
hypothalamus 
↑weight 
gain, food 
and water 
intake 
starting 
from day 
14 of 
treatment 
(Lian et al. 
2015) 
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RIS 
 
0.3, 1 or 3 
mg/kg/day 
 
IP 21 days 
 
PND22 to 
PND 42 
 
Male SD 
rats 
24 hours 
 
Not studied ↑D1 in NAc and 
STR with 1 and 
3 mg/kg (cf. No 
change in 
adults) 
↑D2 and ↑D3 in 
mPFC, NAc, 
STR and hippo 
e with higher 
doses (same 
changes in 
adults) 
Normal D3 
Not 
studied 
(Moran-
Gates et al. 
2007) 
 
RIS 
 
0.3, 1 or 3 
mg/kg/day 
 
IP 21 days 
 
PND22 to 
PND 42 
 
Male SD 
rats 
24 hours 
 
Not studied ↓NMDA in both 
NAc and STR 
with higher 
doses (cf.  
↓NMDA in 
STR and Hippo 
in adults) 
↑AMPA in 
mPFC and STR 
(cf. ↑AMA in 
STR only in 
adults) 
Normal kainate 
binding 
Not 
studied 
(Choi et al. 
2009) 
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RIS 
 
0.3, 1 or 3 
mg/kg/day 
 
IP 21 days 
 
PND22 to 
PND 42 
 
Male SD 
rats 
24 hours 
 
Not studied ↑5HT1A in 
mPFC and 
Hippo (cf. 
↑5HT1A in 
mPFC only in 
adults) 
↓5HT2A in 
mPFC (same 
change in 
adults) 
Not 
studied 
(Choi et al. 
2010b) 
HAL  0-5 mg/kg IP, Oral 
or ICV 
Single 
administration 
PND30, 56 
or 100 
Male SD 
rats 
None Catalepsy and 
ptosis by 
HAL/PPZ: 
PND30 rats > 
PND56 and 100 
rats regardless 
of the route 
Not studied Not 
studied 
(Campbell 
et al. 1988) 
PPZ  0-10 
mg/kg 
HAL 0.03, 0.1 
or 0.3 
mg/kg 
 
IP 
 
Single 
administration 
PND22, 40 
or 70 
Male and 
female 
LE rats 
None; 1 
h after 
injection 
↓locomotion  by 
higher doses in 
PND40 and 
PND22 rats; no 
effect on 
PND70 rats  Not studied 
Not 
studied 
(Wiley 
2008) 
CLZ  1, 3, 10 
mg/kg 
 
IP ↓locomotion by 
10 mg/kg only 
in ♀ PND40 
rats 
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HAL  0.03, 0.1 
or 0.3 
mg/kg 
IP 
10 days 
 
PND40 to 
PND49 
Male and 
female 
LE rats 
None; 1 
h after 
injection 
Motor 
suppression by 
both APDs in 
both sexes; No 
change  in 
motor effects 
over 10-day 
period CLZ 1, 3 or 10 
mg/kg 
IP 
HAL 0.3 
mg/kg/day  
IP 10 days 
PND30 to 
PND39 or 
>PND70 to 
>PND80 
Male and 
female 
LE rats 
None; at 
30 min 
after 
injection 
Catalepsy by 
HAL: ♂ 
adolescents<♂ 
adults and ♀of 
both ages; 
increasing 
motor 
suppression 
across 10 days 
in both ages 
Catalepsy by 
CLZ: ♀ 
adolescents >♀ 
adults; no 
difference in ♂;  
Not studied 
Not 
studied 
(Wiley and 
Evans 2008) CLZ 10 
mg/kg/day 
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HAL  0.5 
mg/kg/day 
IP 21 days 
PND49 to 
PND69 
Female 
Lister 
rats 
None  Not studied Not studied 
↑Weight 
gain from 
day 3 of 
injection 
until day 
21 (except 
ZPD); 
↑intra-
abdominal 
fat  and 
abnormal 
oestrous 
cycles 
(except 
ZPD); 
↓uterine 
weight in 
HAL- & 
SUL-
treated rats  
(Fell et al. 
2005) 
RIS 0.5 
mg/kg/day 
OLZ 4 
mg/kg/day 
ZPD 2.5 
mg/kg/day 
SUL 10 
mg/kg/day 
FLZ 1 mg/kg 
IP 21 days 
PND22 to 
PND42 
Male SD 
rats 
24 hours Not studied 
↓D1 in mPFC 
with all 3 
APDs; ↓D1 
NAc with FLZ; 
(cf. No change 
in adults) 
↑D2 in NAc, 
STR, Hippo 
with FLZ and 
OLZ; ↑D2 in 
Hippo with 
Not 
studied 
(Moran-
Gates et al. 
2006) 
 
OLZ  5 mg/kg 
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CLZ 20 mg/kg 
twice 
daily 
CLZ; (cf. ↑D2 
in mPFC in 
adults) 
↑D4 in NAc, 
STR with all 3 
APDs (same 
outcome in 
adults) 
Normal D3 
RIS 0.3 mg/kg 
t.i.d. 
Cookie 
dough 
20 days PND 23  
PND 52 
Male and 
Female 
SD rats 
2 days Not studied  RIS: ↓5HT2A in 
PFC in ♀; ↓D1 
in PFC in ♂; 
OLZ: ↓5HT2A 
and ↓5HT2C in 
PFC NAc and 
striatum in both 
♂ and ♀;  
ARZ: ↓5HT2A 
in PFC only in 
♂;  
Not 
studied 
(Lian et al. 
2016) 
OLZ  1 mg/kg 
t.i.d. 
ARZ 1 mg/kg 
t.i.d. 
5HT = 5-hydroxytryptamine; AgRP = agouti-related peptide; AMPA = 2-amino-3-(3-hydroxy-5-methyl-isoxazol-4-yl)propionic acid; CaBP = calcium 
binding protein; CAR = conditioned avoidance response; CLZ = clozapine; CPP = conditioned place preference test; DA = dopamine; FLZ = 
fluphenazine; GABA = gamma-amino butyric acid; GFAP = glial fibrially acidic acid protein; HAL = haloperidol; Hippo = hippocampus; ICV = 
intracerebroventricular; IP = intraperitoneal injection;  LE = Long Evans; mPFC = medial prefrontal cortex; NAc = nucleus accumbens; NMDA = 
N-methyl-D-aspartic acid; NPY = neuropeptide Y; OFC = orbital frontal cortex; OLZ = olanzapine; PCP = phencyclidine; PL = prelimbic cortex; 
PND = postnatal day; PPZ = perphenazine; PV = parvalbumin; qPCR = real-time quantitative polymerase chain reaction; RIS = risperidone; SC = 
subcutaneous injection; SD = Sprague Dawley; SUL = sulpiride; VEH = vehicle; WM = water maze test; ZPD = ziprasidone;
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1.3.1. APD treatment in ‘healthy’ adolescent animals 
1.3.1.1 Behavioural effects of adolescent APD administration 
1.3.1.1.1. Locomotor and reward behaviour  
Given the prominent effect of APDs on locomotion, this is the most widely investigated behaviour 
in adolescent APD studies in animals. Locomotor effects of APDs vary with age, sex, drug, dose, 
duration of treatment and drug withdrawal.  
Early studies reported that, with acute administration, adolescent male rats were more sensitive to 
motor suppressive effects of haloperidol and perphenazine than adults over the dosage range tested 
regardless of the route of administration (Campbell and Baldessarini 1981; Campbell et al. 1988; 
Wiley 2008). Female adolescent rats, in particular PND22, were also sensitive to low dose (0.03 
mg/kg) haloperidol-induced motor suppression while this dose actually increased motor activity in 
adult female rats (Wiley 2008). By contrast, motor suppression by acute clozapine (1, 3 and 10 
mg/kg) occurred only in male early-adolescent rats (PND22), without any effect on male rats at 
PND40 and PND70. Overall, motor suppressive effects of acute administration of APDs appear 
more prominent in early-adolescent animals, with sex-dependent variation in drug response. By 
contrast, repeated exposure to either haloperidol or clozapine for 10 days produced less motor 
suppression in adolescent animals compared to the outcomes in adults (Wiley 2008; Wiley and 
Evans 2008).  
Of more interest, long-term off-drug motor outcomes (i.e. after a drug-free interval from adolescent 
APD exposure), which may indicate persistent nature of APDs’ effects, have been demonstrated in 
several recent studies. Adolescent treatment with 0.7 or 2.5 mg/kg haloperidol, a typical APD, from 
PND30 to PND37 induced a long-term increase in adult motor activity at PND80 as measured in 
circling and open field tests whereas the same regimen at younger (PND20-PND27) and older 
(PND40-PND47) ages did not lead to such outcomes (Soiza-Reilly and Azcurra 2009). In another 
study, rats treated subcutaneously with risperidone, an atypical APD, from PND14 to PND42, 
which spans both juvenile and early-adolescent periods in rats, were observed to have spontaneous 
hyperlocomotion at the 7th day of drug withdrawal (i.e. PND49) (Bardgett et al. 2013). This 
increased motor activity in both males and females was more robust with a higher dose (3 mg/kg) of 
risperidone, compared with the lower dose (1 mg/kg), and persisted until PND270. Lack of any 
significant deficits in T maze spatial discrimination task in the same rats suggests that the adverse 
effects of juvenile risperidone exposure at least in this study may be restricted to motor activity. 
Similarly, an increase in adult locomotor activity was reported with adolescent risperidone 
15 
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administration from PND22 to PND50 and this long-term motor outcome was observed only in 
males, not in females (De Santis et al. 2016). 
After adolescent treatment (PND44-PND48) with olanzapine (1 or 2 mg/kg) or clozapine (10 or 20 
mg/kg), an increase in spontaneous ‘baseline’ locomotion developed at PND50 and persisted until 
adulthood (PND75 and PND90) (Shu et al. 2014a). Another study from the same group has shown 
that adult rats who had adolescent exposure to risperidone (0.3 or 1 mg/kg/day from PND44 to 
PND48) showed an increased sensitivity to motor effects of a challenge dose (0.3 mg/kg) of this 
APD (Qiao et al. 2014a). However, the rats in these studies were examined for the effects of APDs 
on repeated phencyclidine-induced hyperlocomotion during adolescence. The rats treated with 
vehicle alone or a combination of vehicle and PCP did not show such abnormal locomotion. 
Therefore, the observed locomotor abnormalities would be contributed mainly by APD treatment; 
still the contribution of PCP treatment could not be ruled out. 
Long-term adult motor outcomes in control animals treated with APDs in adolescence (within 
studies of rodent schizophrenic models) also provided further evidence of persistent motor 
abnormalities induced by chronic adolescent APD administration (Table 1-3). Despite variations in 
APDs, dosage and route used, these studies consistently showed that ‘neurodevelopmentally 
normal’ control animals treated with APDs during adolescence developed locomotor abnormalities 
in adulthood. When treated with risperidone during adolescence (0.045 or 1.2 mg/kg from PND34 
to PND47), control rats not exposed to maternal immune activation (MIA) had decreased 
locomotion both at baseline and after amphetamine (1 mg/kg) challenge in adulthood (Piontkewitz 
et al. 2011). This long-term locomotor abnormality was selective to high dose (1.2 mg/kg) 
risperidone exposure. Similarly, another group has reported that non-immune challenged control 
rats which were treated in adolescence with risperidone or aripiprazole (0.45 and 0.66 mg/kg/day 
respectively in drinking water from PND35 to PND70) developed abnormal increase in locomotion 
after saline injection and in the post-stereotypic phase of high dose (5 mg/kg) amphetamine-induced 
locomotion in adulthood (PND91-92) (Richtand et al. 2011; Richtand et al. 2012). In mouse MIA 
model, adolescent haloperidol treatment in controls (3 mg/kg/day in drinking water from PND35 to 
PND65) induced an increased locomotion at baseline and after challenge with saline, amphetamine 
and MK801, when these mice reached adulthood (PND90-120) (Meyer et al. 2010). In control rats 
of neonatal ventral hippocampal lesion model, adolescent risperidone treatment (0.085 mg/kg) 
increased novelty-induced locomotion selectively, without any effect on amphetamine-induced 
hyperlocomotion (Richtand et al. 2006). Therefore, these studies collectively suggest that long-
lasting motor effects can occur in adulthood after adolescent exposure to both typical and atypical 
APDs.  
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In contrast with the findings discussed above, APD-induced long-term locomotor abnormalities 
were not observed in a limited number of other studies. For instance, rats treated in adolescence 
with risperidone (1 mg/kg/day for 5 days via subcutaneous injections (SC)) (Qiao et al. 2014a) or 
haloperidol (0.05 mg/kg/day SC or 0.25 mg/kg/day via osmotic minipumps for 4 weeks) (Gao and 
Li 2014) did not show any significant locomotor alteration when challenged in adulthood with 
quinpirole, a D2 agonist. Similarly, adolescent 21-day olanzapine exposure administration (7.5 
mg/kg/day via drinking water) did not alter in spontaneous motor behaviour in the open field test in 
adulthood (Milstein et al. 2013). This study however did not examine psychostimulant induced 
locomotor response. By contrast, when reward behaviour was assessed in conditioned place 
preference, rats treated with the same adolescent olanzapine regimen showed significantly higher 
preference to amphetamine-paired chamber (Vinish et al. 2013). Chronic adolescent clozapine 
exposure treatment in rats (7.5 mg/kg/day from PND34 to PND47) (Piontkewitz et al. 2009) and in 
mice (15 mg/kg/day in drinking water from PND35 to PND65) (Meyer et al. 2010) also did not 
alter baseline or amphetamine-induced locomotion in adulthood. Differences in experimental 
conditions including drug, dose, route of administration, duration of treatment and method of 
locomotor assessment (baseline or psychostimulant-induced) may perhaps explain discrepancy in 
locomotor findings. In general, when given to adolescents at sufficient dose and duration, both 
typical and atypical APDs (risperidone and haloperidol in particular) induce long-lasting motor 
abnormalities in adulthood at baseline or after psychostimulant challenge.  
Given the lack of a comparison age group in the aforementioned studies, we indirectly compared 
these findings with the reported data on adult APD treatment. In adults, chronic treatment with 
typical and atypical APDs differentially affects the sensitivity to locomotor and/or stereotypic 
effects of dopamine-releasing agents. For instance, after withdrawal from chronic treatment with a 
well-known typical APD haloperidol (0.25-1 mg/kg/day for 14-21 days), there were abnormally 
increased locomotor responses to amphetamine or cocaine (Bédard et al. 2013; Carvalho et al. 2009; 
Fukushiro et al. 2008; Montanaro et al. 1982; Samaha et al. 2007) and increased stereotypic 
response to apomorphine (Rupniak et al. 1985; Saldaña et al. 2006). By contrast, chronic exposure 
to atypical APDs such as clozapine, risperidone and olanzapine in adults did not induce such an 
effect (Bédard et al. 2013; Rupniak et al. 1985; Saldaña et al. 2006; Samaha et al. 2007). Instead, 
co-treatment with risperidone has been reported to counteract the effects of haloperidol in 
locomotor response to amphetamine challenge (Carvalho et al. 2009). Similarly, when APD-
induced change in reward behaviour was assessed in the operant chambers, chronic treatment in 
adults with haloperidol, but not olanzapine, significantly increased the lever presses to amphetamine 
reward (Bédard et al. 2013).  
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Thus, administration of typical APDs induces similar effects on locomotion and reward outcomes in 
both adolescents and adults whereas chronic exposure to atypical APDs induces long-lasting 
motoric and/or reward effects selectively in adolescents. This differential sensitivity to atypical 
APDs suggests that specific maturation processes of adolescent brain may be more vulnerable to the 
effects of these drugs. This increased sensitivity of the adolescent brain to atypical APDs may have 
important clinical implications given these atypical APDs such as risperidone are the ones most 
often prescribed to adolescents in clinical practice. The question remains, “What is the underlying 
neural mechanism(s) that increase(s) the sensitivity of the adolescent brain to long-term motor 
effects of atypical APDs?” In adult exposure, a hyper-responsive dopaminergic system, sometimes 
referred to as ‘dopamine supersensitivity’ (Montanaro et al. 1982; Samaha et al. 2007), has been 
suggested to underlie abnormal locomotor responses following chronic exposure to high-potency 
D2 antagonists such as typical APDs. However, this would appear a less likely explanation for the 
effects of adolescent atypical APDs given their affinities for a broad range of different receptors 
such as 5HT, α and muscarinic receptors. The fact that abnormal locomotion can develop with 
chronic adolescent treatment with aripiprazole, an atypical APD with partial DA agonist function 
(Shapiro et al. 2003), also questions the central role of ‘dopamine supersensitivity’. Changes in 
interactions between dopaminergic and glutamatergic pathways which have been implicated in 
locomotor sensitization induced by psychostimulants such as amphetamine (Vanderschuren and 
Kalivas 2000) or 5HT systems have yet to be investigated.  
What is the target brain region mediating the long-term locomotor effects of adolescent atypical 
APD exposure? Given the role of the NAc in control of locomotor activity (Beninger 1983; Kelly et 
al. 1975; Staton and Solomon 1984), this brain region may be a target for long-lasting effects of 
atypical APDs given to adolescents. The adolescent NAc undergoes major maturation changes in 
dopaminergic receptors (Tarazi and Baldessarini 2000; Tarazi et al. 1998) and transporters 
(Matthews et al. 2013). In addition, functional interaction of dopaminergic (D1 and D2) and 
glutamatergic receptors (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-
Methyl-D-aspartic acid (NMDA)) in the adolescent cortico-accumbens circuits has not reached the 
adult level (Huppe-Gourgues and O'Donnell 2012; Huppé-Gourgues and O'Donnell 2012). D2 
receptor-mediated modulation of NAc medium spiny neurons also functionally matures from 
adolescence to adulthood (Benoit-Marand and O'Donnell 2008). Therefore, chronic atypical APD 
treatment in adolescence may perhaps interfere with one or more of these maturation changes in the 
NAc. There may be some support for these hypotheses. For example, increased D1 and NMDA 
receptor binding in the NAc was observed selectively with chronic adolescent risperidone treatment 
at 24 hours after this regimen (Moran-Gates et al. 2007). Some changes, for example, increased D2 
binding in the NAc induced by olanzapine treatment appear to persist from adolescence to 
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adulthood given reports of these changes both proximal to (Moran-Gates et al. 2006) and long after 
chronic exposure (Vinish et al. 2013). Chronic adolescent olanzapine administration could also 
induce long-lasting changes in the NAc such as reduced D1 receptor binding, increased D2 receptor 
binding, decreased evoked DA release (Vinish et al. 2013) and reduced levels of glutamate and 
GABA (Xu et al. 2015). Nonetheless, the precise neural mechanisms of locomotor/reward effects of 
adolescent atypical APD treatment are still unknown. It is also unclear whether the reported 
changes in the NAc may also represent downstream or compensatory effects of alterations in 
neurotransmission in other regions such as the PFC, the VTA or the striatum.  
1.3.1.1.2. Conditioned avoidance response (CAR) and catalepsy  
CAR is a preclinical behavioural test which enables screening of novel drugs with antipsychotic 
potential with high predictive validity and reliability (See reviews (Wadenberg 2010; Wadenberg 
and Hicks 1999)) whereas APD-induced cataleptic response in rodents predicts the potential to 
induce EPS in humans such as parkinsonism (Hoffman and Donovan 1995; Porsolt et al. 2010; 
Sanberg et al. 1988). In schizophrenic patients, therapeutic efficacy of APDs is thought to only be 
obtained when 60-80% of D2 receptors are occupied whereas higher doses inducing >80% D2 
occupancy lead to EPS (Kapur et al. 2000). Similarly in the preclinical models, suppression of CAR 
occurs with 60-80% blockade of dopamine receptors whereas cataleptic response is observed with 
>80% dopamine receptor occupancy (Wadenberg et al. 2000; Wadenberg et al. 2001b).  
In the CAR paradigm, Li and colleagues have examined different APDs in adolescent rats in a 
series of studies. In this paradigm, repeated daily injections of APDs for 5 days or 4 weeks 
progressively suppressed the avoidance response in adolescents. After a drug withdrawal period, 
challenge with the same APD induced a sensitized suppression of CAR, i.e. higher blockade of 
avoidance by a challenge dose occurred in APD-treated rats than in APD-naïve rats. This APD-
induced sensitized suppression of CAR in adolescence persists until adulthood (PND76-92). This 
long-lasting increased drug response in CAR has been demonstrated with adolescent treatment with 
olanzapine (Qiao et al. 2013), risperidone (Qiao et al. 2014a), asenapine (Shu et al. 2014b) and 
haloperidol (Gao and Li 2014). The exception was clozapine which induces an opposite effect, a 
tolerance-like state with less suppression of the avoidance response in rats with prior adolescent 
exposure. Clozapine-induced tolerance response is not long-lasting until adulthood (Qiao et al. 
2013). In addition, adult rats previously treated in adolescence with risperidone demonstrated cross-
sensitization to olanzapine and cross-tolerance to clozapine in the CAR paradigm (Qiao et al. 
2014b).  
Sensitization-like effects of APDs on CAR do not seem to be confined to adolescent exposure given 
similar findings with adult exposure to olanzapine, risperidone, haloperidol and asenapine (Gao and 
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Li 2013; Mead and Li 2010). However, neurobiological mechanisms underpinning these 
behavioural changes in CAR, although not thoroughly understood, seem to be different in 
adolescents and adults. Putative neural circuits involved in acquisition of CAR as well as 
suppression of this behaviour are discussed in details in Section 6.2. Here I discuss the findings 
from existing studies related to sensitized suppression of CAR. In adult APD treatment, alterations 
in DA system may be responsible for sensitized CAR suppression response. Two lines of evidence 
supporting this theory are: (1) DA neurotransmission in the striatum (Darvas et al. 2011) and the 
NAc (McCullough et al. 1993; Oleson et al. 2012) plays an important role in the maintenance of 
CAR and (2) local injection of sulpiride, a D2 antagonist, into the NAc induces suppression of CAR 
(Wadenberg et al. 1990b). Li and colleagues have also suggested that, in adult APD treatment, 
abnormal D2 receptor function may underlie sensitization-like CAR response. Through a challenge 
with 1 mg/kg quinpirole, a D2 agonist, the authors have demonstrated a robust increase in D2-
mediated locomotor response in rats treated as adults with risperidone (1 mg/kg/day for 5 days) 
(Gao and Li 2013).  
However studies do not support abnormal D2 function as the sole underlying mechanism for 
behavioural changes in CAR in animals treated with APDs in adolescence. For instance, heightened 
locomotor responses to quinpirole were not observed in animals that were treated as adolescents 
with risperidone (1 mg/kg/day for 5 days) (Qiao et al. 2014a) or haloperidol (0.05 or 0.25 
mg/kg/day) (Gao and Li 2014). A recent study also did not find a quantitative change in D2 receptor 
protein levels in striatum, PFC and hippocampus of adult rats expressing sensitized CAR responses 
after adolescent asenapine treatment (Shu et al. 2014b). Thus, changes in D2 receptor per se, at least 
in the striatum, may not be responsible for development of long-term sensitized CAR responses 
following adolescent APD administration. Functional roles of neuro-receptors in the mesocortico-
limbic system such as the NAc have yet to be thoroughly examined. In a recent study, using 5-
bromodeoxyuridine (BrdU) incorporation, Li and colleagues have also suggested a possible link 
between hippocampal cell survival and olanzapine-induced sensitization in CAR in adolescent rats 
(PND51) at least 2-days after olanzapine exposure (Chou et al. 2015). Yet this finding still needs to 
be replicated. Given that sensitized CAR responses were observed selectively with repeated 
injections, but not with continuous delivery through osmotic minipumps (Gao and Li 2014), stress 
associated with injections and handling as well as pharmacokinetic factors may perhaps play a role 
in this behavioural outcome. Therefore, several questions remain unanswered and future 
investigations are required to map out the neural mechanism(s) of APD-induced long-lasting CAR 
changes in adolescents.  
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APDs can also induce catalepsy in rodents particularly if given at high doses. Again cataleptic 
responses to APDs are different in adolescents and adults. Adolescent rats have been reported to be 
more sensitive to cataleptic effects of acute administration of typical APDs than adult rats 
regardless of the route of administration (Campbell and Baldessarini 1981; Campbell et al. 1988; 
Wiley 2008). By contrast, repeated haloperidol injections (0.5 mg/kg/day) for 10 days induced less 
catalepsy in adolescent male rats (PND30-PND39), compared to adult rats (>PND70) of both 
sexes(Wiley and Evans 2008). The mechanism for this apparent switch in adolescents from higher 
sensitivity to catalepsy with acute treatment to lower sensitivity following repeated treatment is still 
unknown. Blockade of striatal dopamine neurotransmission by APDs is tightly correlated with their 
cataleptic effect (Wadenberg et al. 2000; Wadenberg et al. 2001b). Therefore, ongoing maturation 
processes in both pre- and post-synaptic dopamine systems of the adolescent striatum [See, for 
examples, (Matthews et al. 2013; Teicher et al. 1995)] may perhaps play a role in differential on-
drug cataleptic response. Long-term cataleptic responses after a drug-free interval are yet to be 
investigated with APD administration to adolescents. This is important given the clinical reports of 
APD-induced movement disorders in the young population (Sikich et al. 2004; Wonodi et al. 2007). 
1.3.1.1.3. Cognition, anxiety and social interaction  
Cognitive outcomes following adolescent APD administration have been examined in preclinical 
studies. Adult rats treated previously with olanzapine during adolescence (7.5 mg/kg/day from 
PND28 to PND49) had deficits in working memory (longer time to reach the criteria in delayed 
non-match to sample task) (Milstein et al. 2013). The same study reported deficits in fear 
conditioning: olanzapine-treated rats showed abnormal increase in freezing responses to both 
unpaired conditioned stimulus and context as well as impaired extinction response although the 
acquisition process was not affected. This adolescent olanzapine regimen was also reported to 
induce deficits in novel object recognition (NOR) after 10 days of drug-free period i.e. in adulthood 
(Llorente-Berzal et al. 2012); however risperidone treatment in adolescence (0.5 mg/kg from 
PND42 to PND56) did not affect NOR at PND 60, i.e. after 4 drug-free days (Zhu et al. 2014). 
Social interaction responses in adulthood were normal after chronic adolescent treatment with 
typical APD haloperidol (Gao and Li 2014) and atypical APDs such as risperidone (Zhu et al. 2014) 
or olanzapine and aripiprazole (De Santis et al. 2016) regardless of the route of administration.  
Adult spatial memory and measures of anxiety appear to be minimally affected by adolescent 
exposure to atypical APDs. Adult rats with prior adolescent olanzapine or clozapine treatment did 
not show any impairment in either Morris Water Maze (MWM) test or elevated plus maze (EPM) 
(Milstein et al. 2013; Piontkewitz et al. 2009). However, a recent study reported that adult rats 
treated with aripiprazole or risperidone treatment in adolescence spent longer time in the centre and 
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the open part in EPM and these findings were selective to males (De Santis et al. 2016). Reversal 
learning in T maze in adulthood was also not altered by chronic risperidone administration in 
juvenile and early-adolescent period (Bardgett et al. 2013). However, chronic adolescent exposure 
to typical APDs seems to have adverse outcomes on these measures. Chronic haloperidol treatment 
(1 or 2 mg/kg/day for 3 or 6 weeks) in mid-adolescent mice (PND42) could decrease the 
performance in both Y maze and MWM tests when examined at 2 or 4 days after treatment (Xu et 
al. 2012). Given the age of mice being 6-week old (i.e. at PND42) at the start of the treatment in this 
study, we consider these animals to be mid-adolescent although the authors described them as adult 
mice.  
In adult APD treatment, deficits in NOR were observed following chronic exposure to haloperidol, 
risperidone or clozapine at high dose but not at low dose (Ozdemir et al. 2012; Schröder et al. 2005; 
Terry Jr et al. 2007b). The findings on cognitive performance in MWM and radial arm maze (8 or 
12 arms) are inconsistent, varying with experimental conditions such as dose and duration of APD, 
withdrawal period and cognitive tests employed. Adverse outcomes have been observed with both 
typical and atypical APDs in a few studies (Didriksen et al. 2006; Terry Jr et al. 2007a) although 
this is far from universal (Hutchings et al. 2013; Ortega-Alvaro et al. 2006; Terry Jr et al. 2007a; 
Terry Jr et al. 2003). A direct comparison between adults and adolescents with respect to the effects 
of APDs on cognition has been hampered by experimental variations such as drug, dose and 
duration of treatment, withdrawal period and cognitive test used. Thus, well-designed studies which 
simultaneously examine the same APD exposure in adolescents and adults are required.  
To sum up, it would appear select domains of cognition and measures of anxiety are susceptible to 
the long-term impact of adolescent APD treatment but the outcomes seem to be drug-dependent. 
Yet, it is unclear whether these reported cognitive deficits are selective to adolescent APD 
administration given the lack of a comparison age group in the aforementioned studies. Neural 
substrates potentially responsible for these APD-induced cognitive deficits are also still unknown. 
Since the prefrontal cortex, which undergoes extensive maturation during adolescence, plays a 
central role in cognitive performance (Miller 2000; Ridderinkhof et al. 2004), APD-induced 
changes in this region may be crucial. Indeed, some studies have reported neurochemical changes in 
adult PFC following adolescent APD exposure (See Section 1.3.1.3.2). Other brain regions such as 
hippocampus which has been implicated in T maze performance [See review (Lalonde 2002)], are 
yet to been examined for adolescent APD-induced effects.  
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1.3.1.1.4. Sensorimotor gating  
Prepulse inhibition (PPI) of the startle reflex is a behavioural test widely used to examine 
sensorimotor gating. Deficits in PPI have been reported in neuropsychiatric patients as well as 
animal models of schizophrenia (Braff et al. 2001; Swerdlow et al. 2001).  
Several studies have shown that rats treated with atypical APDs such as olanzapine, clozapine and 
risperidone during adolescence have normal PPI when tested either at 24 hours after APD exposure 
or even after a lengthy drug washout period (Qiao et al. 2014a; Qiao et al. 2013; Shu et al. 2014a). 
Similarly, no significant PPI change was observed in adult mice which were treated in adolescence 
with clozapine (15 mg/kg/day from PND35 to PND65) (Meyer et al. 2010). These findings in 
adolescents are consistent with data from adult exposure studies, which reported no change in PPI 
either whilst on drug or 14 days drug-free after chronic treatment with atypical APDs such as 
olanzapine, risperidone and sertindole (Andersen and Pouzet 2001; Terry Jr et al. 2005). Thus, in 
both adolescents and adults, chronic treatment with atypical APDs does not alter sensorimotor 
gating. However, there has been one report that continuous treatment with risperidone (1 mg/kg/day 
in drinking water for 140 days) in male Wistar rats from adolescence to adulthood induced a 
significant increase in PPI at Day 75 of administration (Castellano et al. 2009). Given the prolonged 
treatment vastly exceeded the duration of adolescence in rats in this study, the observed PPI 
increase might not be specific to the adolescent exposure. This was confirmed by the authors’ 
findings that changes in PPI and grooming behaviour was not observed at shorter (21 and 35 days) 
or surprisingly, longer (91 days) time-points of treatment.  
In regards to typical APDs, chronic administration of haloperidol to adults at low dose (0.08 
mg/kg/day via osmotic pumps for 20 days) (Andersen and Pouzet 2001) or high dose (2 mg/kg/day 
in drinking water for 60-180 days) (Terry Jr et al. 2005) also produced no significant effects on PPI. 
By contrast, chronic haloperidol treatment in adolescent mice (3 mg/kg/day in drinking water from 
PND35 to PND65) has been reported to induce long-term reductions in PPI in these same animals 
when they reached adulthood (Meyer et al. 2010). This finding suggests that the adolescent brain 
may be more susceptible to PPI-altering effects of typical APDs.  
Taken together, the existing literature suggests that adolescent exposure to atypical APDs produces 
no long lasting effect on PPI whereas the typical APD haloperidol may have long-lasting effect 
adverse effects. Future studies are required to confirm the detrimental nature of adolescent exposure 
to typical APDs on PPI.  
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Table 1-2 Long-term outcomes of adolescent APD administration in neurologically intact adolescent animals 
APD  Dose Route Duration 
Age of 
treatment 
Species, 
Strain, 
Sex 
Washout 
period 
Behavioural changes 
Neurochemical 
changes 
References 
HAL  0.7 or 2.5 
mg/kg/day 
IP 8 days PND20-27, 
PND30-37 
or PND40-
47 
Male SD 
rats 
33-53 
days 
↑circling velocity, 
↑motor activity at 
PND80 selectively 
with PND30-PND37 
exposure;  
Normal striatal D2 
receptor on both 
radioligand 
binding and qPCR 
(Soiza-Reilly 
and Azcurra 
2009) 
HAL  
0.05 
mg/kg/day  
SC 
28 days 
PND44 to 
PND72 
Male SD 
rats 
7 days 
SC >> minipumps in 
CAR blockade 
during chronic 
exposure;  
↑CAR suppression 
by HAL challenge at 
PND80-82 only with 
SC route. 
Normal social 
interaction and 
quinpirole (0.5 or1 
mg/kg)-induced 
locomotion with both 
regimens   
Not studied  
(Gao and Li 
2014) 
0.25 
mg/kg/day 
Osmotic 
minipump
s 
24 
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RIS 1 or 3 
mg/kg/day 
SC 29 days PND14 to 
PND42 
Male and 
female 
LE rats 
7 days  ↓weight which 
normalized at 3rd day 
of drug withdrawal; 
↑spontaneous 
locomotion from 
PND49 until 
PND270; Normal 
reversal learning in T 
maze 
Not studied (Bardgett et al. 
2013) 
RIS 0.5 or 1 
mg/kg 
SC 5 days PND40 to 
PND 44 
 
 
Male SD 
rats 
~ 35 days 
↑CAR suppression  
by RIS challenge at 
PND80 in 1 mg/kg 
RIS group;  
Normal quinpirole-
induced 
hyperlocomotion and  
PPI;  Not studied 
(Qiao et al. 
2014a) 
RIS ± 
PCP 
3.2 
mg/kg 
0.3 or 1 
mg/kg 
SC 5 days PND44 to 
PND48 
↑suppression of 
PCP-induced 
hyperlocomotion by 
RIS challenge in 0.3 
mg/kg group at 
PND76 
RIS 1 
mg/kg/day 
SC 5 days PND40 to 
PND44 
Male SD 
rats 
~ 24 - 30 
days 
↑PPI only on 
PND45;  
Normal learning of 
CAR with two 
different conditioned 
stimuli at PND77-79 
Cross-sensitization 
Not studied (Qiao et al. 
2014b) 
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to OLZ and cross-
tolerance to CLZ 
challenge in CAR at 
PND80-84 
RIS 0.045 
mg/kg/day 
IP 14 days PND34 to 
PND47 
Male 
Wistar 
rats 
72 days Not studied Changes in PFC 
proteomics at 
PND120: 
pathways of 
mitochondrial 
function, protein 
trafficking and 
cytoskeleton  
(Farrelly et al. 
2014) 
OLZ 7.5 
mg/kg/day 
Drinking 
water 
21 days PND28 to 
PND49 
Male LE 
rats 
 
70-220 
days 
↓learning in delayed 
non-match to sample 
test; 
No deficit in spatial 
memory but 
↑swimming speed on 
WM; 
↑contextual freezing 
on fear conditioning 
test; 
Normal OFT and 
EPM 
Region-specific 
alterations in 
dendritic spine 
pruning; 
↓D1 receptor and 
↑GABAA receptor 
binding in medial 
PFC and OFC; 
↑D2 receptor 
binding in medial 
PFC;  
(Milstein et al. 
2013) 
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OLZ 7.5 
mg/kg/day 
Drinking 
water 
21 days PND28 to 
PND49 
Male LE 
rats 
 
~ 135 – 
210 days 
↑Preference for 
amphetamine-paired 
chamber on CPP;  
No change in body 
weight  
↓D1 and ↑D2 
receptor binding 
and ↓stimulus-
evoked DA 
release in the NAc 
core 
(Vinish et al. 
2013) 
OLZ 7.5 
mg/kg/day 
Drinking 
water 
21 days PND28 to 
PND49 
Male LE 
rats 
 
40 days Not studied ↓GABA and 
↓glutamate in 
NAc at PND90-
120 
(Xu et al. 
2015) 
ASE ± 
PCP 2 
mg/kg 
0.05, 0.1 
or 0.2 
mg/kg/day  
SC 5 days PND43 to 
PND47 
Male SD 
rats 
28 days ↑CAR suppression 
by asenapine 
challenge with 0.1 or 
0.2 mg/kg ASE  
↓locomotion with 0.1 
mg/kg ASE 
challenge 
Normal D2 
receptor and 
∆FosB proteins in 
striatum, PFC and 
hippocampus 
(Shu et al. 
2014b) 
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OLZ 1 or 2 
mg/kg 
SC 5 days 
PND43 to 
PND47 
Male SD 
rats 
~ 33 days 
↑avoidance 
suppression by OLZ 
challenge at PND48, 
76 and 92 
↓avoidance 
suppression by CLZ 
challenge only at 
PND48, not at 
PND76 and 92.   
Normal PPI 
Not studied (Qiao et al. 
2013) 
CLZ 10 or 20 
mg/kg 
OLZ  ± 
PCP3.2 
mg/kg 
1 or 2 
mg/kg 
SC 5 days 
PND44 to 
PND48 
Male SD 
rats 
~ 2 days 
or 29 days 
↑spontaneous 
locomotion at 
PND50, 75 and 90 
PCP-induced 
hyperlocomotion:  
↑suppression by 
OLZ challenge at 
PND76 and 91, not 
at PND51;  
↓suppression by CLZ 
challenge at PND51 
and 76, not PND91.  
Normal PPI 
Not studied 
(Shu et al. 
2014a) 
CLZ ± 
PCP3.2 
mg/kg 
10 or 20 
mg/kg 
Chapter 1  
 29 
ARZ 
 
 
 
1 mg/kg 
t.i.d. # 
Cookie 
dough 
28 days 
PND22 to 
PND50 
Male and 
Female 
SD rats 
22 days 
♂ - ↑motor activity 
in OFT with RIS; 
↑centre and open 
part duration with all 
3 APDs; ↑climbing 
and floating with 
OLZ;  
♀ - ↓climbing and 
↑floating in FST 
with OLZ and RIS; 
normal motor and 
EPM test.  
Normal social 
interaction in both 
sexes 
Not studied 
(De Santis et 
al. 2016) 
OLZ 1 mg/kg 
t.i.d. # 
RIS 0.3 mg/kg 
t.i.d. # 
AgRP = agouti-related peptide; ASE = asenapine; CaBP = calcium binding protein; CAR = conditioned avoidance response; CLZ = clozapine; CPP 
= conditioned place preference test; DA = dopamine; EPM = elevated plus maze; GABA = gamma-amino butyric acid; GFAP = glial fibrially acidic 
acid protein; HAL = haloperidol; ICV = intracerebroventricular; IP = intraperitoneal injection;  LE = Long Evans; NPY = neuropeptide Y; OFC = 
orbital frontal cortex; OFT = open field test; OLZ = olanzapine; PCP = phencyclidine; PL = prelimbic cortex; PPZ = perphenazine; PV = 
parvalbumin; qPCR = real-time quantitative polymerase chain reaction; RIS = risperidone; SC = subcutaneous injection; SD = Sprague Dawley; 
VEH = vehicle; WM = water maze test; ZPD = ziprasidone; 
# 3-step increase over 7 days from starting doses to achieve the stated target doses.  
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1.3.1.2 Brain structural effects of adolescent APD administration 
Only a limited number of preclinical studies have examined the effects of adolescent APD treatment 
on brain structures.  
At gross regional structural level, adolescent treatment with high doses of risperidone (1.2 
mg/kg/day IP from PND34 to PND47) was shown to reduce whole brain volume in adulthood 
(PND120), along with a small reduction in hippocampal volume (Piontkewitz et al. 2011). Other 
brain structures such as striatum and prefrontal cortex were not examined in this cross-sectional 
MRI study given the focus of this study on schizophrenia-related structural phenotypes. In addition, 
voxel-wise changes in brain volume or alterations in shape or geometry of brain regions were not 
examined in the study by Piontkewitz et al. given the use of manual segmentation method. Another 
study has reported that prolonged exposure to risperidone (1 mg/kg/day in drinking water) for 140 
days from adolescence to adulthood did not induce a significant change in cortical thickness of the 
prelimbic cortex or the number of cells positively stained with glial fibrillary acidic protein 
(GFAP), parvalbumin or calbidin in this brain region (Castellano et al. 2009). Another study by 
Piontkewitz et al. showed that adolescent clozapine treatment (7.5 mg/kg/day from PND34 to 
PND47) did not induce any long-lasting brain structural change (Piontkewitz et al. 2009).  
A longstanding change in whole brain volume with only 2 weeks of risperidone treatment in 
adolescence (Piontkewitz et al. 2011) raises a question on the selective vulnerability of the 
adolescent brain structures given that, in adults, a prolonged administration (≥ 8 weeks) is required 
to induce reductions in whole brain volume. For example, adult rats treated with either haloperidol 
or olanzapine (2 or 10 mg/kg/day respectively via osmotic mini-pumps) developed a reduction in 
volumes of whole brain and cortex only at 8 weeks of treatment, but not at 4 weeks, while other 
structures such as striatum, hippocampus and corpus callosum were unaffected (Vernon et al. 2011). 
Structural changes induced by APD treatment in adults have also been reported to be dependent on 
dose, duration of treatment and withdrawal. High doses of haloperidol (2 mg/kg/day) delivered via 
osmotic minipumps for 8 weeks could induce more robust structural changes (increased striatal 
volume and decreased cortical volume) than low doses (0.5 mg/kg/day) and the observed brain 
structural changes were reversible with normalization after 8 weeks of drug-free interval (Vernon et 
al. 2012). Increased striatal volume has been reported in adult rats when examined after both 4 
(haloperidol at 1 mg/kg/day) and 8 months (haloperidol and clozapine at 1 and 20 mg/kg/day 
respectively) of continuous treatment (Andersson et al. 2002). By contrast, risperidone (1 
mg/kg/day for 4 or 8 months) did not induce any change in caudate putamen volume in adults at any 
time point.  
30 
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At the ultrastructural level, pruning of dendritic spines from adolescence to adulthood seems to be 
affected by adolescent olanzapine treatment (7.5 mg/kg/day from PND28 to PND49), with region-
specific changes in dendritic architecture such as abnormal dendritic spine density in the medial and 
orbital prefrontal cortex, the NAc and the dentate gyrus (Milstein et al. 2013). For example, 
immediately after termination of treatment in adolescence, dendritic spine density (both apical and 
basal dendrites) in the mPFC layer 3 of olanzapine-treated rats was lower than that of vehicle-
treated rats. By contrast, on reaching adulthood, olanzapine-treated rats had higher dendritic spine 
density in the same region than vehicle-treated controls. These findings suggest that adolescent 
treatment with atypical APDs can alter developmental trajectory of dendritic architecture. In 
addition, this study by Milstein et al. also highlights the importance of longitudinal assessment.  
In summary, among the small number of studies examining the structural outcome, two studies have 
reported brain structural changes at the levels of both ultrastructure and gross regional volume 
induced by adolescent treatment with atypical APDs. It appears that the structural outcomes may be 
dependent on brain region, drug, dose and route. Further studies are also required to replicate the 
structural findings with adolescent exposure to risperidone and olanzapine as well as to investigate 
the underlying mechanisms. Several questions are yet to be answered. For example, it is not known 
whether long-standing changes in cortical or striatal volume, in addition to whole brain, can occur 
with chronic adolescent APD treatment. The former brain structure is important since major 
maturation changes occur in cortical structures of adolescent brain (Giedd et al. 1999; Gogtay et al. 
2004) and the impact of APDs on these maturation changes is still largely unknown. Studies in 
adult rats have suggested a possible reversal of APD-induced brain structural changes after a 
prolonged drug-free interval (Vernon et al. 2012). The question as to whether brain structural 
effects of adolescent APD treatment are reversible still needs to be addressed while existing studies 
have indicated possible long-lasting effects (Milstein et al. 2013; Piontkewitz et al. 2011). Although 
studies in adults suggest a need for prolonged exposure to detect a significant structural change, 
investigators should also be aware that the duration of adolescence in rodents, as discussed in 
Section 1.1, is a maximum of 5-6 weeks and any extended treatment longer than this duration [for 
example, (Castellano et al. 2009)] will not be able to tease apart the adolescent exposure-specific 
findings. Changes in geometry and shape of brain structures have been reported with chronic APD 
treatment in adults in addition to volumetric changes (Crum et al. 2016). The outcomes of 
adolescent APD treatment on brain morphometry are still to be investigated. Given the limitations 
of traditional manual segmentation approach for volumetric analysis, future studies should also 
employ voxel-based morphometry or tensor-based morphometry analysis to achieve a more 
sensitive measurement of voxel-wise changes. Investigation of mechanisms of APD-induced 
structural changes can also be a good future direction. For example, in adult rats with APD-induced 
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reduction in anterior cingulate cortex, increased density of neurons and astrocytes have been 
reported, without any significant alteration in the total number of these cells (Vernon et al. 2014). It 
is still unknown whether adolescent APD treatment can induce similar changes in neuronal and 
astrocytic density. 
1.3.1.3 Neurochemical effects of adolescent APD administration 
In this section, I examine neurochemical changes (i) proximal to adolescent APD exposure i.e. 
within a few days after termination of APD exposure and (ii) long after exposure i.e. weeks or 
months after APD exposure. The majority of the studies examining neurochemical outcomes after 
adolescent APD exposure focus on changes within the striatum, the NAc and the PFC.  
1.3.1.3.1. Neurochemical effects proximal to adolescent APD administration 
One earlier study showed early-adolescent rats (PND30) were more sensitive to acute haloperidol-
induced changes in DA metabolites compared to juveniles (PND18) and adults (PND110) (Teicher 
et al. 1993). This higher sensitivity in adolescence was selective to the NAc. In the striatum and the 
frontal cortex, PND18 rats showed the highest sensitivity to haloperidol-induced metabolite 
changes.  
Alterations in several neural receptors immediately after cessation of chronic treatment with 
different APDs in adolescents have been demonstrated in a series of studies from Tarazi’s group 
(Choi et al. 2009; Choi et al. 2010; Moran-Gates et al. 2006; Moran-Gates et al. 2007). Through 
retrospective comparison of adolescent and adult exposure to similar doses of APDs, these studies 
have identified neuro-receptor changes which are selective to adolescent or adult treatment and 
those common to both ages. For example, adolescent risperidone administration (3 mg/kg/day for 
21 days) selectively increased radioligand binding of both accumbal and striatal D1 and 
hippocampal 5HT1Areceptors, while decreasing accumbal NMDA receptor binding. By contrast, a 
reduction in hippocampal NMDA receptor binding was observed only with adult risperidone 
treatment (Moran-Gates et al. 2007). Chronic olanzapine treatment (5 mg/kg/day for 21 days) in 
adolescents downregulated D1 receptor binding in the medial PFC while the same regimen in adults 
upregulated medial PFC D2 receptors and hippocampal D4 receptors (Moran-Gates et al. 2006). 
Other neuro-receptor changes such as increased D2 and D4 binding in the NAc and the striatum 
were observed with both adolescent and adult exposure to risperidone and olanzapine. Another 
study in mice has also reported that the protein levels of striatal D1 and D2 receptors and 
hippocampal D2 receptors were elevated, without a significant change in the PFC dopamine 
receptors, at 3-6 days after chronic haloperidol exposure in mid-adolescence (1 or 2 mg/kg/day for 3 
or 6 weeks from PND42) (Xu et al. 2012).  
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In addition to neuro-receptors, the effects of adolescent APD treatment on presynaptic glutamate 
neurotransmission have been examined. In the PFC of rats treated with risperidone or paliperidone 
in adolescence (both at 0.01 mg/kg/day from PND35 to PND55), the basal glutamate levels on 
microdialysis were normal when examined 1-3 days after exposure to these drugs, i.e. at PND56-58. 
However, the same rats showed a blunted response to MK801-induced increases in extracellular 
glutamate in the PFC (Roenker et al. 2011). This study suggests that glutamatergic 
neurotransmission might have been suppressed at least proximal to adolescent APD exposure. 
Despite these neurochemical changes, adolescent risperidone administration (0.5 mg/kg/day from 
PND42 to PND55 via gastric gavage) was reported not to alter immune function in certain brain 
regions. At PND65, following treatment with this APD, no significant change in Iba-1 labelled 
activated microglia was observed in the cerebral cortex, the hippocampus and the thalamus of 
risperidone-treated rats (Zhu et al. 2014).  
The studies reviewed above are informative about short-term neural changes proximal to adolescent 
exposure to different APDs. Nonetheless, important questions on the chronicity and persistence of 
the observed neural changes have yet to be addressed.  
1.3.1.3.2. Neurochemical outcomes that persist long after adolescent APD withdrawal  
When examined in adulthood following adolescent olanzapine administration (7.5 mg/kg/day from 
PND28 to PND49), changes in both postsynaptic (a reduction in D1 receptor binding and an 
increase in D2 receptor binding) and presynaptic (a decrease in induced DA release) dopaminergic 
system of the NAc have been observed (Vinish et al. 2013). Moreover, a significant decrease in D1 
receptor binding in both medial and orbital prefrontal cortices (MPC and OPC) and an increase in 
D2 receptor binding in MPC and GABAA receptor binding in OPC and MPC were also observed in 
adult rats treated in adolescence with the same olanzapine regimen (Milstein et al. 2013). 
Similarities of findings on dopamine receptors (a reduced D1 binding in MPC and increased D2 
binding in NAc) at both proximal to (Moran-Gates et al. 2006) and long after chronic adolescent 
exposure as in the above two studies suggest that these changes may indeed persist from 
adolescence to adulthood. Moreover, chronic olanzapine treatment in adolescence has also been 
reported to induce a long-lasting reduction in levels of glutamate and GABA in the NAc (Xu et al. 
2015).  
While functional changes in the NAc induced by adolescent APD exposure are evident from the 
literature, neurochemical changes in other brain regions, such as the PFC and the striatum, are still 
far from clear. As shown in a recent proteomic study, adolescent risperidone treatment from PND34 
to PND47 induced changes in PFC protein profile at PND120 (Farrelly et al. 2014). Proteins with 
roles in regulation of cell death, protein trafficking, cytoskeleton, vesicle-mediated transport and 
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mitochondrial function, were shown to be altered, potentially reflecting a long-term change in brain 
metabolism remodelling. To date, a few studies have reported normal striatal dopamine D2 receptor 
levels following adolescent APD administration. When examined as adults at PND120, rats with 
prior adolescent haloperidol treatment (0.7 or 2.5 mg/kg/day from PND30 to PND37) showed 
normal striatal D2 receptor levels as measured by radioligand binding and real-time polymerase 
chain reaction (RT-PCR) (Soiza-Reilly and Azcurra 2009). The protein levels of D2 receptor and 
ΔFosB proteins in the striatum, the PFC and the hippocampus in adulthood (PND77) were also not 
altered by adolescent asenapine treatment (0.05, 0.1 or 0.2 mg/kg/day from PND43 to PND47) (Shu 
et al. 2014b). However, the striatum to date has not been examined thoroughly with adolescent 
exposure to other commonly prescribed atypical APDs such as risperidone and olanzapine.  
Long-lasting changes in neurogenesis in the dentate gyrus also appear to develop with adolescent 
APD exposure. Following adolescent risperidone treatment (0.045 mg/kg from PND34 to PND47), 
both an increase in BrdU-positive cells and a decrease in number and percentage of cells double-
labelled with BrdU, a cell proliferation marker, and NeuN, a neuronal marker, have been reported in 
the dentate gyrus at PND72 (Piontkewitz et al. 2012).  
Taken together, the NAc appears to be particularly labile to adolescent APD treatment, with long-
lasting alterations in dopaminergic, GABAergic and glutamatergic systems. These APD-induced 
alterations may perhaps reflect the locomotor readouts of adolescent APD administration. This is 
not surprising since the adolescent NAc undergoes several maturation changes as discussed earlier. 
A more detailed examination with techniques to detect functional change is still needed for other 
regions such as the striatum, PFC and VTA which undergo important changes in adolescence. For 
instance, a recent report indicates that the dopamine synthesis capacity of adolescent dorsal striatum 
is still immature with lower levels of TH and DAT proteins, compared to adult counterparts 
(Mathews et al. 2009; Matthews et al. 2013). The effects of adolescent APDs on this major 
maturation change have not been investigated yet. Moreover, adolescent APD-induced changes in 
the 5HT system, which has important interactions with DA [see reviews (Di Giovanni et al. 2008; 
Di Matteo et al. 2008)], are still to be investigated. This is relevant given atypical APDs such as 
olanzapine and risperidone, which are most frequently prescribed to adolescents, have high 
affinities for 5HT receptors (Schotte et al. 1996).  
1.3.1.4 Metabolic effects of adolescent APD administration 
In rodents, the metabolic effects of APD treatment appear to be more robust in females [See review 
(Van Der Zwaal et al. 2014)]. The preclinical findings in female adolescent rodents are in line with 
the clinical reports that adolescent patients are susceptible to the metabolic effects of APDs. As 
reported by Fell and colleagues, chronic 21-day treatment with both typical and atypical APDs in 
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adolescent female hooded Lister rats induced abnormal metabolic and endocrine effects (Fell et al. 
2005). A significant increase in intra-abdominal fat, weight and abnormal estrous cycles were 
observed immediately after cessation of treatment with all APDs studied (risperidone 0.5 mg/kg, 
olanzapine 4 mg/kg, haloperidol 0.5 mg/kg, sulpiride 10 mg/kg). The exception was 2.5 mg/kg 
ziprasidone which did not induce a significant metabolic effect. In another recent study, chronic 21- 
day risperidone treatment of adolescent female rats was shown to significantly increase both food 
and water intake, and weight gain starting after Day 12 of treatment. The authors proposed that 
upregulation of histamine H1 receptor, neuropeptide Y and agouti-related peptide in mediobasal 
hypothalamus in these adolescent female rats would be the underlying mechanism for weight gain-
inducing effects of risperidone (Lian et al. 2015).  
To date, one preclinical study has investigated long-term metabolic outcomes of adolescent APD 
exposure. Following adolescent olanzapine administration, long-term abnormalities in triglyceride 
levels at PND75 have been reported in both males and female rats (Llorente-Berzal et al. 2012). 
Interestingly, no significant change in triglyceride was observed immediately after cessation of 
adolescent treatment. The findings of this study suggest that APD-induced metabolic changes may 
have a delayed emergence during the drug withdrawal.  
In summary, a limited number of preclinical studies have examined short- and long-term metabolic 
effects and possible underlying mechanisms of adolescent APD treatment. Given a high prevalence 
of metabolic outcomes in the young population in clinical practice, more studies are required to 
better understand APD-induced long-term metabolic effects and associated mechanisms and ways 
to prevent them. In preclinical studies, olanzapine has been reported to disturb gut microbiota in 
rodents along with producing metabolic sides effects (Davey et al. 2012) and this effect of 
olanzapine has been reported to be corrected with antibiotic cocktail therapy (Davey et al. 2013). 
Thus, a possible future direction can be investigation of effects of adolescent APD treatment on the 
gut microbiota in addition to those on central nervous system.      
1.3.2. Adolescent APD treatment in animal models of neuropsychiatric disorders 
Although not yet recommended as a standard practice, early intervention with APDs to prevent the 
onset of clinical psychosis has been trialed in individuals who satisfy research criteria for being “at-
risk mental state” (for example, see (McGlashan et al. 2006; McGorry et al. 2002)). To complement 
these clinical studies, several preclinical studies have examined the outcomes of early adolescent 
APD treatment in the animal models of schizophrenia. In this section, the effects of adolescent APD 
treatment on these model animals will be presented whereas the outcomes of the same adolescent 
APD regimens on the respective control animals have been presented under specific domains in the 
previous section.  
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1.3.2.1 Maternal immune activation models (MIA) 
Maternal infection and its consequent immune activation response during critical stages of 
pregnancy is a significant risk factor for development of schizophrenia in the offspring (Brown 
2006; Brown and Patterson 2011). In rodents, maternal infection and immune activation (MIA) can 
be modelled in two primary ways (Brown 2011): (1) injection of pregnant dams with viral mimic 
polyriboinosinic-polyribocytidylic acid (Poly I:C) (for example (Shi et al. 2003)) or bacterial 
lipopolysaccharide (LPS) (for example, (Romero et al. 2007)) and (2) direct inoculation with an 
infectious agent (for example, (Fatemi et al. 2002)). The offspring of immune-activated dams have 
been shown to have schizophrenia-like phenotypes changes in behaviour, brain structures and 
neurochemistry which are relevant to schizophrenia.  
In the rat Poly I:C model, adolescent treatment with clozapine (7.5 mg/kg) (Piontkewitz et al. 2009) 
or risperidone (0.045 or 1.2 mg/kg) (Piontkewitz et al. 2012) prevented the adult onset of altered 
phenotypes such as structural brain abnormalities (enlarged lateral ventricles and reduced 
hippocampal volume) and behavioural deficits in latent inhibition (LI), reversal learning and 
amphetamine-induced locomotor response. Adolescent risperidone treatment (0.045 mg/kg) 
reversed Poly I:C-induced reduction in calretinin-positive cells and parvalbumin-positive neurons in 
the dentate gyrus at PND72, with partial rescue of vascular abnormalities at PND100. However, in 
both MIA and non-MIA control rats that received adolescent risperidone treatment, BrdU-positive 
cells significantly increased in adult dentate gyrus at PND72 while both number and percentage of 
cells doubled with BrdU and NeuN decreased (Piontkewitz et al. 2012).  
As adults, Poly I:C-exposed rats showed an abnormal increase in basal extracellular glutamate 
concentration in the PFC at PND55-58. This altered glutamate level was prevented by adolescent 
treatment with risperidone or paliperidone (both at 0.01 mg/kg/day from PND35 to PND56) 
(Roenker et al. 2011). The same group has reported that amphetamine-induced locomotor 
abnormalities at PND91-92 in Poly I:C rats can be ameliorated by adolescent treatment with 
risperidone or paliperidone (Richtand et al. 2011) or aripiprazole (Richtand et al. 2012).  
In a mouse MIA model, similar protective effects of APDs were also reported in another study that 
examined adolescent treatment with 3 mg/kg/day haloperidol or 15 mg/kg/day clozapine (Meyer et 
al. 2010). In Poly I:C mice, adolescent haloperidol treatment prevented the adult onset of 
behavioural deficits in LI and abnormal locomotor sensitivity to amphetamine and MK-801, but this 
treatment could not correct Poly I:C-induced PPI reductions. By contrast, adolescent clozapine 
treatment prevented the adult onset of Poly I:C-induced deficits in PPI and LI without any 
protective effect on the abnormal locomotor response to psychostimulants.  
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In summary, these studies suggest that APD treatment prevents the progression of selected 
behavioural, brain structural and neurochemical changes in adolescent MIA rodents at risk of 
developing phenotypes relevant to schizophrenia. It is still largely unknown how adolescent APD 
treatment can prevent these changes induced by MIA although APDs have been suggested to 
possess anti-inflammatory properties [see review (Drzyzga et al. 2006; Kato et al. 2011)]. However, 
a recent preclinical study has suggested that chronic APD treatment per se can alter immune 
responses, by demonstrating increased density and amoeboid reactive morphology of activated 
microglia in brain regions such as hippocampus, striatum and anterior cingulate cortex after chronic 
treatment with haloperidol and olanzapine in adult naïve rats (Cotel et al. 2015). By contrast, an 
earlier study did not find any significant change in activated microglia with chronic risperidone 
treatment in adolescent rats (Zhu et al. 2014). Therefore, it remains unanswered how APDs exert 
their immunoregulatory effects and whether the underlying neuropathological status can determine 
APDs’ action on the immune response.  
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Table 1-3 Outcomes of adolescent APD administration in animal models of neuropsychiatric disorders 
Model APD  Dose Route Duration 
Age of 
treatment 
Species, 
Strain 
and Sex 
Effects  on model 
animals 
Effects on 
corresponding 
control animals 
References 
MIA by IV 4 
mg/kg poly 
I:C on GD15 
 
RIS 0.045 or 
1.2 
mg/kg/day 
IP 
 
14 days 
 
PND34 
to 
PND47 
 
Male 
Wistar 
rats 
 
No effect on body 
weight 
Prevention of adult 
structural 
abnormalities 
(↑ventricles and 
↓hippocampus) and 
loss of LI, 
abnormal rapid 
reversal and 
hypersensitivity to 
AMPH 
No effect on body 
weight 
↓whole brain 
volume  
↓locomotion after 
saline challenge 
(Piontkewitz 
et al. 2011) 
 
RIS 0.045 
mg/kg/day  
↑BrdU-labelled DG 
cells at PND72;  
↓ cells (%) double-
labelled with BrdU 
and NeuN at 
PND72  
Prevention of poly 
I:C induced ↓ 
CR(+) cells and 
PV(+) cells 
↑BrdU-labelled DG 
cells at PND72 
↓ cells (%) double-
labelled with BrdU 
and NeuN at 
PND72 
(Piontkewitz 
et al. 2012) 
38 
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MIA by IP 8 
mg/kg poly 
I:C on GD14 
 
RIS 0.045 
mg/kg/day 
 
Drinking 
water 
35 days 
PND35 
to 
PND70 
Male and 
female 
SD rats 
Prevention by RIS 
and PAL of 
abnormal 
locomotor response 
to 1 mg/kg AMPH 
on PND91;  
No effect on 
response to 5 
mg/kg AMPH on 
PND92; 
↑locomotion on 
saline challenge at 
PND91 and ↑post-
stereotypic 
locomotion with 5 
mg/kg AMPH at 
PND92 with RIS 
exposure;  
No change with 
PAL treatment. 
(Richtand et 
al. 2011) 
PAL  0.05 
mg/kg/day 
RIS or PAL  0.01 
mg/kg/day 
(both at 
same dose) 
Drinking 
water 
21 days PND35 
to 
PND55 
Male SD 
rats 
Reversal of Poly 
I:C induced ↑ basal 
glutamate level of 
PFC at PND55-58  
No change in PFC 
basal glutamate 
with both drugs; 
↓MK-801 induced 
PFC glutamate 
levels with both 
RIS & PAL at 
PND55-58 
(Roenker et 
al. 2011) 
MIA by IV 4 
mg/kg poly 
I:C on GD15 
CLZ 7.5 mg/kg IP 14 days PND34 
to 
PND47 
Male 
Wistar 
rats 
Prevention of adult 
structural 
abnormalities 
(↑ventricles and 
↓hippocampus), 
loss of LI and 
abnormal 
sensitivity to 
AMPH at PND90-
120+ 
No effect on brain 
structures, 
locomotion and 
Morris water maze 
performance at 
PND90-120+ 
(Piontkewitz 
et al. 2009) 
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MIA by IV 4 
mg/kg/ poly 
I:C at GD15 
OLZ 1 or 2 
mg/kg 
SC 5 days PND44 
to 
PND48 
Male and 
female 
SD rats 
↑ avoidance 
suppression by 
OLZ challenge on 
PND51; 
Normal 
hippocampal 
BrdU(+) cells at 
both 2 and 9 days 
post-BrdU 
injection;   
(+)correlation 
between 
hippocampal 
BrdU(+) cells at 2 
days post-BrdU 
injection and 
change in 
avoidance 
suppression from 
PND44 to PND45;  
↑avoidance 
suppression by OLZ 
challenge on 
PND51; 
Normal 
hippocampal 
BrdU(+) cells at 
both 2 and 9 days 
post-BrdU 
injection; 
(-) correlation 
between 
hippocampal 
BrdU(+) cells at 9 
days post-BrdU 
injection and 
change in avoidance 
suppression from 
PND44 to PND51;  
(Chou et al. 
2015) 
MIA by IV 2 
mg/kg poly 
I:C on GD9 
HAL  3 mg/kg 
Drinking 
water 
30 days 
PND35 
to 
PND65 
Male and 
female 
C57BL/6 
mice 
prevention of adult 
deficits in LI and 
sensitivity to 
AMPH and 
MK801, not PPI 
sensitivity 
↓PPI, ↑locomotion 
(at baseline, after 
saline, AMPH and 
MK801 challenge) 
(Meyer et al. 
2010) 
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CLZ 15 mg/kg prevention of adult 
PPI and LI deficits; 
no effect on  
psychostimulant 
sensitivity 
minimal effect 
except ↑ startle 
response 
 
Fluox 20 mg/kg prevention of PPI 
deficits and AMPH 
sensitivity; no 
effect on LI and 
MK801 
LI deficits and 
abnormal sensitivity 
to MK801 
MIA by IP 8 
mg/kg poly 
I:C on GD14  
ARZ  0.66 
mg/kg/day 
Drinking 
water 
35 days 
PND35 
to 
PND70 
Male and 
female 
SD rats 
Correction by 
FLUOX and ARZ 
of abnormal 
locomotor response 
to 1 mg/kg AMPH 
on PND91;  
No change on 
response to novelty 
or saline or 5 mg/kg 
AMPH at PND92 
↑locomotion on 
challenge with 
saline, not with 1 
mg/kg AMPH on 
PND91; 
No effect on 
locomotor response 
to 5 mg/kg AMPH 
at PND92 
(Richtand et 
al. 2012) 
FLUOX 10 
mg/kg/day 
Bilateral 
ibotenic acid 
injection (10 
µg/µl) into 
VH on PND7 
RIS  0.045 or 
0.085 
mg/kg 
IP 22 days PND35 
to 
PND56 
Male SD 
rats 
Prevention of (1) 
↑locomotion to 
novelty by both 
doses, (2) AMPH-
induced 
hyperlocomotion 
and (3) ↑ nocturnal 
locomotion by 
0.045 mg/kg but 
not 0.085 
↑locomotor 
response to novelty  
No effect on the 
response to AMPH 
and nocturnal 
locomotion 
 
(Richtand et 
al. 2006) 
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Bilateral LPS 
injection (10 
µg/µl) into 
VH on PND7 
RIS ± 
Minocycline 
40 
mg/kg/day  
0.05 
mg/kg 
Injections 
(route not 
specified) 
14 days PND42 
to 
PND55 
Male SD 
rats 
Both regimens: 
Reversal of deficits 
in social 
interaction, NOR 
and PPI at PND58-
63 and ↑activated 
microglia in CCx, 
hippocampus, 
thalamus at 
PND65.  
No abnormal 
findings with either 
RIS or 
RIS+minocycline 
(Zhu et al. 
2014) 
Maternal 
deprivation x 
24 hours at 
PND9 
OLZ  7.5 
mg/kg/day 
Drinking 
water 
21 days PND28 
to 
PND49 
Male and 
female 
Wistar 
rats 
Correction of 
deficits in stress-
induced 
corticosterone 
response at PND70-
71 only in females; 
partial correction of 
↓CB1 receptor 
levels in MD rats; 
No effect on NOR 
and PPI 
↓discrimination 
index in NOR; 
↓plasma 
triglyceride levels 
on PND75 in both 
males and females 
 
(Llorente-
Berzal et al. 
2012) 
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10 mg/kg 
PCP SC on 
PND 2, 6, 9, 
12  
RIS 
 
0.84 
mg/kg/day 
Drinking 
water 
63 days 
 
PND35-
PND97 
 
Male 
Wistar 
rats  
 
Correction of 
↓GSH and ↓γGCL, 
↓GPx, ↓GR  in CCx 
and hippocampus  
↓GSH and ↑γGCL 
in STR 
No effect on altered 
GPx in STR and 
GR in thalamus and 
STR, SOD in all 
regions  
↑GSH and ↓GPx in 
thalamus 
↓SOD in CCx, 
Hippocampus, 
thalamus, and STR 
↓lipid peroxidation 
in Cortex 
 
(Stojković et 
al. 2012) 
Correction of ↓bone 
trabeculae in femur 
No effect on ↓spine 
bone density, ↓peri-
epididimal and 
retroperitoneal fat   
↓peri-epididimal 
and retroperitoneal 
fat 
↑weight gain at 
PND100 
(Petronijevic 
et al. 2013) 
Neontal lesion 
of dopamine 
neurons by 
intracisternal 
100 µg 6-
OHDA on 
PND3 
OLZ 5 
mg/kg/day 
Drinking 
water 
42 days  
PND45-
PND86  
Female 
SD rats 
No effect on 
supersensitive 
behavioural 
response to 
repeated PCP 
treatment    
Not studied 
(Moy et al. 
2004) 
CLZ  30 
mg/kg/day 
HAL  2.5 
mg/kg/day 
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AMPH = amphetamine; BrdU = 5-5-bromo-2'-deoxyuridine; CAR = conditioned avoidance response; CCx = cerebral cortex; CLZ = clozapine; 
FLUOX = fluoxetine; GD = gestational day; HAL = haloperidol; IP = intraperitoneal; IV = intravenous; LI = latent inhibition; LPS = 
lipopolysaccharide; MD = maternal deprivation; MIA = maternal immune activation; NOR = novel object recognition; OLZ = olanzapine; PAL = 
paliperidone; PPI = prepulse inhibition; RIS = risperidone; VEH = vehicle; VH = ventral hippocampus; (-) – negative; (+) – positive;  
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1.3.2.2 Neonatal ventral hippocampal lesion (NVHL) models 
NVHL is another widely accepted neurodevelopmental model of schizophrenia, with post-pubertal 
emergence of increased locomotor responsiveness to stress, novel environment, and amphetamine 
(Lipska et al. 1993) and deficits in PPI (Lipska et al. 1995). Treatment with risperidone in 
adolescence from PND35 to PND56 corrected amphetamine-induced hyper-locomotion at PND57 
in NVHL rats, with partial effects on novelty-induced and nocturnal locomotor abnormalities 
(Richtand et al. 2006). This effect was observed with 0.045 mg/kg risperidone, not with higher 
doses 0.85 mg/kg, suggesting that optimal dosing may be required to ameliorate a specific 
behavioural deficit.  
In another model of neonatal ventral hippocampal lesion, this time using the bacterial inflammatory 
agent LPS, adolescent treatment with risperidone (0.5 mg/kg/day from PND42 to PND55) alone or 
together with minocycline (40 mg/kg/day) via gastric gavage has been studied (Zhu et al. 2014). 
Immediately after cessation of the treatment, the behavioural deficits (impairment in social 
interaction, novel object recognition and PPI) and an increase in activated microglia in cerebral 
cortex, hippocampus and thalamus as identified by labelling with ionized calcium binding adaptor 
molecule 1 (Iba-1) were reversed in LPS-exposed animals again suggesting neuroprotective effects 
of APDs in adolescent rodents at risk of schizophrenia-related phenotypes.  
1.3.2.3 Maternal deprivation (MD) models 
Maternal deprivation (MD) has been used to model neuropsychiatric disorders including 
schizophrenia in rodents. MD for 24 hours in early postnatal period (PND9) has been shown to 
induce schizophrenia-like behavioural abnormalities such as deficits in PPI and LI, abnormal 
sensitivity to amphetamine and apomorphine (Ellenbroek and Riva 2003). The outcomes of 
adolescent APD treatment in the MD model have also been studied (Llorente-Berzal et al. 2012). In 
this study, adolescent olanzapine treatment (7.5 mg/kg/day) reversed stress-induced corticosterone 
abnormalities in MD-exposed females. This treatment induced only partial reversal of CB1 
cannabinoid receptor abnormalities in the hippocampus without any significant effect on deficits on 
novel object recognition.  
1.3.2.4 Other models of neuropsychiatric disorders 
Perinatal/neonatal treatment with phencyclidine (PCP) constitutes another animal model of 
schizophrenia with adult onset of behaviours relevant to positive symptoms and cognitive deficits 
[for example, see (Mouri et al. 2007; Wang et al. 2001)]. Neonatal PCP treatment also induces 
deficits in glutathione and antioxidant mechanisms in the cortex and the hippocampus at adulthood 
(Radonjić et al. 2010). Adolescent treatment with risperidone has been reported to reverse these 
45 
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deficits (Stojković et al. 2012). In addition to conventional APDs, adolescent treatment with novel 
APDs such as metabotropic glutamate receptor modulators has been examined in this model. 
Exposure to these agents at adolescence prevents adult onset of behavioural deficits in novel object 
recognition (Clifton et al. 2013) and PPI (Kjaerby et al. 2013). 
Neonatal lesion of dopaminergic neurons by intracisternal injection of 6-hydroxydopamine (6-
OHDA) on PND3 induced supersensitive behavioural responses to repeated PCP treatment in 
adulthood (>PND60) (Moy and Breese 2002). In this model, 6-week treatment with olanzapine, 
clozapine or haloperidol in adolescence did not correct the abnormal sensitized behavioural 
response to PCP. Only lengthy treatment with olanzapine for 10 months was able to reverse this 
sensitivity (Moy et al. 2004). 
1.3.2.5 Summary: Adolescent APD treatment in animal models 
Preclinical studies of adolescent APD treatment in rodent models of neuropsychiatric disorders 
indicate that this treatment can provide beneficial outcomes in models where brain development has 
been altered. Surprisingly, the low number of available preclinical studies has concentrated on a 
limited range of models. The outcomes of adolescent APD treatment have not been explored in 
genetic models (for example, DISC1 knock-out (KO), dysbindin KO, reelin KO and neuregulin1 
and ErB4 KO), repeated NMDA receptor antagonist models (for example, phencyclidine, 
dizocilpine or MK801), repeated amphetamine models or gestational methylazoxymethanol acetate 
(MAM) model. In the rodent models investigated, adolescent APD treatment could prevent or delay 
the adult onset of certain deficits in behaviour, such as amphetamine-induced locomotor response 
and LI, changes to brain structures such as ventricles and hippocampus, and neurochemistry such as 
reduced PFC glutamate. These preclinical findings have been supportive for the early intervention 
approach. However, recent meta-analyses of clinical trials on early intervention and the 
commentaries have challenged the roles of APDs for at risk individuals (Amos 2014; Preti et al. 
2014; Stafford et al. 2013; Van Der Gaag et al. 2013). Indeed, this is supported in some preclinical 
studies. Meyer and colleagues have also reported that early intervention with APDs in adolescence 
can ameliorate only selected behavioural deficits whilst creating adverse phenotypes in control 
animals (Meyer et al. 2010). This was discussed previously in Section 1.3.2 and is detailed in Table 
1-3. The exception was adolescent clozapine treatment which did not induce any adverse outcomes, 
at least in the studies reviewed above.  
As discussed in Section 1.2, APDs are most often prescribed to adolescents for behavioural 
symptoms while only a subset of adolescent APD prescription accounts for treatment of either early 
onset schizophrenia or at-risk mental status individuals. Therefore, it raises the question as to 
whether or not the existing models of neuropsychiatric disorders focussing on schizophrenia may 
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have face, construct or predictive validity for the spectrum of behavioural disorders that APDs are 
prescribed for in the young population. In addition to model animals of neuropsychiatric disorders, 
studies in neurobiologically intact adolescent rodents are therefore required to further investigate 
mechanisms by which APDs produce specific behavioural and/or neurochemical change. This aim 
will be more difficult to be achieved in studies of adolescent APD treatment in animal models of 
neuropsychiatric disorders, in which neurobiological changes are still not thoroughly understood. 
From the basic understanding of how a specific behavioural or neurochemical change is produced 
by APDs in an intact adolescent brain, a mechanistic insight can also be achieved as to improve 
understanding of alterations in neurodevelopmentally aberrant brains, critical windows of 
intervention and ways of early efficient amelioration.  
1.4. Conclusion 
As examined in the previous sections, preclinical studies have provided valuable insight into short- 
and long-term outcomes of adolescent APD exposure. In the case of the neurobiologically altered 
brain as encountered in animal models of neuropsychiatric disease, the administration of APDs 
during adolescence has been shown to reduce or even abolish certain disease-related 
neurobiological or behavioural phenotypes. This encouraging result provides justification for 
further studies aimed at establishing the exact neurobiological targets of such interventions. It is 
hoped that such future studies may translate directly to the clinic.  
However, APD treatment in healthy neurologically intact adolescent animals also has adverse 
behavioural, structural and neurochemical consequences both proximal to and long after chronic 
administration. Behavioural measures such as locomotion and reward behaviour, CAR and working 
memory appear to be susceptible to long-term effects of adolescent APD exposure while adverse 
metabolic outcomes have also been demonstrated in rodent studies. In particular, the adolescent 
brain appears to be more susceptible to the effects of atypical APDs, compared to the adult brain. 
Chronic exposure to atypical APDs in adolescence can induce long-standing changes in locomotor 
and reward behaviour. No such effects are observed in adult animals chronically exposed to 
atypical APDs. Given atypical APDs such as risperidone and olanzapine are most frequently 
prescribed to adolescents (Hollingworth et al. 2013; Olfson et al. 2006; Olfson et al. 2012), results 
from preclinical studies may prove informative for clinicians.  
The neural substrates behind how atypical APDs preferentially affect adolescent animals are still 
unclear. Neurochemical changes induced by adolescent atypical APD treatment as reviewed above 
have provided potential leads for the underlying mechanisms. Changes in dopaminergic, GABA-
ergic and glutamatergic systems of different brain regions have been reported mainly proximal to 
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chronic adolescent APD exposure. Recently, a few studies have reported persistent changes in these 
systems even after a lengthy washout period from chronic adolescent APD exposure (Milstein et al. 
2013; Vinish et al. 2013; Xu et al. 2015) (Figure 1-2). In particular, long-standing neurochemical 
alterations in the NAc appear to be important in mediating the reported behavioural changes. Yet, it 
is unclear which neural maturation pathway in the adolescent NAc is more sensitive to chronic 
APDs. In addition, reported changes in the NAc may perhaps represent the downstream effects of 
alterations in neural pathways in other brain regions such as the PFC or VTA. Careful examination 
of these target regions with functional measures is thus needed in addition to those techniques 
detecting quantitative change.  
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Figure 1-2 Summary of the neurochemical changes induced by chronic adolescent treatment with atypical 
APDs (risperidone, olanzapine and clozapine) in major brain regions.Short-term changes refer to the 
findings observed proximal to the atypical APD exposure (i.e. within a few days) and long-term changes to 
those after a prolonged drug-free interval (i.e. weeks).  AMPA – α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid; NAc – nucleus accumbens; NMDA – N-Methyl-D-aspartic acid; PFC – prefrontal 
cortex; VTA – ventral tegmental area. 
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Use of translationally relevant neuroimaging techniques such as functional magnetic resonance 
imaging (fMRI) and proton magnetic resonance spectroscopy in both clinical and preclinical studies 
may prove important in the future to longitudinally examine neurochemical alterations induced by 
adolescent APD treatment. These techniques have matured significantly over the recent years, 
enabling the research community to examine the trajectory of drug-induced neural activation 
changes longitudinally from adolescence (during ongoing treatment) to adulthood (after drug-free 
interval). Robust capability of these techniques to longitudinally monitor brain activity in rodents 
has been demonstrated in several studies (Moreno et al. 2006; Schobel et al. 2009; Weber et al. 
2006). Whole brain mapping of APD-induced neural changes using fMRI or pharmacological MRI 
[See reviews (Martin and Sibson 2008; Schrantee and Reneman 2014)] can reveal systems-level 
alterations. Moreover these techniques can help identify adolescent APDs’ target brain regions, 
which in animals could be complemented by other functional measures such as radioligand binding, 
microdialysis, fast scan cyclic voltammetry or electrophysiology. Behavioural tests on the same 
animals will also help identify the neural correlates of short- and long-term functional changes.  
Another area of interest may be to determine which stage of adolescence (early, mid or late (Burke 
and Miczek 2014; Tirelli et al. 2003)) is more critical to the effects of APDs. For example, studies 
examining social isolation or defeat have shown that early adolescence is a more vulnerable 
window to these environmental factors (Bingham et al. 2011; Makinodan et al. 2012). To some 
extent this is now being considered for the long-term effect of haloperidol (Soiza-Reilly and 
Azcurra 2009). Atypical APDs such as risperidone and olanzapine, the most frequently prescribed 
drugs in adolescents (Hollingworth et al. 2013; Olfson et al. 2006; Olfson et al. 2012), have not 
been examined in this regard.  
The majority of the studies reviewed here utilized male animals, perhaps due to higher rate of APD 
prescription to male patients in the clinic. Preclinical studies show that metabolic outcomes of 
adolescent APD administration are more prominent in female rats (Fell et al. 2005; Lian et al. 2015; 
Van Der Zwaal et al. 2014), in agreement with the clinical reports (Seeman 2009). However, gender 
differences in other neural outcomes of adolescent APD treatment have often been ignored in most 
studies. A recent study has elegantly demonstrated the need for inclusion of both males and 
females, by showing long-term differential behavioural outcomes in males and females treated with 
the same APD regimens in adolescence (De Santis et al. 2016). Future studies should further 
investigate sex-dependent outcomes of adolescent APD treatment.  
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Since all currently used APDs target dopamine receptors existing studies have concentrated on 
dopamine-enriched brain regions such as the striatum and the NAc. Despite evidence of important 
maturation changes in other regions such as PFC and VTA these have not been as thoroughly 
examined for adolescent APD-induced changes. Alterations in these regions may provide insight 
into reported sub-cortical neurochemical alterations or mechanisms related to cognitive 
performance influenced by adolescent exposure to APDs. Given the symptom-targeted approach of 
clinicians, polypharmacy (APD plus other psychotropic drugs such as antidepressants or 
methylphenidate) is common in children and adolescents (Rettew et al. 2015). The outcomes with 
APD polypharmacy have still to be examined in preclinical studies.  
Preclinical studies with antidepressants are instructive here. Using the same antidepressant regimen 
in adolescent and adult rodents, these studies have shown differential age-dependent long-term 
outcomes in behaviour, neurochemistry and drug-induced brain activity, demonstrating the sensitive 
targets of the adolescent brain (for example, (Homberg et al. 2011; Iñiguez et al. 2010; Karanges et 
al. 2011; Klomp et al. 2012; Oh et al. 2009)). However, to date no studies that have thoroughly and 
systematically examined chronic APD exposure treatment in adolescents and adults although the 
importance of the comparison age group in adolescent studies has been highlighted (Fuhrmann et al. 
2015; Spear 2007). Since the existing guidelines for APD prescription in adolescents are largely 
based on adult findings, comparative examination of APD treatment in adolescents and adults 
would help identify which maturation processes during adolescence are more vulnerable to APDs 
compared to adults.  
Another critical issue in preclinical adolescent studies is the choice of a clinically relevant treatment 
with APDs with regards to route, dose and duration of exposure. As can be observed from Section 
1.3 and Table 1-1 and 1-2, different studies have utilized different doses, routes and durations of 
APD treatment. Such experimental variations have impeded a direct comparison of the findings 
across different laboratories. The route of administration has been suggested to be an important 
determinant of certain behavioural and neurochemical changes. For instance, as demonstrated by 
Gao and colleagues, chronic adolescent haloperidol administration could induce differential long-
term behavioural outcomes in CAR depending on whether the treatment was delivered via 
subcutaneous injections or osmotic minipumps (Gao and Li 2014). Subcutaneous or intraperitoneal 
injections appear to induce more robust long-term effects on CAR and locomotion. However, this 
route has a drawback that sustained blood levels of APDs cannot be achieved due to the rapid 
metabolism of rodents (Kapur et al. 2003) and that handling and restraint can induce stress in the 
animals. Studies examining acute single dose treatment in adolescent animals may have little 
translational value to the clinic since the clinical use of APDs in children and adolescents is seldom 
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of this short duration. Given that the duration of APD prescription in adolescents and children is on 
an increasing trend (Kalverdijk et al. 2008), it may be more translationally relevant to examine 
chronic or subchronic administration in preclinical studies. The majority of preclinical studies 
examining the outcomes of APD treatment have determined what dose is clinically relevant based 
on DA receptor occupancy as advocated by Kapur and colleagues (Kapur et al. 2003). Given the 
diversity of the disorders that APDs are prescribed for and given the nature of symptom-targeted 
treatment in adolescents, the dosing approach based on DA receptor occupancy may not be the most 
optimal. To mimic the clinical scenario of dose titration to response of the patients, a possible 
optimal approach can be to administer a range of doses of APDs, instead of one dose, to adolescent 
rodents and determine the outcomes. As discussed in details elsewhere (Spear 2000; 2007), 
pharmacokinetic factors such as age-related differences in drug metabolism and their possible 
contribution to the observed outcomes should also be taken into consideration in adolescent APD 
studies. For example, adolescent mice have been reported to have lower levels of cocaine in plasma 
and brain than adult mice following acute single dose administration of the same dose (20 mg/kg); 
however, this difference in plasma and brain levels was not observed following chronic treatment 
(McCarthy et al. 2004), suggesting a role of chronicity of treatment in determining 
pharmacokinetics or metabolic adaptation. To the best of my knowledge, no study to date has 
compared pharmacokinetics in adolescents and adults with both acute and chronic administration of 
APDs. Measurement of achieved plasma and brain drug concentration and dopamine receptor 
occupancy during ongoing treatment may help address this issue. Therefore, a careful consideration 
to these factors must be undertaken in preclinical studies of chronic adolescent APD administration.  
In conclusion, investigations of APD treatment in adolescent rodents may indeed prove useful in 
understanding the neurobiology behind this early treatment. Preclinical studies have provided 
evidence that, in neurodevelopmentally intact brains, chronic adolescent APD treatment may have a 
long-lasting impact on behaviour, brain structure and neurotransmission. Future studies should be 
designed to understand how dosage, chronicity and critical windows of adolescent APD 
administration can contribute to long-term neurobiological outcomes including secondary adverse 
effects. Studies using newer advanced imaging capabilities may allow us to understand the 
trajectory of APD-induced alterations in adolescent brain maturation. Future studies will thus 
expand our scientific knowledge of APD administration to adolescents and sensitive targets of the 
adolescent brain. It is imperative that we understand the effects of APDs on the adolescent brain 
given the increasing APD use in this age group.  
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1.5. Aims and significance of this thesis 
The main goal of this thesis was to identify structural, molecular and behavioural targets within the 
adolescent brain which can be altered by chronic APD exposure. The main focus was on risperidone 
which is the most commonly prescribed atypical APD prescribed to adolescents although I have 
also examined other APD namely clozapine and haloperidol. Here I have examined risperidone 
treatment in neurodevelopmentally normal adolescent outbred rats and compared my findings with 
the same treatment in adults.  
Specific aims of my thesis are as follows.  
(1) To identify short-term behavioural changes selective to adolescent APD treatment during 
chronic treatment and long-term behavioural alterations after a lengthy drug-free interval in 
comparison with the same treatment in adults.  
(2) To examine short-term neurochemical changes proximal to (at 24 hours after) adolescent APD 
treatment and long-term neurochemical alterations after a drug-free interval in comparison with the 
same regimen in adults 
(3) To examine short-term neurometabolic changes during chronic treatment and long-term 
neurometabolic alterations after a drug-free interval in adolescents in comparison with the same 
exposure in adults using 1H MRS 
(4) To examine long-term brain structural changes with risperidone treatment in adolescence in 
comparison with the same treatment in adulthood, using MRI 
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2.1. Subjects 
Male Sprague Dawley (SD) rats were used in all experiments. All procedures were approved by the 
University of Queensland Animal Ethics Committee and followed the guidelines of the National 
Health and Medical Research Council of Australia. Rats were pair-housed in Macrolon cages (390 
mm x 235 mm x 160 mm) with Sani chip bedding (Able Scientific) and wire lids in a temperature 
(21±1 °C) and lighting (lights on at 06:00 h and off at 18:00 h) controlled room. All rats were given 
ad libitum access to food and water throughout the whole experiment. Behavioural training and 
testing were conducted during the light phase of the diurnal cycle.  
2.2. Preparation of drugs 
All APDs used (haloperidol, clozapine and risperidone (Sigma Aldrich)) were dissolved in 1% 
acetic acid in water and further diluted in sterile 0.9% normal saline (pH adjusted to 5.7–5.9), to 
make up to desired volume. Drug concentrations were spectrophotometrically confirmed, using UV 
absorbance with a known molar absorption coefficient of each APD. The vehicle solution (VEH) 
was 1% acetic acid diluted with 0.9% normal saline at pH 5.7–5.9. APDs and vehicle were 
administered to the rats through once-daily intraperitoneal (IP) (1 ml/kg) for 21/22 days except 
haloperidol which was administered through subcutaneous (SC) injection. Rats were weighed daily 
approximately 30 min before drug administration. Approximately 60–80% D2 receptor occupancy 
is required in order to acutely impair CAR behaviour (Natesan et al. 2007; Wadenberg et al. 2001b). 
The doses of APDs in this study were chosen to achieve such a level of clinically relevant D2 
occupancy in SD rats (Kapur et al. 2003; Natesan et al. 2008; Natesan et al. 2006a) and disrupt 
avoidance responses (Natesan et al. 2008; Natesan et al. 2006a; Wadenberg et al. 2001b) (Also see 
Chapter 3). Intermittent delivery via IP/SC injection was chosen instead of continuous delivery via 
osmotic minipumps or oral administration as the delivery route for the following reasons: (1) 
Delivery through osmotic minipums has been reported to induce breakthrough dopamine 
supersensitivity and treatment failure during ongoing treatment (Samaha et al. 2007). (2) SC 
injections have been reported to induce more robust effects on CAR suppression than osmotic 
minipumps in both adolescent (Gao and Li 2014) and adult (Samaha et al. 2008) rats. (3) Oral 
administration may have unpredictable absorption and therefore unstable pharmacokinetic profile.     
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Table 2-1 Molar absorption coefficients (ε) and wavelengths (λ) of absorption of APDs used 
APD 
Lambda max (λ)  
(nm) 
Epsilon (ε)  
(M-1 cm-1) 
Solvent Reference source 
Risperidone 238 nm  15300  0.1M HCl Courtesy of Jansen pharmaceutica   
Clozapine 297 nm  10500 Ethanol Merck Index online 
Haloperidol  247 nm 13300 1.0M HCl Merck Index online 
 
2.3. Behavioural tests 
2.3.1. Conditioned avoidance responding (CAR) 
2.3.1.1 CAR apparatus 
Rats were trained and tested in eight identical two-way shuttle boxes, which were individually 
housed in sound-attenuating cubicles and equipped with 16 photobeam sensors, automatic guillotine 
door, tone generators and stainless steel grid floor (MedAssociates, USA). The grid floor was 
connected to aversive stimulus generator to give a mild footshock (0.6 mA) as the unconditioned 
stimulus (US). The chambers and shock generator were controlled by MED-PC IV software in a 
computer. A background noise of approximately 68 dB was provided from the fan in the sound-
attenuating chamber. 
2.3.1.2 CAR training and testing 
CAR training was conducted with 40 continuous trials per session per day for 5/7 consecutive days. 
Following habituation to the CAR boxes for 10 min, each trial began with the presentation of the 
conditioned stimulus (CS) (80 dB white noise) generated by the centrally located speaker. 
Movement of the rat into the other chamber within 10 seconds (s) of CS presentation terminated the 
CS and an avoidance response was recorded. If the rat did not move into the other chamber during 
the first 10 s of CS presentation, CS was accompanied by US for another 10 s. Movement during 
this next 10 s of CS-US presentation terminated both CS and US and an escape response was 
recorded. If the rat failed to make a crossing during the entire 20 s period, both CS and US were 
terminated and an escape failure was recorded. The inter-trial interval varied randomly from 20 to 
40 seconds (Natesan et al. 2006b; Wadenberg et al. 2001b). The avoidance performance in each rat 
was calculated as the percentage of avoidances (% avoidance) out of the total trials in the session 
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(either 20 or 40 trials depending on experiment). Escape failure response was also expressed 
similarly as a percentage. Motor activity was recorded as the number of chamber crossings.  
In CAR tests, rats were first injected with APD and avoidance response was examined in 20/40 CS-
US trials at 20 min, 90 min, 240 min and 24 hr or 60 min after injection depending on the 
experiment.   
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(a)          (b) 
   
Figure 2-1 CAR chambers used in my study (a) Eight sound-attenuating chambers, aversive stimulus generators and the controlling computer were shown. (b) A 
two-way shuttle box inside a sound-attenuating chamber was shown.  
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2.3.2. Catalepsy test 
2.3.2.1 Bar apparatus 
Horizontal bar test to examine risperidone-induced cataleptic response was performed using 
catalepsy chamber which was built in-house (35 cm x 20 cm x 25 cm). This chamber had a grid 
floor and a horizontal bar (1 cm in diameter) with adjustable height (10 cm for adolescents and 13 
cm for adults) (Figure 2-1).  
2.3.2.2 Procedure 
One hour after injection with vehicle or risperidone, rats were individually placed into bar 
apparatus. The forepaws of rats were gently placed on the horizontal bar and the time rats stayed on 
the bar was video-recorded. If rats voluntarily removed their paws from the bar, they were placed 
back on to the bar after a waiting time of 10 seconds. Each rat was examined for a maximum 
duration of 3 minutes (180 s) or a maximum of 12 trials of placing the forepaws on the bar. The 
purpose of 12 trials as opposed to single trial determination was to minimize the variability in 
behavioural response induced by handling stress (Chinen and Frussa-Filho 1999; Wiley 2008).  
Videos were coded and analysed in Media Player Classic Home video viewer. The analyst was 
blind to treatment. The duration rats stayed with both of their forepaws on the bar (time on-bar) was 
noted in millisecond resolution. The average duration of time on-bar out of 12 trials in each test was 
calculated for each animal. 
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Figure 2-2 Catalepsy chamber and video camera used in my study 
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2.3.3. Open field test (OFT) 
2.3.3.1 OFT apparatus 
OFT was performed in four black plexiglass chambers (45 cm x 45 cm x 30 cm) which were 
equipped with infrared beam transmitters and receivers. The locomotor data collected from infrared 
beam units were transmitted to activity monitor and collection software (Activity Monitor, 
MedAssociates).  
2.3.3.2 Procedure for OFT 
Immediately after the completion of catalepsy test (approximately 65 minutes after injection with 
risperidone or vehicle), rats were placed in OFT chambers. Locomotor activity was recorded for 30 
minutes. Total distance travelled (cm), total ambulatory count and total vertical count were 
recorded.  
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Figure 2-3 Locomotor activity boxes equipped with infrared beam detectors and the controlling computer 
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2.4. High performance liquid chromatography (HPLC) 
After completion of behavioural tests, rats were sacrificed with an overdose of pentobarbitone 
sodium (Lethabarb, Virbac) and striatal and accumbal tissues (Paxinos and Watson 2005) collected 
and immediately frozen in liquid nitrogen and store at -80˚C until use. Brain tissues were quickly 
weighed (wet weight) and homogenised on ice in a minimum volume of 0.1 ml of 0.1M perchloric 
acid and 50 mg/ml deoxyepinephrine (internal standard for catecholamines), using an ultrasonicator 
probe (Vibra-Cell, Sonics & Materials, Inc. CT.). After centrifugation at 13,000 rpm for 5 minutes, 
supernatant from each sample was collected and filtered through 0.2 µm nylon filter. Next, 10 µl of 
each sample was injected into a HPLC system and dopamine, serotonin, noradrenaline and their 
metabolites (dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA), 3-methoxytyrarmine 
(3-MT) and 5-hydroxyindoleacetic acid (5-HIAA)) measured. The HPLC system consisted of an 
degasser, autosampler and an isocratic HPLC pump (Model 1100, Agilent Technologies, Inc. CA), 
a Sunfire C18 column, 4.6 mm x 150 mm, 5 um; (Waters Corporation, MA) and a Coulochem III 
(ESA Laboratories, Inc. MA) electrochemical detector. The mobile phase consisted of a 12% 
acetonitrile / 75mM potassium dihydrogen phosphate buffer containing 25uM EDTA and 1.7mM 
octane sulfonic acid adjusted to pH 4.13 with phosphoric acid. Flow rate was 1.2ml/min. Detector 
settings were as follows: conditioning cell (Model 5020, ESA Laboratories, Inc. MA) at +350mV; 
analytical cell (Model 5014B, ESA Laboratories, Inc. MA) with the first and second electrodes 
maintained at -150 and +250 mV, respectively. Data were processed offline with Chemstation 
software (Rev B.01.03, Agilent Technologies, Inc. CA). The amount of catecholamines and their 
metabolites were expressed as pictogram per milligram (pg/mg) wet tissue, after correction for the 
dilution.  
2.5. Plasma corticosterone assay 
Saphenous blood samples were collected in EDTA tubes from rats under mild restraint. Blood 
samples were centrifuged at 8000 rpm for 10 min at 4˚C and plasma collected and stored at -20˚C 
until use. Plasma corticosterone levels were determined by an in-house liquid chromatography 
tandem mass spectroscopy (LC-MS/MS) assay. The system consisted of a Shimadzu Nexera® 
UPLC system with a Phenomenex Kinetex® 1.7u XB-C18 100Å (50x2.1mm) column attached to an 
ABSciex QTrap-5500® triple-quadrupole mass spectrometer. Briefly, in 96-well plates, 20 µl of 
plasma samples and standards were mixed with 10 µl each of internal standards (500 nM 
corticosterone-[²H4] in 1:1 acetonitrile : water) and 10 µl of 1M ZnSO4 and 600 µl of extraction 
solvents (9:1 ethyl-acetate : acetonitrile). After centrifugation at 500 rpm for 20 min, 500 µl each of 
sample mixture was transferred to another clean 96-well plate, evaporated to dryness at 55˚C for 20 
min in the vacuum concentrator and reconstituted in 50 µl of 1:1 methanol : water. 20 µl sample 
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extract was then injected in a 384-well plate and assayed overnight. A gradient elution method at 
0.5mL/min was used with the mobile phases A= 0.1% aqueous formic acid and B= 0.1% formic 
acid in 9:1 acetonitrile : water. The mixture was increased from 50%B to 95%B over 2 min, held at 
95%B for 0.5 min and then returned to 50%B for 1 min.  This resulted in a retention time of 1.2 
min. The mass-spectrometer detection was by way of positive-mode, scheduled multiple reaction 
monitoring with electrospray ionisation. The mass spectrometer parameters were as follows: for 
corticosterone: m/z= 247.1 → 329.1, declustering potential (DP)=100V, exit potential (CXP)=12, 
collision energy (CE)= 23V; for corticosterone-[2H4]: m/z= 351.1 → 333.0, DP=100, CXP=15, 
CE=23. Calibration standards over the range 1000 – 10nM and quality controls at three levels were 
prepared in stripped plasma. Differential quality control samples were prepared by spiking rat 
serum with 75nM of corticosterone. A ±15% acceptance criterion was applied to all quality 
controls. 
2.6. Real-time polymerase chain reaction (RT-PCR) 
After completion of behavioural tests, rats were euthanised with an overdose of pentobarbitone 
sodium (Lethabarb, Virbac). Brains were rapidly dissected on ice and either NAc (both core and 
shell) or striatum (left hemisphere) (Paxions and Watson 2005) collected in RNALater solution 
(Invitrogen), kept at 4°C overnight and stored at -80°C until RNA was extracted. Briefly, total RNA 
was extracted from each tissue sample using QIAzol and RNeasy Mini Kit (Qiagen, Australia). For 
each sample, 0.9/1.0 µg of RNA per 21 μl reaction was reverse-transcribed to cDNA with 
SuperScript IV First-Strand Synthesis System (Invitrogen). RT-PCR was performed in 12 µl 
reaction volume on a Roche LightCycler 480 (Roche Diagnostics, Australia), using SYBR Green in 
384-well plates. The PCR conditions were as follows: denaturation at 95°C for 5 min followed by 
40 cycles of amplification (95°C for 10 s, then 60°C for 20s, then 72°C for 20 s). Relative 
expression of the target genes (threshold cycle, Ct) was normalized to that of endogenous control, 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (∆Ct) (Schmittgen and Livak 2008). The 
primer sequences of the target genes (dopaminergic, serotonergic and GABAergic markers) in this 
study are listed in the table in Appendix A. All PCR experiments were performed twice. Gene 
expression data was only considered if significant changes were observed in both experiments. A 
universal control sample was included in each PCR plate to enable across-age group comparison of 
2-∆Ct values. 
2.7. Structural magnetic resonance imaging (MRI) 
MRI scans were performed either longitudinally (PND36, PND57, PND79 and PND120 in 
Experiment 1A, Chapter 3) or cross-sectionally (PND120 in Experiment 1B, Chapter 3). Rats were 
anaesthetized with isoflurane (5% for induction and 1.5–1.8% for maintenance with 1.5 L/min 
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oxygen). The respiratory rate was maintained at 45-60 breaths per minute by adjusting the level of 
isoflurane as required and the body temperature at 37°C with circulating warm water through the 
animal bed. Coronal two-dimensional T2-weighted fast spin echo images were acquired at 
horizontal bore Bruker Biospec 9.4Tesla MRI scanner with Paravision 5.1/6.0 (Bruker, Germany) 
using with rapid acquisition with relaxation enhancement sequence (RARE) with the following 
parameters: effective echo time (TE) – 40 ms; repetition time (TR) – 4000 ms; field of view (FOV) 
– 35 mm x 35 mm; matrix – 256 x 256; in-plane resolution – 0.14 x 0.14 mm; slice thickness – 500 
μm; number of slices – 38; RARE factor – 8; number of averages – 10; scan time – 21 minutes. 
MRI images were coded and the analyst blinded to treatment. A manual segmentation method in the 
open-source OSIRIX software by a single rater was used to identify the regions of interest (ROI) in 
both hemispheres. Our laboratory has good experience with this method to detect robust changes in 
brain volumes in animal model of schizophrenia (Harms et al. 2012). ROIs analysed included whole 
brain, cerebral cortex, prefrontal cortex, striatum, hippocampus and lateral ventricles using well-
established criteria from a rat brain atlas (Paxinos and Watson 2005) and following published 
methods (Piontkewitz et al. 2011; Vernon et al. 2011). Volume of each ROI was computed by 
summation of the areas from all respective slices multiplied by slice thickness from both 
hemispheres. Statistical analysis was performed on regional volumes with or without correction for 
total brain volumes.  
2.8. Proton magnetic resonance spectroscopy (1H MRS) 
2.8.1. Data acquisition 
1HMRS data were acquired together with structural MRI data in Chapter 3. In Chapter 5, only 
1HMRS data were acquired given the focus on brain metabolites in this Chapter. After induction of 
anaesthesia with 5% isoflurane, rats were mounted on MRI-compatible animal bed. Respiratory rate 
was maintained at 45-60 breaths per min by adjusting the level of isoflurane as required (1.5-1.7%) 
with an O2 flow rate at 1.2 L/min and body temperature at 37°C with circulating warm water 
through the animal bed.  
T2-weighted axial and sagittal localizer images were acquired using the following TurboRARE 
sequence (TE – 40 ms; TR – 3000 ms; average – 2; repetition – 1; RARE factor – 8; matrix – 256 x 
128 for sagittal and 256 x 256 for axial; FOV – 35 mm x 20 mm; 23 x 1 mm slices for axial and 16 
x 1 mm slices for sagittal). A voxel of interest (6 mm x 2 mm x 2 mm for adults and 5.5 mm x 1.8 
mm x 2 mm for adolescents (PND36)) was placed bilaterally over the NAc (Figure 2-4) following 
the published literature (Xu et al. 2015). The NAc was chosen for 1HMRS given the reported role of 
this brain region in behavioural tests used in the current thesis, namely CAR (Wadenberg et al. 
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1990a) and locomotion (Kelly et al. 1975), and given reported long-term changes in GABA and 
glutamate in this brain region with adolescent olanzapine treatment (Xu et al. 2015). Adjustment of 
first-order, second-order and third-order shims over the voxel was performed with MAPSHIM 
procedure. A non-suppressed reference water signal from the voxel was obtained for assessment of 
linewidths and as a metabolite concentration reference. A point-resolved spectroscopy sequence 
(PRESS) was used to obtain water-suppressed metabolite spectra from the NAc with the following 
parameters: TE – 9.9 ms; TR – 2500 ms; averages – 356; repetition – 1/15. Chemical shift selective 
(CHESS) method was used for suppression of the water signal. PRESS was chosen over MEGA-
PRESS given that PRESS allows detection of multiple metabolites of interest including N-
acetylasparate (NAA), glutamate and GABA whereas MEGA-PRESS can only detect GABA. 1024 
complex points were collected over a spectral/sweep width of 5597.0 Hz/14 ppm and a final 50% 
linewidth of 13.09  0.13 Hz or 0.032  0.0003 ppm.  
2.8.2. Data analysis 
1H MRS data were processed on TOPSPIN and analysed in Linear Combination of Model spectra 
(LCModel version 6.3-1J) software (Provencher 1993), using the reference basis sets with the same 
data acquisition parameter.  Figure 2-5 shows an example of LCModel fitting of 1H MRS data in 
my study.  
Given that Cramer-Rao Lower Bounds (CRLB) or %SD ≤ 20 has been reported as acceptable level 
of quantification reliability (Provencher 2001), metabolites with CRLB or %SD >20 were rejected 
from the analysis unless otherwise described. The concentration of individual metabolites was 
expressed as a ratio to total creatine (Cr + PCr) following the guidelines in LCModel manual. 
Calculation of ‘absolute metabolite concentration’ with water-scaling was not performed since this 
approach needs large uncertain corrections for water concentration and relaxation, and possible 
instrumental attenuation of unsuppressed water signal according to LCModel manual.  
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Figure 2-4 Bilateral localization of voxel over nucleus accumbens for both (a) coronal and (b) axial sections. 
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Figure 2-5 An example of LCModel fitting of 1H MRS data.The red line of the plot indicates LCModel fit of 
the data, the thin black line the baseline and the upper plot the residuals i.e. data minus the fit to the data. 
The columns on the right indicate the metabolites and their concentration. The metabolites with %SD 
(Cramer-Rao Lower Bounds (CRLB)) below 15 are highlighted in blue. In MISCELLANEOUS OUTPUT in 
the lower part of the column, full width at half-maximum (FWHM) is also indicated. Data with %SD >20 
and FWHM >0.1 ppm are rejected from analysis. tCr = total creatine (Cr + PCr). 
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3.1. Introduction 
As discussed in Chapter 1, studies in both humans and rodents have shown that important 
maturation processes are occurring during adolescent brain development. Such data has led to the 
proposal that adolescence can be conceived as a period of vulnerability to the onset of psychiatric 
disorders (Paus et al. 2008). In addition, it has been hypothesized that psychopharmacological 
agents, when given in adolescence, can alter the trajectory of brain maturation, subsequently 
inducing persistent changes in neural function in adulthood (Andersen 2003; Andersen and Navalta 
2004; Fuhrmann et al. 2015; Spear 2007). 
Exposure to antipsychotic drugs (APDs) in adolescence is important in this regard given a dramatic 
rise in prescription of these drugs to adolescents over the past twenty years. APDs target multiple 
neurotransmitter systems (for example, see (Kapur et al. 2000; Lieberman et al. 2008)) and can 
induce structural alterations in certain brain regions (Gur et al. 1998; Lieberman et al. 2005). Given 
that neural systems targeted by APDs are still maturing in adolescence, it seems plausible that such 
systems may be permanently affected by adolescent APD exposure. However, the long-term effects 
of chronic APD treatment on immature adolescent brains are poorly understood. This state of affairs 
is receiving increasing attention and concerns continue to be raised regarding the safety of 
adolescent APD use (Arango et al. 2004; Ben Amor 2012; Correll 2008; McKinney and Renk 
2011). Comprehensive preclinical studies will help to both clarify the long-term neurobiological 
consequences of such exposures and begin to address whether such concerns are warranted (Vitiello 
et al. 2009).  
In preclinical studies, conditioned avoidance response (CAR) is a well-validated behavioural test 
widely used for screening of pharmacological compounds with APD potential (Wadenberg 2010; 
Wadenberg and Hicks 1999). Adolescent APD treatment suppresses CAR both during 
chronic/repeated treatment and after a drug-free interval of 2-3 days or several weeks. Like 
psychomimetics, APDs would also appear to produce drug sensitisation when assessing CAR. 
Treatment in adolescence with both atypical APDs such as olanzapine (Qiao et al. 2013), 
risperidone (Qiao et al. 2014a) and asenapine (Gao and Li 2013) and typical APDs i.e. haloperidol 
(Gao and Li 2014) have all been shown to induce a sensitization-like CAR suppression response to 
a later challenge dose of these same APDs after drug washout. Practically this is observed as a 
higher suppression of avoidance response by the challenge dose in rats with prior exposure to APD 
compared to APD-naïve rats. This sensitized response has been reported at both short term i.e. 
approximately after 2 days of drug-free interval and at long term i.e. after 25-30 days of drug 
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washout. By contrast, adolescent clozapine treatment has been shown to induce tolerance i.e. lower 
suppression of avoidance by a challenge dose in rats with prior clozapine treatment compared to 
that seen in clozapine-naïve rats (Qiao et al. 2013). However, in these studies, the duration of 
treatment with the atypical APDs was brief, being only for 5 days (the aforementioned study with 
haloperidol was for 28 days). Therefore the duration of treatment may not mimic the clinical 
scenario of a more chronic APD exposure in adolescents. In addition, given a lack of a comparison 
age group in these studies, it is unknown whether the behavioural changes in the CAR paradigm 
were selective to adolescent treatment. Despite the reports in the literature that sensitization-like 
response to a challenge dose of APD can develop with adult APD treatment (for example, (Gao and 
Li 2013; Mead and Li 2010)), experimental discrepancies such as different ages at the time of CAR 
training and testing have impeded direct comparison between adolescent and adult studies.  
The underlying neural mechanism for how APDs induce sensitization in the CAR paradigm 
following adolescent treatment is still unknown. In adult APD treatment, an increase in D2 receptor 
neurotransmission has been suggested as a possible mechanism at least for sensitized CAR response 
(Gao and Li 2013). These investigators have demonstrated an increased locomotor response to 
quinpirole, a D2 agonist, in rats with sensitized CAR suppression following adult risperidone 
treatment. However, this mechanism appears to be less likely in the sensitized CAR response 
following adolescent risperidone treatment since no significant increase in quinpirole-induced 
locomotor response was observed in adolescents (Qiao et al. 2014a). In addition, it is still unknown 
which major brain region is responsible for sensitized responses in the CAR. The NAc has been 
reported to play a central role in the maintenance of avoidance response (McCullough et al. 1993; 
Oleson et al. 2012). Intra-NAc injection of APD has also been reported to induce suppression of 
avoidance in a similar manner to systemic injection of APD (Wadenberg et al. 1990b). Therefore, 
the NAc seems the likely brain region. However no study to date has thoroughly examined the 
neurochemical correlates of such behaviour in the adolescent or adult NAc after APD treatment.  
Given reports of brain structural changes with APD treatment in clinical studies (Gur et al. 1998; 
Ho et al. 2011; Lieberman et al. 2005) and preclinical studies in macaque monkeys (Dorph-Petersen 
et al. 2005) and in adult rats (Vernon et al. 2011), it is plausible that early exposure to APDs may 
also affect adolescent brain structural maturation. This hypothesis has been supported by a 
preclinical study which showed a reduction in whole brain volume in adulthood following 
adolescent risperidone treatment in ‘neurodevelopmentally normal’ rats (Piontkewitz et al. 2011). 
However, this study did not examine important brain structures such as PFC and striatum. Therefore 
further studies are still required to further investigate APD-induced structural changes.   
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The aim of the current study was to test the hypothesis that chronic adolescent exposure to APDs, 
especially risperidone, the atypical APD most commonly prescribed to adolescents (Hollingworth et 
al. 2013; Olfson et al. 2012; Ronsley et al. 2013), can induce long-lasting changes in brain structure, 
function and neurochemistry when compared with the same exposure in adults. I compared chronic 
APD treatment in adolescents and adults with regards to changes in (1) the behaviour in the CAR 
paradigm, (2) brain structures and (3) neurochemistry which may possibly underlie the behavioural 
change. I first established that the selected doses and routes of three common APDs (risperidone, 
clozapine and haloperidol) were behaviourally active in the CAR paradigm in adults. Next I 
screened these three APDs for their short- and long-term effects on the CAR and brain structures in 
adolescents, in comparison with adults. Following up on the behavioural finding, I examined 
risperidone treatment in adolescents and adults in greater detail. 
3.2. Pilot experiment: Examination of acute single doses of APDs in adults 
The aims of this pilot experiment were: 
(1) To determine the dose and route of selected APDs and  
(2) To choose the optimal time point for examination of APD-induced suppression of avoidance 
response.  
3.2.1. Materials and methods 
3.2.1.1 Subjects 
Adult male SD rats (12-15 weeks old) were utilized in this experiment. Rats were pair-housed in 
Macrolon cages with Sani chip bedding and wire lids in a temperature (21 ± 1 °C) and lighting 
(lights on at 06:00 h and off at 18:00 h) controlled room. All rats were given ad libitum access to 
food and water throughout the whole experiment. Behavioural training and testing were conducted 
during the light phase of the diurnal cycle.  
3.2.1.2 CAR training 
Rats (n = 26) were trained in 40 CS-US trials per session per day for 5 consecutive days. At the end 
of the training, 20 rats of 26 (77% success rate) reaching the criteria of 70% avoidance were 
selected and assigned to receive a single injection of vehicle, haloperidol, risperidone, or clozapine.  
3.2.1.3 CAR test with single dose administration of APDs 
One day after CAR training, intact CAR was confirmed in all rats prior to injection (0 min test). 
Next, rats were injected with either vehicle (IP, n = 10), 0.05 mg/kg haloperidol (SC, n = 4), 1.3 
mg/kg risperidone (IP, n = 6) or 15 mg/kg clozapine (IP, n = 4) and drug response was examined in 
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another 4 sessions of 20 CS-US trials at 20 min, 90 min, 240 min and 24 hours respectively after the 
injection. Avoidance, escape failures and crossings were recorded in each CAR test session. 
3.2.1.4 Statistical analysis 
Data were analysed with repeated measures one-way ANOVA with Dunnett’s post hoc tests. 
Statistical significance was defined as p < 0.05. Avoidance and chamber crossing data were 
expressed as mean  SEM. Escape failure data were expressed as median  semi-interquartile 
range.  
3.2.2. Results 
Significant suppression of avoidance response by all three APDs was observed between 20 and 90 
min after injection (Figure 3-1). By 240 min, the drug effect had started to wear off and by 24 hours 
after injection, rats had regained their pre-APD avoidance levels. Repeated measures ANOVA 
confirmed the finding with a significant main effect of time (F4,80 = 34.3, p < 0.001), drug (F3,20 = 
62.4, p < 0.001) and time x drug interaction (F12,80 = 7.2, p < 0.001). Post-hoc tests further 
confirmed the significant suppression of CAR by all three APDs at 20 and 90 min after injection 
(all p < 0.05). 
Chamber crossings (Figure 3-2) were also suppressed by APDs (significant main effect of time 
(F4,80= 6.71, p < 0.001) and time x drug interaction (F12,80 = 2.38, p = 0.011) but no significant effect 
of drug (F3,20 = 2.394, p = 0.099); repeated measures one-way ANOVA). Further analysis showed 
that crossings were significantly lowered by both clozapine and risperidone, but not by haloperidol, 
at 90 minutes after injection (both p < 0.05). 
As shown in Table 3-1, the three APDs did not significantly induce escape failures at any time point 
examined (significant main effect of time (F4,80 = 3.158, p = 0.018) but no main effect of drug (F3,20 
= 1.023) or time x drug interaction (F12,80 = 1.093), both p >0.05). 
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Figure 3-1 Avoidance suppression by acute administration of single doses of risperidone, clozapine and 
haloperidol. Error bars – mean  SEM. n=10 for VEH, n = 6 for RIS, n = 4 each for HAL and CLZ. * p< 
0.05 VEH vs all APDs. VEH – vehicle; RIS – risperidone; HAL – haloperidol; CLZ – clozapine   
 
Figure 3-2 Suppression of chamber crossings by acute administration of single doses of risperidone and 
clozapine, but not haloperidol. Error bars – mean  SEM. n=10 for VEH, n = 6 for RIS, n = 4 each for HAL 
and CLZ. * p < 0.05 for both VEH vs RIS and VEH vs CLZ. VEH – vehicle; RIS – risperidone; HAL – 
haloperidol; CLZ – clozapine 
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Table 3-1 No significant increase in escape failures with acute administration of single dose of APDs in 
adults 
APD 
%Escape failures 
0 min  20 min  90 min  240 min  24 h 
VEH 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
RIS 0 ± 0 0 ± 1.88 0 ± 0 0 ± 0 0 ± 0 
CLZ 0 ± 0 1.25 ± 7.81 0 ± 10.94 0 ± 1.88 0 ± 0 
HAL 0 ± 0 0 ± 1.25 2.5 ± 2.5 0 ± 1.88 0 ± 0 
Data are expressed as median ± semi-interquartile interval. n=10 for VEH, n = 6 for RIS, n = 4 
each for HAL and CLZ.  VEH – vehicle; RIS – risperidone; HAL – haloperidol; CLZ – clozapine 
3.2.3. Discussion 
In this pilot experiment, I established that the selected dose of each APD disrupted the avoidance 
response in adult rats with the chosen route of administration. Suppression of avoidance was 
maximal between 20 and 90 minutes after injection, accompanied by suppression of chamber 
crossings. By 240 minutes, rats returned to their pre-drug avoidance level. This reflects rapid 
metabolism of APDs in rodents consistent with the reported half-life of APDs being around 1-2 
hours (Kapur et al. 2003).  
APDs are known to disrupt CAR at doses occupying 60-80% of striatal dopamine D2 receptors 
(Wadenberg et al. 2000; Wadenberg et al. 2001b). This level of D2 occupancy is also thought to be 
optimal for antipsychotic drug action (Kapur et al. 2000). At the doses chosen in my experiment 
(1.3 mg/kg for risperidone, 15 mg/kg for clozapine and 0.05 mg/kg for haloperidol), this level of 
dopamine D2 receptor occupancy would appear to have been achieved (Kapur et al. 2003; Natesan 
et al. 2007; Wadenberg et al. 2001b). Higher rates of D2 receptor occupancy are associated with 
extra-pyramidal side-effects (Natesan et al. 2007; 2008; Natesan et al. 2006a; Wadenberg et al. 
2001b). Here I showed that these doses of APDs disrupted avoidance response without inducing 
any significant increase in escape failures. Therefore these doses would not appear to be achieving 
> 80 D2 occupancy rates.  
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These data largely replicated the reported findings in the literature of the effects of acute APDs’ 
action on CAR (Natesan et al. 2008; Natesan et al. 2006a; Wadenberg et al. 2001b), thus confirming 
the reliability of the CAR paradigm in detecting APD action on the brain (Wadenberg 2010; 
Wadenberg and Hicks 1999). 
In summary, I confirmed that the chosen doses and routes of APD administration could disrupt 
avoidance response in adult rats. Based on these findings the time to examine CAR in Experiment 1 
was determined to be 1 hour after injection in subsequent experiments. 
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3.3. Experiment 1: Comparative examination of chronic APD treatment in 
adolescent and adult rats 
3.3.1. Experiment 1A: Screening of three APDs for behavioural and structural outcomes in 
adolescents and adults 
In Experiment 1A, chronic 21-day treatment of three well-known APDs (risperidone, clozapine and 
haloperidol) was examined in adolescents in comparison with the same treatment regimens in 
adults. APD-induced changes in CAR and in brain structures during ongoing treatment (short-term) 
and after a drug-free interval (long-term) in adolescents were compared in those at older age 
windows.  
The aims of Experiment 1A are as follows:  
(1) To compare the effects of chronic APD treatment on CAR behaviour in adolescents and adults  
(2) To compare brain structural changes induced by chronic APD treatment in adolescents and 
adults 
To achieve these aims, longitudinal assessment of behaviour and brain structures was performed in 
the same animals treated with either one of the three APDs or vehicle as adolescents, young adults 
or adults (a total of 12 subgroups).  
3.3.1.1 Materials and methods 
3.3.1.1.1. Subjects 
Male SD rats arrived at the animal facility in three breeding waves as weaners on PND23. During 
the 7-day acclimatization period, they were housed in groups of eight in Macrolon cages. After the 
behavioural training from PND30 to PND34, rats from the same age and drug groups were pair-
housed in Macrolon cages with Sani chip bedding and wire lids in a temperature (21 ± 1 °C) and 
lighting (lights on at 6 am and off at 6 pm) controlled room. All rats were given ad libitum access to 
food and water throughout the whole experiment. Behavioural training and testing were conducted 
during the light phase of the diurnal cycle. 
3.3.1.1.2. Antipsychotic drugs 
All drugs and vehicle were administered to the rats through once-daily IP injection (1 ml/kg) for 21 
days (between 14:30 h and 16:30 h) except haloperidol, which was given SC. The rats were 
weighed daily before drug administration. Approximately 60–80% D2 occupancy is required in 
order to acutely impair CAR behaviour. The APD doses in this study (haloperidol at 0.05 
mg/kg/day, risperidone at 1.3 mg/kg/day and clozapine at 15 mg/kg/day) have been shown to have 
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such a level of 60-80% D2 occupancy in SD rats (Kapur et al. 2003) and disrupt avoidance 
responses as shown in Pilot Experiment. 
3.3.1.1.3. Experimental design 
To examine age-related differences in the effects of APDs on the brain, adolescent, young adult and 
adult animals (See Below) were exposed to one of three APDs (clozapine, risperidone and 
haloperidol). The timeline of the experiment is depicted in Figure 3-3. The experiment consisted of 
three main phases as follows. 
3.3.1.1.3.1. CAR training and group assignment 
First, all rats were trained in the CAR paradigm for 5 days from PND30 to PND34. Only rats with 
≥70% avoidance (90 out of 120 rats, 75% success rate) on last 2 days of CAR training (PND33 and 
PND34) were selected. These animals were matched on their performance and assigned into three 
age groups of 21-day APD treatment at either: adolescence (PND36-PND56); young adulthood 
(PND58-PND78) or adulthood (PND80-PND100). Each age group had three independent APD 
treatment groups (clozapine, risperidone and haloperidol, n = 6 per drug group) and a control group 
(CON, n = 12). Half of CON received the vehicle solution (VEH, n = 6) and the other half never 
received an injection (NO) to control for the handling effect on the behaviour. These groups were 
combined in the final analysis as handling effects were minimal. Longitudinal brain MRI was 
conducted in all groups except for the NO group (See below). 
3.3.1.1.3.2. CAR test at Day 17 of chronic treatment 
To investigate each APD’s action on the CAR during chronic treatment, the avoidance response 
was examined in 40 CS-US trials at 1 hour after APD injection at Day 17 of chronic APD treatment 
(i.e. at PND52, PND74 and PND96 for adolescent, young adult and adult exposure respectively). 
CAR testing was performed 1 hour after APD injection as determined by the findings of the Pilot 
experiment.  
3.3.1.1.3.3. CAR test after a drug-free interval 
The final CAR testing after drug washout period was performed over 3 days. On Day 1 (PND116), 
the retention of avoidance response was examined in all rats with 20 trials of CS-only test (without 
foot shock). A lower number of trials was used in the retention test to prevent any possible 
extinction effect. On Day 2 (PND117), the rats were retrained for 40 CS-US trials to regain a high 
avoidance level prior to drug challenge. On Day 3 (PND118), animals were challenged with a half 
dose of the APD or vehicle they had been previously chronically exposed to (7.5 mg/kg clozapine, 
0.65 mg/kg risperidone, 0.025 mg/kg haloperidol or vehicle) and CAR examined over 40 CS-US 
trials. On P127, all rats were sacrificed for collection of brain tissue samples. 
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Figure 3-3 Timeline of Experiment 1A. Rats with ≥70%avoidance levels after CAR training from PND30-PND34 were divided into three age groups of chronic 21-
day antipsychotic exposure: (a) adolescence from PND36-PND56 (white box), (b) young adulthood PND58-PND78 (gray box) and (c) adulthood PND80-PND100 
(black box). Avoidance response was examined on Day 17 of drug treatment in each age window (Black arrows, CAR test Day17). After drug-free period, rats from 
all age groups underwent retention test, retraining and half dose drug challenge test on PND116, PND117 and PND118 respectively. The same rats from all age 
groups had longitudinal live MRI scans at PND35, PND57, PND79 and PND120 (White Arrows). On PND127, the brain tissues were collected for real-time qPCR.
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3.3.1.1.3.4. Longitudinal structural MRI scans and analysis 
To examine APD-induced changes in brain structural maturation, longitudinal MRI scans were 
performed at PND35, PND57, PND79 and PND120 on all rats except those in NO group. Rats were 
anaesthetized with isoflurane (5% for induction and 1.8–2.2% for maintenance with 1.5 L/min 
oxygen). The respiratory rate was maintained at 45-60 breaths per minute and the body temperature 
at 37°C with circulating warm water through the animal bed. Coronal T2-weighted MRI images 
were acquired with horizontal bore Bruker Biospec 9.4 Tesla MRI scanner with Paravision 5.1  
(Bruker, Germany) at Centre for Advanced Imaging, The University of Queensland. 
MRI images were acquired using a 40 mm circularly polarized rat head volume coil. Two-
dimensional T2-weighted fast spin echo images were acquired using with rapid acquisition with 
relaxation enhancement sequence (RARE) with the following parameters: effective echo time (TE) 
– 40 ms; repetition time (TR) – 4000 ms; field of view (FOV) – 35 mm x 35 mm; matrix – 256 x 
256; in-plane resolution – 0.14 x 0.14 mm; slice thickness – 500 μm; number of slices – 38; RARE 
factor – 8; number of averages – 10; scan time – 23 minutes.  
MRI images were coded and analyst was blinded to treatment. Manual segmentation method in the 
open-source OSIRIX software was used to identify the regions of interest (ROI). ROIs analysed 
included whole brain (WB), cerebral cortex (CCx), prefrontal cortex (PFC) and striatum (STR) 
using well-established criteria (Paxinos and Watson 2005) and following published methods 
(Piontkewitz et al. 2011; Vernon et al. 2011). Volume of each region was computed by summation 
of the areas from all respective slices corrected for slice thickness 
3.3.1.1.4. Statistical analysis 
Statistical analysis was conducted with SPSS Version 20, using a general linear model. CAR data 
were expressed as mean % avoidance, % escape failure and number of chamber crossings (n = 6 per 
APD group and n = 12 for CON for a given age group). CAR data and gene expression data were 
analyzed with one-way or two-way analyses of variance (ANOVA) with Tukey’s post hoc test. 
Longitudinal MRI data and body weight data were analysed with repeated-measure three-way 
ANOVA (time x age x drug) and Tukey’s post hoc test. To enable comparison among different age 
groups, avoidance data from Day 17 CAR test and half dose challenge test were plotted and 
analyzed as % avoidance normalized to the performance of age-matched controls. All data are 
expressed as mean ± SEM and statistical significance was defined as p< 0.05.  
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3.3.1.2 Results 
3.3.1.2.1. Behaviour during chronic treatment 
To investigate the behavioural effects during chronic APD administration, rats were tested for 
avoidance response on Day 17 of drug treatment at each age of exposure. Since the avoidance 
responses of two control groups (VEH and NO) did not differ significantly, they were pooled as a 
single control group (Table 3-2). Two clozapine-treated rats (one from young adult group and 
another from adult group) were excluded from the study since they had to be sacrificed due to 
development of sudden distress with abdominal distension after termination of drug treatment.  
3.3.1.2.1.1. Avoidance suppression with chronic APD treatment  
Two-way ANOVA on the avoidance yielded significant main effects of drug group (F3,75 = 30.4, p< 
0.001) and age (F2,75 = 4.2, p = 0.019) on CAR performance without any significant interaction 
between drug group and age (F6,75 = 0.8, p = 0.57). Post hoc tests showed that the APD groups 
differed significantly from CON (p = 0.01 for clozapine groups,  p < 0.001 for both risperidone and 
haloperidol groups). Moreover, avoidance suppression was significantly lower in all clozapine 
groups compared with risperidone (p = 0.026) and haloperidol (p < 0.001) groups. In general, 
avoidance levels were higher in adolescents than the older ages with this effect being significant 
between adolescents and adults (p = 0.007). Given that the avoidance behaviour varied significantly 
with age, subsequent analyses of the effects of APDs on CAR were conducted on data normalized 
to each control group at that age.  
The avoidance data as normalized to age-matched controls for individual age groups is depicted in 
Table 3-2. On separate analysis of individual age groups, a significant main effect of drug was 
detected at all ages:  F3,26 = 8.7 in adolescents, F3,24 = 8.9 in young adults and F3,25 = 17.1 in adults 
(all p < 0.001). Compared with its respective control group, clozapine no longer significantly 
impaired avoidance after 17 consecutive days of treatment at any age, suggesting tolerance to this 
drug had developed. By contrast, chronic treatment with risperidone and haloperidol continued to 
significantly disrupt avoidance in all age windows of exposure (p = 0.005 and p = 0.001 for 
adolescent risperidone and haloperidol respectively; p = 0.03 and p < 0.001 for young adult 
risperidone and haloperidol respectively; p < 0.001 for both adult risperidone and haloperidol). 
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Table 3-2 CAR performance of APD-treated and control rats at Day 17 of chronic drug treatment. 
CAR test on Day 17 of chronic APD treatment 
Age group of chronic 
APD treatment 
Drug 
Group 
Normalized 
%Avoidance 
%Escape Failures No. of Crossings 
Adolescent (PND36-
PND56) 
CON 100 ± 6.5 0.2 ± 0.2 51.4 ± 3.6 
CLZ 66 ± 18.8 0 ± 0 46.3 ± 2.0 
RIS 39.0 ± 17.2** 16.3 ± 14.8 35 ± 6.0* 
HAL 25.6 ± 9.9*** 7.1 ± 5.0 38.5 ± 1.4 
Young Adult (NDP58-
PND78) 
CON 100 ± 10.3 0 ± 0 48.8 ± 3.2 
CLZ 50.2 ± 15.0 0 ± 0 43.7 ± 1.7 
RIS 47.6 ± 21.7* 19.6 ± 13.1 35.8 ± 6.4 
HAL 9.6 ± 2.9*** 26.7 ± 6.8* 31 ± 2.8* 
Adult (PND80-
PND100)  
CON 100 ± 11.1 0 ± 0 45.8 ± 1.8 
CLZ 83.7 ± 22.4 0 ± 0 46.8 ± 2.7 
RIS 9.2 ± 4.0*** 24.6 ± 16.2 31.2 ± 5.8* 
HAL 4.9 ± 2.5*** 39.6 ± 6.2** 26.2 ± 2.6*** 
Two-way ANOVA 
Drug F3,75 = 30.4, p< 
0.001 
F3,75 = 11.6, p < 
0.001 
F3,75 = 16.3, p< 
0.001 
Age F2,75 = 4.2, p = 
0.019 
F2,75 = 2.3, p = 
0.111 
F2,75 = 1.7, p = 
0.187 
Age x 
Drug 
F6,75 = 0.8, p = 
0.57 
F6,75 = 1.3, p = 
0.258 
F6,75 = 0.6, p = 
0.74 
Data are expressed as mean ± SEM. n = 12 for adolescent and adult CON groups and n = 11 for 
young adult CON and n = 6 for each drug group except n = 5 for young adult and adult clozapine 
groups.  *p < 0.05, **p < 0.005, ***p < 0.001 relative to respective CON; CON – control; CLZ – 
clozapine; RIS – risperidone; HAL – haloperidol  
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3.3.1.2.1.2. Escape failures with chronic APD treatment  
APDs can also induce catalepsy at sufficiently high doses or with repeated treatment. This effect 
obviously might impact on apparent avoidance behaviour. Therefore escape failures were also 
examined (Table 3-2). Two-way ANOVA revealed a significant main effect of drug (p < 0.001) but 
no main effect of age (F2,75 = 2.3, p = 0.111) or age x drug interaction (F6,75 = 1.3, p = 0.258). Post 
hoc tests showed that risperidone and haloperidol groups produced significantly higher escape 
failures than CON (both p < 0.001). There were no escape failures with CLZ.  
When the three age groups were examined separately, a significant main effect of drug was 
observed in young adults (F3,24 = 4.7, p = 0.01) and adults (F3,25 = 7.3, p = 0.001), but not in 
adolescents (F3,26 = 1.4, p = 0.257). Post hoc tests showed that, relative to the age-matched CON, 
chronic haloperidol caused a significant increase in escape failures in young adults (p = 0.019) and 
adults (p = 0.002), but not in adolescents (p = 0.85). Chronic clozapine did not significantly affect 
escape failures at all three ages. 
3.3.1.2.1.3. Chamber crossings with chronic APD treatment  
Examination of APD-induced suppression of chamber crossings revealed that risperidone and 
haloperidol groups had significantly lower crossings than CON (p < 0.001) while clozapine groups 
did not (p = 0.85) (two-way ANOVA results shown in Table 3-2). This indicates that locomotor 
impairments might have partly contributed to the apparent CAR suppression by chronic risperidone 
and haloperidol in all age groups. Next individual age groups were analysed separately. 
A significant main effect of drug was observed in all age groups: (F3,26 = 4, p = 0.019) in 
adolescents; (F3,24 = 4.5, p = 0.012) in young adults and (F3,25 = 10.7, p< 0.001) in adults. Post hoc 
tests confirmed that, compared to their respective age-matched control, chronic risperidone retarded 
crossings in adolescents and adults (both p < 0.05) but not in young adults. By contrast, chronic 
haloperidol significantly decreased the crossings in young adults and adults (p < 0.05) but had no 
effect in adolescents. Chronic clozapine did not affect crossings at any age window.  
3.3.1.2.2. Behaviour after a drug-free interval  
After chronic APD treatment, all rats were given a drug-free period before being retested at the 
same age to minimize the potential confound of differences in final assessment age. This equated to 
60 days, 38 days and 15 days for the adolescent, young adult and adult treatment groups, 
respectively. Assessment of avoidance both during retention (absence of US) on PND116 and 
retraining (presence of US) on PND117 did not reveal any significant difference for any individual 
drug at any age of exposure indicating variable drug washout periods were not a factor for any 
possible difference in subsequent APD re-challenge experiments. On PND118, APD-treated rats 
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were challenged with the same APD at half of the dose they were chronically exposed to at earlier 
ages (7.5 mg/kg clozapine, 0.65 mg/kg risperidone or 0.025 mg/kg haloperidol). Half doses were 
chosen to prevent any floor effect in the likely event of sensitization after drug washout. 
3.3.1.2.2.1. Avoidance suppression with half dose challenge 
The data from half dose challenge test along with statistics is shown in Table 3-3. Two-way 
ANOVA yielded a significant main effect of drug (F3,75 = 9.5, p <0.001) without any main effect of 
age (F2,75 = 0.3, p = 0.78) or of age x drug interaction on CAR (F6,75 = 1.2, p = 0.33). Post hoc tests 
confirmed that risperidone and haloperidol rats produced significantly lower avoidance levels 
compared to CON rats (p < 0.001 and p = 0.001 respectively). The half dose of clozapine had no 
effect on CAR. The individual age groups were next examined.   
Overall, the rats previously exposed to APDs as adolescents (F3,26 = 6.5, p = 0.002) and young 
adults (F3,24 = 3.4, p = 0.033), but not as adults (F3,25 = 2.1, p = 0.132), showed a significant main 
effect of drug in half dose APD challenge. Post hoc tests, however, showed that at this half-dose, 
only risperidone was capable of significantly impairing CAR and this was significant only in the 
rats treated previously with risperidone as adolescents (p = 0.002), not in those treated as young 
adults (p = 0.053) or adults (p = 0.55). Challenge with the other two APDs did not significantly 
affect avoidance in all age groups (p > 0.05).  
3.3.1.2.2.2. Escape failures with half dose challenge 
Again, two-way ANOVA showed a significant main effect of drug (F3,75 = 4, p < 0.01) but no main 
effect of age (F2,75 = 0.4, p = 0.67) or age x drug interaction (F6,75 = 0.3, p = 0.93). Posthoc tests 
confirmed significantly higher escape failures in risperidone groups (p = 0.007) compared with 
controls, but no significant difference was observed for clozapine and haloperidol groups.  
When individual age groups were examined however, there was no significant main effect of any 
drug group at any age (Table 3-3). 
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Table 3-3 CAR performance with half dose APD challenge after drug washout 
Half dose challenge CAR test at PND118 
Age group of prior 
chronic APD exposure 
Drug 
group 
Normalized 
%Avoidance 
%Escape Failures No. of crossings 
Adolescent (PND36-
PND56) 
CON 100 ± 6.7 0 ± 0 50.3 ± 2.7 
CLZ 84.9 ± 18.1 2.1 ± 2.1 49.8 ± 4.9 
RIS 25.8 ± 16.8** 10.8 ± 9.4 36.8 ± 3.0* 
HAL 50.4 ± 18.8 3.8 ± 2.6 43.8 ± 2.5 
Young Adult (PND58-
PND78) 
CON 100 ± 9.3 0 ± 0 48 ± 2.1  
CLZ 50.3 ± 15.5 0 ± 0 49.2 ± 6.1 
RIS 46.2 ± 17.5 9.6 ± 7.6 42.8 ± 4.7 
HAL 62.4 ± 20.4 0 ± 0  48 ± 5.8  
Adult (PND80-PND100) 
CON 100 ± 9.5 0.2 ± 0.2  52 ± 3.2 
CLZ 92.7 ± 21.3 0.5 ± 0.5 49.6 ± 4.1  
RIS 71.4 ± 20.6 5.0 ± 5.0 45 ± 4.2  
HAL 46.6 ± 20.6 3.3 ± 2.2 40.2 ± 1.2  
Two-way ANOVA 
Drug F3,75 = 9.5, p < 
0.001 
F3,75 = 4, p = 
0.01 
F3,75 = 3.8, p = 
0.013 
Age F2,75 = 0.3, p = 
0.78 
F2,75 = 0.4, p = 
0.67 
F2,75 = 0.3, p = 
0.77 
Drug x 
Age 
F6,75 = 1.2, p = 
0.33 
F6,75 = 0.3, p = 
0.93 
F6,75 = 0.8, p = 
0.60 
Data are expressed as mean ± SEM. n = 12 for adolescent and adult CON groups and n = 11 for 
young adult CON and n = 6 for each drug group except n = 5 for young adult and adult CLZ 
groups. *p < 0.05, **p < 0.005 relative to respective CON; CON – control; CLZ – clozapine; RIS – 
risperidone; HAL – haloperidol 
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3.3.1.2.2.3. Chamber crossings with half dose challenge  
Two-way ANOVA showed a significant main effect of drug (F3,75 = 3.8, p < 0.013) but no main 
effect of age (F2,75 = 0.3, p = 0.77) or age x drug interaction (F6,75 = 0.8, p = 0.60). Post hoc tests 
confirmed significantly lower crossings for risperidone-challenged animals (p = 0.019) compared to 
CON but not for clozapine and haloperidol groups.  
When individual age groups were examined, there was a significant main effect of drug only in rats 
previously treated as adolescents (F3,26 = 3.4, p = 0.032). Post hoc tests showed that crossings were 
significantly lower only in risperidone-challenged rats from adolescent exposure group (p = 0.031) 
(Table 3-3). Thus again the findings indicate that after a prolonged drug-free interval, only rats with 
prior adolescent risperidone exposure remained behaviourally sensitive to this challenge with lower 
dose. 
3.3.1.2.3. Brain structural changes with APD treatment  
The impact of chronic 21-day APD treatment on the trajectory of structural brain development was 
examined using longitudinal in vivo MRI. In general, all ROIs increased steadily from PND35 
through PND79 and plateaued from PND79 to PND120 (Table 3-4). This trajectory of brain 
development was not significantly altered by chronic APD exposure at any age examined (only 
significant main effect of time; no significant main effect of drug, age, age x drug interaction or 
time x age x drug interaction for all ROIs examined). Statistical analysis on either regional volumes 
normalised to total brain volumes or changes in regional volumes from PND35, i.e. baseline level, 
also did not show any significant difference induced by APDs at any age. Moreover, correlation 
analyses did not reveal any significant relationship between volume of target brain structure and 
CAR performance either at Day 17 of chronic treatment or during half-dose challenge.  
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Table 3-4 Brain structural trajectory with chronic APD exposure 
ROI Age Group 
Drug 
Group 
Age at MRI Scans 
PND35 PND57 PND79 PND120 
W
B
 V
o
lu
m
e 
(m
m
3
) 
Adolescent 
(PND36-PND56) 
VEH 1159.6 ±  23.7 1292.8± 17.1 1374.3 ± 4.7 1396 ± 18.5 
CLZ 1160.3 ± 32.2 1236.9 ± 29.9 1351.5 ± 21.2 1366 ± 35.4 
RIS 1167.5 ± 16 1309.9 ± 19.2 1397.1 ± 33.9 1423.4 ± 22.2 
HAL 1192.7 ± 12.8 1301.4 ± 10.8 1362.4 ± 13.4 1405.1 ± 17.9 
Young Adult 
(PND58-PND78) 
VEH 1147.7 ± 23.3 1279.1 ± 25.1 1325.4 ± 23.0 1380 ± 35.6 
CLZ 1229 ± 28.6 1360.1 ± 31.4 1390.2 ± 40.4 1426.8 ± 35.6 
RIS 1225.3 ± 17.5 1366.2 ± 20.7 1384.8 ± 30.4 1456 ± 18.5 
HAL 1220.7 ± 23.4 1340.3 ± 34.1 1410.6 ± 57.3 1431.6 ± 45 
Adult 
(PNDP80-
PND100) 
VEH 1203.6 ± 18.9 1332.4 ± 32.1 1398.4 ± 41.3 1428.5 ± 33.4 
CLZ 1179.7 ± 14.6 1314.7 ± 14.9 1366.8 ± 16.1 1384.2 ± 22.3 
RIS 1163.5 ± 38.2 1289.9 ± 34.7 1390.2 ± 21.1 1382.4 ± 42.8 
HAL 1179.8 ± 27.9 1299.3 ± 20.5 1356.9 ± 18.5 1397.3 ± 23.7 
S
T
R
 V
o
lu
m
e 
(m
m
3
) 
Adolescent 
(PNDP36-PND56) 
VEH 87.1 ± 1.4  99.8 ± 1.2  108.5 ± 1.4 110.4 ± 1.9 
CLZ 88 ± 1.8 96.1 ± 2.2 107.1 ± 2.3 107.9 ± 2.4 
RIS 89.2 ± 1.2 103.3 ± 2.3 108.5 ± 1.8 114.1 ± 1.5 
HAL 88.4 ± 0.8 101.5 ± 1 106.2 ± 0.5 109.5 ± 1.2 
Young Adult 
(PND58-PND78) 
VEH 85.5 ± 1.3 99 ± 0.6 105.8 ± 0.3 109.2 ± 1.3 
CLZ 93.6 ± 1.6 105.3 ± 2.5 109.8 ± 2.8 114 ± 3.0 
RIS 90.7 ± 2 106.1 ± 2.2 111.8 ± 1.6 115.1 ± 2.1 
HAL 88.8 ± 1.9 104.4 ± 2.2 111.8 ± 3.5 112.8 ± 2.1 
Adult 
(PND80-PND100) 
VEH 92.2 ± 1.2 105.2 ± 1.9 113 ± 4 114.3 ± 2.8 
CLZ 90.2 ± 0.8 102  ± 1 108.3 ± 1.1 108.2 ± 1.2 
RIS 89.6 ± 2.4 99.9 ± 2.3 110.9 ± 2.9 107.6 ± 3.5 
HAL 90 ± 2.6 101.4 ± 1.5 107.2 ± 1.5 110.4 ± 1.4 
C
C
x
 V
o
lu
m
e 
(m
m
3
) Adolescent 
(PND36-PND56) 
VEH 486.1 ± 8.7 517.4 ± 9.3 545 ± 7.7 542.2 ± 11.6 
CLZ 492.5 ± 4.2 506.1 ± 10.8 534.3 ± 7.5 543.9 ± 14.1 
RIS 499.9 ± 8.5 526.6 ± 10.9 551.9 ± 17.9 567.4 ± 15.6 
HAL 499.4 ± 5.4 526.3 ± 4.6 542.9 ± 9 552.8 ± 8.8 
Young Adult 
(PND58-PND78) 
VEH 480.9 ± 13.2 506.9 ± 11.3 520.8 ± 10 546.3 ± 12.7 
CLZ 498.4 ± 12.5 535.8 ± 12.8 534.7 ± 15.7 574.4 ± 16 
RIS 513 ± 9 542 ± 8.9 552.8 ± 15.6 580.8 ± 13.3 
HAL 504.6 ± 13.8 535.4 ± 16.5 558.2 ± 27.3 569.2 ± 21.3 
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Adult 
(PND80-PND100) 
VEH 499.6 ± 8.4 513.1 ± 14.4 543.6 ± 20.2 563.4 ± 20.1 
CLZ 490.2 ± 10.6 502 ± 8.4 535.1 ± 8.3 547.5 ± 13.6 
RIS 481.5 ± 13.6 503.7 ± 15.5 549.7 ± 12.4 551.4 ± 21.1 
HAL 496.9 ± 15.2 506.8 ± 9.9 522.7 ± 6.6 554.4 ± 10.5 
P
F
C
 V
o
lu
m
e 
(m
m
3
) 
Adolescent 
(PND36-PND56) 
VEH 16.2 ± 0.2 19 ± 0.7 21.6 ± 0.2 21 ± 0.7 
CLZ 16.6 ± 0.2 19.1 ± 0.3 20.3 ± 0.2 21.1 ± 0.7 
RIS 16.9 ± 0.2 19.7 ± 0.5 21.9 ± 0.6 21.7 ± 0.5 
HAL 16.6 ± 0.2 19.9 ± 0.2 21.3 ± 0.8 21.9 ± 0.3 
Young Adult 
(PND58-PND78) 
VEH 16.3 ± 0.3 19.6 ± 0.4 21 ± 0.3 20.8 ± 0.6 
CLZ 17.5 ± 0.3 20.4 ± 0.4 21.6 ± 0.4 21.2 ± 0.3 
RIS 17.5 ± 0.6 20.7 ± 0.7 22.8 ± 1 22 ± 0.5 
HAL 18.1 ± 0.9 21 ± 0.5 22.8 ± 0.8 22 ± 0.4 
Adult 
(PND80-PND100) 
VEH 16.7 ± 0.4 20.3 ± 0.9 22.6 ± 0.9 21.5 ± 0.5 
CLZ 16.9 ± 0.3 18.8 ± 0.8 21.6 ± 1.2 20.5 ± 0.4 
RIS 16.5 ± 0.5 20.4 ± 0.9 22.4 ± 0.7 20.7 ± 0.7 
HAL 16.6 ± 0.3 19.1 ± 0.3 21.6 ± 0.4 20.9 ± 0.7 
Data are expressed as mean ± SEM. n = 6 for each drug group except n = 5 for young adult and 
adult clozapine groups. n = 4 per drug group at PND79 scan due to scanner failure. CCx = 
cerebral cortex, CLZ – clozapine, HAL – haloperidol, PFC = prefrontal cortex, RIS – risperidone, 
STR = striatum, WB = whole brain.  
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3.3.2. Experiment 1B: Further examination of chronic risperidone treatment in adolescents 
and adults 
In the second part of Experiment 1, I increased experimental sample size for the most promising 
agent, risperidone. Risperidone was chosen for further study for the following reasons: - 
(a) Risperidone is the atypical APD most commonly prescribed to adolescents and children in the 
clinic (Hollingworth et al. 2013; Olfson et al. 2006; Olfson et al. 2012). Therefore, it will be 
clinically more relevant to examine risperidone administration in adolescent rats.   
(b) A preclinical study has reported a long-term change in adult whole brain volume with 
adolescent risperidone treatment in neurodevelopmentally normal rats (Piontkewitz et al. 2011) but 
this finding has not been replicated. In addition to the regions examined in Experiment 1A, I also 
wanted to determine changes in other regions such as hippocampus and ventricles.  
(c) The findings of Experiment 1A provided a lead that a long-term change in behavioural response 
could develop selectively with risperidone treatment in adolescence. I aimed to confirm this finding 
in a larger sample size and investigate the underlying neural mechanism(s). Justifications for 
increasing sample size are as follows: with the statistical analyses used in my study, for example, 
two-way ANOVA (age x drug), a sample size of n= 6 per group will not provide adequate statistical 
power and positive predictive power with a possible winner’s curse effect (Button et al. 2013). 
The aims of Experiment 1B are as follows: 
(1) To confirm that risperidone induces long-term behavioural change in CAR selectively in rats 
treated as adolescents  
(2) To conduct structural brain studies in a larger sample cohort 
(3) To investigate long-term neurochemical change induced by risperidone treatment in adolescents 
In addition to these three specific aims, long-term changes in accumbal metabolites such as GABA, 
glutamate and NAA were also examined with 1H MRS in Experiment 1B. Given a recent report of 
long-term reduction in 1H MRS levels of GABA and glutamate in the NAc induced by adolescent 
olanzapine treatment (Xu et al. 2015), the NAc was chosen for examination of metabolites.  
3.3.2.1 Materials and methods 
3.3.2.1.1. Subjects 
As in Experiment 1A, male SD rats that arrived at the animal facility as weaners on PND23 were 
housed in groups of eight in Macrolon cages. After CAR training from PND30 to PND34, the rats 
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from the same age and drug groups were pair-housed in Macrolon cages with Sani chip bedding and 
wire lids in a temperature (21 ± 1 °C) and lighting (lights on at 6 am and off at 6 pm) controlled 
room. 
3.3.2.1.2. Antipsychotic drugs 
Risperidone and vehicle were administered to the rats through once-daily IP injection (1 ml/kg) for 
21 days (between 2:30 and 4:30 pm). Rats were weighed daily before drug administration.  
3.3.2.1.3. Experimental design 
In Experiment 1B, chronic risperidone treatment was examined further only in two age groups, 
adolescents (PND36-PND56) and adults (PND80-PND100) (n = 6 per drug for a given age group). 
Experimental design is the same as in Experiment 1A, with a few modifications. The timeline of the 
experiment is depicted in Figure 3-4. 
3.3.2.1.3.1. CAR training and testing during chronic treatment and after drug-free interval 
As in Experiment 1A, rats were trained in a CAR paradigm from PND30 to PND34. Rats with 
≥70% avoidance (24 out of 30, 80% success rate) on the last 2 days of CAR training (PND33 and 
PND34) were randomly assigned into either adolescent (PND36-56) or adult (PND80-100) 
exposure groups. The effect of chronic risperidone on CAR was examined in 40 CS-US trials at 1 
hour after injection on Day 17 of the 21-day treatment (i.e. at PND52 and PND96 respectively for 
adolescent and adult exposures). After a drug-free interval, the rats were examined for retention of 
avoidance response at PND116 (20 CS-only trials) and retrained at PND117 (40 CS-US trials) and 
challenged with a half dose of risperidone (0.65 mg/kg IP) or vehicle at PND118 (40 CS-US trials).  
3.3.2.1.3.2. Examination of structural change after a drug-free interval  
In Experiment 1B, MRI scans were performed only at PND120 on all rats since the main aim was to 
determine risperidone-induced long-term change in brain structures. The imaging parameters and 
the analysis methodology were the same as in Experiment 1A. In addition to the ROIs analysed in 
Experiment 1A, hippocampus and lateral ventricles were also analysed using well-established 
criteria of rat brain atlas (Paxinos and Watson 2005) and following the published methods 
(Piontkewitz et al. 2011; Vernon et al. 2011). 
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Figure 3-4 Timeline of Experiment 1B.  Rats were treated for 21 days with risperidone or vehicle as adolescents (PND36-PND56) or adults (PND80-100). At Day 
17 of chronic 21-day treatment, CAR was examined at 1 h after injection. After a drug-free interval, rats from both age groups were tested at same age from 
PND116 to PND118. Two days later at PND120, structural MRI was performed on all rats. At PND 127, rats were euthanised for collection of brain tissues.   
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3.3.2.1.3.3. Examination of accumbal metabolites with 1H MRS after a drug-free interval 
Immediately after the structural MRI, single voxel 1H MRS data were acquired to investigate long-
term changes in neural metabolites (glutamate, GABA and n-acetyl aspartate (NAA)) in the NAc. A 
voxel of interest (6 x 2 x 2 mm3) was placed bilaterally over the NAc. After a fast shimming to 
improve B0 magnetic homogenization and first, second and third order shimming, a reference water 
spectrum was acquired. Next, water-suppressed 1H MRS spectra were obtained from the NAc voxel 
using PRESS sequence. 1H MRS data were analysed at LCModel software (version 6.3-1J) 
(Provencher 1993) and the concentration of metabolites expressed as ratio to total creatine (Cr + 
PCr). 
3.3.2.1.3.4. Examination of neurochemistry in adulthood with RT-PCR 
On PND127, following 1-week washout from isoflurane exposure to diminish any possible 
confounds on neurochemical parameters examined, all rats were sacrificed with an overdose of 
pentobarbitone sodium (Lethabarb, Virbac). Brains were rapidly dissected on ice and both core and 
shell regions of the NAc (Paxinos and Watson 2005) collected in RNALater solution (Invitrogen), 
kept at 4°C overnight and stored at -80°C until RNA extraction procedure. Briefly, total RNA was 
extracted from each tissue sample using QIAzol and RNeasy Mini Kit (Qiagen, Australia). For each 
sample, 900 ng of RNA per 21 μl reaction was reverse-transcribed to cDNA with SuperScript IV 
First-Strand Synthesis System (Invitrogen). RT-PCR was performed in 12 µl reaction on Roche 
LightCycler 480 (Roche Diagnostics, Australia), using SYBR Green method in 384-well plates. The 
PCR conditions were as follows: denaturation at 95°C for 5 min followed by 40 cycles of 
amplification (95°C for 10 s, then 60°C for 20s, then 72°C for 20 s). Relative expression of the 
target genes normalized to that of endogenous control GAPDH was calculated following the 
published method (Schmittgen and Livak 2008). Gene expression data was only considered if 
significant changes were observed in every repeat.  
Risperidone-treated and control groups from Experiment 1A and 1B were pooled and examined 
together. No Injection control groups were not examined in PCR reactions, thus giving n = 12 for 
both vehicle controls and risperidone groups for a given age. PCR experiments were performed 
separately for adolescent and adult treatment groups, along with a universal control sample in each 
PCR plate.  
3.3.2.1.4. Statistical analysis 
Statistical analysis was conducted with IBM SPSS Version 22. CAR data were expressed as 
normalized % avoidance (% avoidance normalized to the corresponding age-matched control 
group’s performance), % escape failure and number of chamber crossings (n = 12 for risperidone 
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group and n = 18 for controls for each age group). For chronic exposure in two age groups, CAR 
data and MRI data were analysed with two-way (age x drug) ANOVA, followed by post hoc tests 
with Bonferroni correction. Given non-Gaussian distribution of the data, escape failures were 
analysed with non-parametric independent-samples Mann-Whitney U tests. For change in 
avoidance response from chronic exposure to half dose challenge, delta Z score analysis of 
normalized avoidance data was computed with the following formula [Delta Z = (normalized % 
avoidance on half dose challenge – normalized % avoidance on Day 17) ÷ (normalized % 
avoidance on half dose challenge + normalized % avoidance on Day 17)]. Since PCR reactions of 
two age groups were performed separately, the 2-∆CT values of individual samples were normalized 
to that of the universal sample and analysed with two-way (age x drug) ANOVA followed by post-
hoc tests on each age group. All data were expressed as mean ± standard error of mean (SEM) 
except escape failures data which were expressed as median ± semi-interquartile range following 
the presentation of the published literature (Wadenberg et al. 2000; Wadenberg et al. 2001b). The 
level of statistical significance defined as p < 0.05. 
3.3.2.2 Results 
The data of risperidone treatment and control groups from both Experiment 1A and 1B were pooled 
and presented here. 
3.3.2.2.1. Behaviour during chronic treatment  
As expected, risperidone suppressed CAR in both adolescents and adults. This effect was 
numerically lower in adults (Table 3-5). Two-way ANOVA on normalized avoidance data yielded a 
significant main effect of drug (F1,56 = 78.594, p < 0.001) but the main effects of age and drug x age 
interaction did not reach statistical significance (both F1,56 = 3.104, p = 0.084). This suppression 
was independent of age with both age groups showing significant reductions in CAR (p < 0.001 for 
both adolescents and adults).  
Risperidone also has the capacity to induce catalepsy which obviously may impact on avoidance 
behaviour. Catalepsy during CAR would manifest as an escape failure. Therefore escape failures 
during chronic exposure were also examined. Two-way ANOVA revealed significant main effects 
of drug (F1,56 = 34.295, p < 0.001), age (F1,56 = 7.844, p = 0.007) and drug x age interaction (F1,56 = 
7.975, p = 0.007). Risperidone-treated adolescent rats were not significantly different from their 
controls (p = 0.087). In sharp contrast, rats treated with risperidone as adults had significantly 
higher escape failures than controls (p < 0.001). These findings suggest that escape failures may 
partly contribute to the CAR disruption by risperidone in adults, but not in adolescents.  
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Chronic risperidone treatment suppressed chamber crossings in both age groups. Again, this motor-
suppressive effect of risperidone appeared lower in adolescents than in adults (significant main 
effects of drug (F1,56 = 47.205, p < 0.001) and age (F1,56 = 7.873, p = 0.007) but no significant drug 
x age interaction (F1,56 = 2.860, p = 0.096) on two-way ANOVA). Examination of two age groups 
individually showed that risperidone significantly suppressed chamber crossings in both adolescents 
(p = 0.002) and adults (p < 0.001). This indicates that locomotor impairments may have partly 
contributed to the apparent CAR suppression by chronic risperidone in both age groups. All data is 
displayed in Table 3-5. 
 
Table 3-5 Behaviour during chronic risperidone treatment as adolescents or adults 
Age Drug 
Normalized 
%avoidance 
%Escape failures 
No of chamber 
crossings 
Adolescent  
CON 100 ± 6.46  0  ± 0  49.39 ± 2.48  
RIS 36.36 ± 11.95***  0 ± 8.44 34.42 ± 3.81**  
Adult  
CON  100 ± 10.35  0 ± 0  46.17 ± 1.52  
RIS 4.78 ± 2.25***  71.25 ± 41.56 ***  21.42 ± 4.11***  
**p = 0.002, ***p < 0.001 compared to respective age-matched CON. Avoidance and crossing 
data are expressed as mean ± SEM. Escape failure data are expressed as median ± semi-
interquartile range. n = 18 for control (CON) groups and n = 12 for risperidone (RIS) groups. 
 
3.3.2.2.2. Behaviour after a drug-free interval  
After chronic treatment, all rats were given a drug-free period (60 days and 15 days for adolescent 
and adult treatment groups, respectively) before being retested at the same age. CAR assessed 
during both retention test (absence of US) on PND116 and retraining (presence of US) on PND117, 
was equivalent for both chronically exposed age groups (Figures 3-5 (a) and (b)). This suggests the 
variation in drug washout periods did not differentially affect CAR performance prior to subsequent 
re-challenge experiments.  
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(a)           (b) 
     
Figure 3-5 Avoidance performance of rats at the retention test on PND116 and retraining on PND117.  No difference in avoidance performance at (a) the retention 
test (in the absence of US) on PND116 and (b) retraining on PND 117 was observed in both adolescent and adult cohorts. Data are expressed as mean ± SEM. n = 
18 for CON and n = 12 RIS for a given age. 
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On PND118, risperidone-treated rats were challenged with half of the dose they were chronically 
exposed to at earlier ages (0.65 mg/kg). CAR was impaired by risperidone challenge in both age 
groups (main effect of drug (F1,56 = 24.708, p < 0.001); with no main effects of age or drug x age 
interaction (both F1,56 = 0.813, p = 0.371) on two-way ANOVA). Separate examination of two age 
groups again showed that the challenge dose of risperidone disrupted CAR in both age groups (p< 
0.001 in adolescent group and p = 0.019 in adult group) (Table 3-6). 
   
Table 3-6 Behaviour after drug-free interval at PND118 
Age Drug 
Normalized 
%avoidance 
%Escape 
failures 
No of chamber 
crossings 
Adolescent  
CON 100 ± 5.89  0 ± 0  51.39 ± 2.19  
RIS 34.85 ± 13.03***  0 ± 8.13 36 ± 3.12***  
Adult  
CON  100 ± 10.85  0 ± 0  49.89 ± 2.47  
RIS 54.86 ± 15.11*  0 ± 13.13  38.67 ± 3.39*  
*p<0.05, *** p < 0.001 compared to respective age-matched CO. Avoidance and crossing data are 
expressed as mean ± SEM. Escape failure data are expressed as median ± semi-interquartile range. 
n = 18 for control (CON) groups and n = 12 for risperidone (RIS) groups. 
 
When the level of CAR suppression after drug washout (on half dose) was compared with that seen 
during chronic treatment (Day 17) (on full dose), a significantly different pattern was observed in 
the two age groups. The response in rats treated as adults was predictable. At challenge, the lower 
dose of risperidone (0.65 mg/kg) produced less suppression of CAR compared with the full dose 
(1.3 mg/kg) at Day 17 (Figure 3-6b). By contrast, rats chronically exposed to risperidone as 
adolescents, when challenged as adults with half dose risperidone, had a similar level of avoidance 
suppression as chronic full dose (Figure 3-6a). This differential response was confirmed by delta Z 
score analysis (significant main effects of drug (F1,56 = 7.203, p = 0.010), age and drug x age 
interaction (F1,56 = 11.014 and F1,56 = 10.886 respectively, both at p = 0.002) on two-way ANOVA). 
Further analysis shows that rats with adult risperidone exposure showed significantly higher 
positive Z score than those with the same risperidone exposure in adolescence (p = 0.007).  
This pattern was not influenced by the level of escape failures as the half dose challenge induced 
similar levels of escape failures in rats of both age groups (main effect of drug (F1,56 = 13.518, p = 
0.001), no main effect of age or drug x age interaction (F1,56 = 0.001 and F1,56 = 0.004 respectively, 
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both p > 0.90) on two-way ANOVA). Examination of individual age groups did not reveal any 
significant increase in escape failures (p = 0.059 for adolescents and p = 0.079 for adults). Similarly 
the number of crossings were significantly suppressed by risperidone challenge in both age groups 
(a significant main effect of drug (F1,56 = 23.271, p < 0.001), no main effect of age or drug x age 
interaction (F1,56 = 0.045 and F1,56 = 0.571 respectively, both p > 0.4) on two-way ANOVA). When 
the two age groups were examined separately, no age group was selectively affected (p < 0.001 for 
adolescent group and p = 0.011 for adult group). All data from half dose challenge test is shown in 
Table 3-6.    
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(a)  
 
 
 
 
 
 
 
 
 
(b)  
 
 
 
 
 
 
 
 
 
Figure 3-6 Conditioned avoidance response (CAR) suppression is sensitized in rats treated with risperidone 
in adolescence. (a) Rats previously treated with risperidone as adolescents showed similar CAR suppression 
when rechallenged with half that dose (Figure insert shows negative delta Z score –0.06). (b) Rats 
previously treated with risperidone as adults showed less CAR suppression when rechallenged with half that 
dose (Figure insert shows delta Z score +0.6). n = 18 for control (CON) groups and n = 12 for risperidone 
(RIS) groups. ## p = 0.007 adolescent RIS vs adult RIS 
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3.3.2.2.3. Long-term structural outcome with chronic risperidone treatment in adolescence or 
adulthood 
To examine the hypothesis that chronic risperidone treatment in adolescence could induce long-
lasting structural deficits, we examined the volume of target brain structures with live in vivo MRI 
scans. Table 3-7 shows regional brain volumes in risperidone- or vehicle-treated rats of both age 
groups. Risperidone treatment for 21 days was insufficient to induce any long-lasting structural 
change regardless of the age of exposure. Two-way ANOVA of each ROI confirmed this 
observation, showing no significant main effect of drug, age or age x drug interaction for any of the 
structures examined (all p > 0.05, Table 3-7). Statistical analysis on regional volumes normalised to 
total brain volumes also did not show any significant difference induced by APDs at any age. 
 
Table 3-7 Brain structural outcome at PND120 with chronic risperidone treatment in adolescence or 
adulthood 
Age  Drug 
Volume of ROIs (mm3) 
Whole 
brain 
Cerebral 
cortex 
PFC Striatum Hippocampus 
Lateral 
ventricles 
Adolescent 
CON 
1382.79 ± 
14.49 
544.49 ± 
7.21 
20.46 ± 
0.47 
82.01 ± 
1.07 
110.18 ± 1.47 13.85 ± 
3.82 
RIS 
1384.43 ± 
23.80  
546.17 ± 
11.66  
20.53 ± 
0.67  
82.25 ± 
1.12  
109.41 ± 1.70 18.49 ± 
4.36 
Adult 
CON 
1384.39 ± 
24.64 
547.93 ± 
12.12 
20.26 ± 
0.73  
84.85 ± 
1.71  
110.07 ± 1.56 10.73 ± 
1.94  
RIS 
1367.30 ± 
24.63 
547.01 ± 
11.72  
20.52 ± 
0.59  
83.03 ± 
2.29 
108.69 ± 2.01 14.58 ± 
2.58 
Two-way ANOVA 
statistics 
Main effects of age, drug and age x drug interaction for each individual ROI 
– all F1,43 < 0.4, p >0.05  
All data are expressed as mean ± SEM. n = 12 for control (CON) groups and n = 12 for 
risperidone (RIS) groups except n = 11 for adult CON. CON – vehicle-treated control; RIS – 
risperidone-treated; ROI = region of interest 
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3.3.2.2.4. Long-term change in neural metabolites of the NAc  
In Experiment 1B, I examined the levels of glutamate, GABA and NAA in rats that had been 
treated with risperidone in adolescence or adulthood. All three metabolites of interest can be 
reliably quantified from 1H MRS data (all CRLB < 20%, Table 3-8). As shown in Table 3-8, the 
accumbal levels of glutamate, GABA and NAA at maturity were not altered by risperidone 
treatment in either adolescence or adulthood (no significant main effect of age or drug or age x drug 
interaction; all F < 1.5, p > 0.05). 
Table 3-8 Levels of neural metabolites in the nucleus accumbens at PND120 after risperidone treatment in 
adolescence or adulthood  
Age group Drug Group  Glu/Cr+PCr GABA/Cr+PCr NAA/Cr+PCr 
Adolescent CON 1.11 ± 0.044  0.28 ± 0.023 0.84 ± 0.042  
RIS 1.16 ± 0.044  0.28 ± 0.023  0.85 ± 0.042 
Adult  CON 1.10 ± 0.048 0.29  ± 0.025 0.82 ± 0.046 
RIS 1.13 ± 0.044 0.32 ± 0.023 0.85 ± 0.042 
CRLB 5.04 ± 0.16 15.83 ± 0.78 5.04 ± 0.16 
Two-way ANOVA Main effects of age, drug and age x drug interaction for 
each metabolite – all F1,19 < 1.5, p > 0.05 
All data (ratio of metabolites to total creatine) expressed as mean ± SEM. n = 6 per drug for a 
given age group except n = 5 for Adult CON group. CON – vehicle-treated control; CRLB – 
Cramer-Rao Lower Bounds; RIS – risperidone-treated;    
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3.3.2.2.5. Long-term neurochemical change in the NAc   
Changes in dopaminergic, serotonergic and GABA-ergic molecules in the NAc (See Table in 
Appendix A) were examined since this brain region plays a critical role in APD-induced disruption 
of avoidance response (Wadenberg et al. 1990a). Among neuro-receptors, transporters and enzymes 
examined significant reductions in 5-hydroxytryptamine-2A (5HT2A) and catechol-o-methyl 
transferase (COMT) mRNA levels were observed selectively in the rats treated with risperidone in 
adolescence (Figure 3-7). Two-way ANOVA showed a significant main effect of drug (F1,44 = 5.20, 
p = 0.028) and age (F1,44 = 23.270, p < 0.001) for 5HT2A mRNA levels and a significant main of 
drug only (F1,44 = 4.21, p = 0.046) for COMT mRNA levels. Age x drug interaction of both for 
5HT2A and COMT mRNA levels did not reach statistical significance (F1,44 = 1.05 and F1,44 = 1.63 
respectively, both p > 0.05). Planned comparisons showed that compared to the corresponding 
controls, rats with prior adolescent risperidone exposure showed a significant downregulation of 
5HT2A mRNA levels in the NAc (p = 0.001), along with a small but significant downregulation of 
COMT gene expression (p = 0.033). By contrast, in rats treated with risperidone as adults, the gene 
expression of both 5HT2A and COMT was unaltered (both p > 0.4). Gene expression of other 
markers examined such as tyrosine hydroxylase (TH), D1 and D2 receptors and monoamine oxidase 
A and B (MAO-A, MAO-B) and glutamic acid decarboxylase 65 (GAD65) was unaffected by the 
risperidone treatment regimen at both ages (Table 3-9). 
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(a)           (b) 
   
Figure 3-7 Adolescent risperidone treatment produces long-lasting neurochemical alterations in the nucleus accumbens. Rats with prior adolescent risperidone 
exposure showed a significant downregulation of (a) 5HT2A receptor and (b) COMT mRNA levels. Rats treated with risperidone in adulthood did not show any 
alterations of 5HT2A receptor and COMT. Data are expressed as mean ±SEM. n = 12 each for vehicle-treated control (CON) and risperidone (RIS) groups for a 
given age. *p < 0.05, ***p = 0.001 compared to respective age-matched CON. 
103 
Chapter 3 
 
 
Table 3-9 Gene expression of dopaminergic and GABAergic markers in the NAc with risperidone treatment 
in adolescence or adult 
Age  Drug 
Fold change of the target genes 
D1 D2 TH MAO-A MAO-B GAD65 
Adolescent 
CON 1 ± 0.06 1 ± 0.1 1 ± 0.04 1 ± 0.13  1 ± 0.09 1 ± 0.1  
RIS 0.87 ± 0.06 0.84 ± 0.05  0.99 ± 0.07 0.81 ± 0.08 1.01 ± 0.07  0.98 ± 0.08 
Adult 
CON 1 ± 0.09 1 ± 0.05 1 ± 0.05 1 ± 0.05 1 ± 0.05 1 ± 0.12 
RIS 0.82 ± 0.1  0.86 ± 0.11 1.01 ± 0.09 0.99 ± 0.12 0.98 ± 0.10 0.87 ± 0.12 
All data expressed as mean ± SEM. n = 12 each for vehicle-treated control (CON) and risperidone (RIS) 
groups for a given age. 
3.4. Discussion 
In the current Chapter, I established that the selected doses of APDs could disrupt the CAR in adults 
at the chosen routes of administration. Next, in Experiment 1A, I did a screening of behavioural and 
brain structural outcomes by subjecting rats to chronic APD treatment at different postnatal age 
windows. I showed that the same regimens of chronic APD treatment induced differential 
behavioural outcomes in the CAR paradigm in adolescents and adults, depending on the APD. 
Further, in Experiment 1B, I examined chronic risperidone treatment in adolescents and adults in 
larger sample size. I showed that chronic treatment with risperidone and haloperidol induced lower 
levels of escape failures in adolescents than in adults during ongoing chronic treatment. After a 
drug-free interval, when rechallenged with a low dose of risperidone rats treated with risperidone in 
adolescence appeared to develop a sensitised behavioural response. Accompanying this behavioural 
change, a downregulation in 5HT2A receptors and COMT was observed selectively in the NAc of 
rats treated with risperidone in adolescence. 
3.4.1. Behaviour during chronic treatment 
In Experiment 1, during chronic treatment at three ages, contrasting effects were observed with 
three drugs, especially for haloperidol, the typical APD with predominant affinity for D2 receptors, 
risperidone, the atypical APD with high affinity for both D2 and 5HT2A receptors and clozapine, the 
atypical APD with higher affinity for non-dopaminergic receptors (Miyamoto et al. 2005; Schotte et 
al. 1996). After 17 days of chronic treatment, risperidone and haloperidol continued to impair 
avoidance. Since the avoidance suppression of chronic risperidone and haloperidol was generally 
accompanied by escape failures and reduction in crossings, which are reflective of cataleptic effects 
of these two APDs, it was speculated that at least in part, the avoidance-suppressive effect of 
chronic risperidone and haloperidol might be due to these motor and cataleptic effects during 
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chronic treatment. Such motor initiation deficits have been proposed as a behavioural mechanism 
for APD-induced CAR disruption (Anisman et al. 1982; Fibiger et al. 1975; Posluns 1962).  
More importantly, differential age-dependent effects of risperidone and haloperidol were observed 
with higher levels of locomotor suppression and escape failures with an increase in age. These 
results must be considered in the light of the fact that an acute single dose of any of these APDs did 
not induce any significant escape failure. Older animals appear more vulnerable to the cumulative 
locomotor/cataleptic effects of risperidone and haloperidol after repeated daily injection. In 
agreement with this finding, a sensitization-like cataleptic response, i.e. an increase in cataleptic 
effect with daily injection, has been reported with repeat haloperidol treatment in adult rats despite 
the lack of such cataleptic response with the initial exposure to this drug (Banasikowski and 
Beninger 2012a; Klein and Schmidt 2003; Schmidt et al. 1999). Older animals have previously been 
shown to be more vulnerable to cumulative locomotor/cataleptic effects of APDs after repeated 
daily injection (Wiley and Evans 2008). A proper examination of risperidone-induced cataleptic 
responses in adolescents and adults with either horizontal bar or grid test (Sanberg et al. 1988) will 
provide more information on age-dependent cataleptic outcomes. These behavioural findings during 
chronic treatment provided directions for Chapter 4 which would examine cataleptic responses with 
chronic administration of risperidone in adolescence, in comparison the same regimen in adulthood. 
Why would adolescents be less vulnerable to the cataleptic and locomotor impairing effects of 
risperidone? Adolescence has been reported to be a period of hyper-dopaminergia with dopamine 
receptors reaching their peak levels of expression (Andersen et al. 2000; Teicher et al. 1995) and 
midbrain DA neurons achieving their peak levels of firing (McCutcheon et al. 2012; McCutcheon 
and Marinelli 2009). This relative hyper-dopaminergic state may perhaps overcome any potential 
for cataleptic/locomotor abnormalities as a result of dopaminergic blockade by risperidone and 
haloperidol. Alternately, although dopaminergic firing is highly active at this age, presynaptic 
dopamine innervation of the adolescent dorsal striatum is incomplete compared with adults 
(Matthews et al. 2013; Stamford 1989). Therefore if the synaptic machinery of the subcortical 
dopamine synapse is still under development perhaps the anti-dopaminergic effects of risperidone 
or haloperidol may not be fully experienced. Age-dependent differences in drug metabolism appear 
unlikely since the expression and function of liver cytochrome P450 enzymes have reached adult 
levels by PND30 in rats (Johnson et al. 2000). 
Tolerance was induced to the CAR suppressing effects of clozapine at all ages. Development of 
clozapine tolerance with repeated daily treatment was in line with the reported findings in the 
literature. For example, tolerance developed to 20 mg/kg clozapine developed in a CAR paradigm 
as early as the third day of daily treatment in adult Wistar rats (Sanger 1985). This finding has been 
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replicated in recent studies, with clozapine tolerance developing after 3 days of treatment in adult 
SD rats (Li et al. 2010) and 5 days of treatment in adolescent SD rats (Qiao et al. 2013), which is in 
excellent agreement with my findings. Clozapine tolerance during chronic treatment can have 
important clinical implications since the clinical literature has documented several case reports of 
psychosis relapse (“supersensitivity psychosis”) on sudden clozapine withdrawal or switching from 
clozapine to other APDs (Ekblom et al. 1984; Eklund 1987; Perényi et al. 1985) or lack of 
clozapine efficacy on reintroduction after discontinuation (Grassi et al. 1999). While this finding 
provides a good future direction, further studies with clozapine were not allowed due to ethical 
reasons: (1) at the time of tissue collection, all clozapine-treated rats (18 out of 18) showed signs of 
intestinal adhesions and obstructions and (2) two of 18 clozapine-tread animals had to be sacrificed 
due to distress along with weight loss and abdominal distension. 
3.4.2. Behaviour after a drug-free interval 
To examine whether three weeks of daily APD exposure would produce persistent effects on neural 
function, I chose to probe CAR behaviour after re-exposure. The use of a half dose challenge was to 
prevent any floor effect in the likely event of sensitization after drug washout as suggested in the 
literature (Qiao et al. 2014a; Qiao et al. 2013; Qiao et al. 2014b).  
Predictably, after a lengthy drug washout period, rats with risperidone pre-treatment in adulthood 
showed lower avoidance suppression by this lower dose compared with the earlier administered full 
dose. By contrast, rats treated as adolescents responded to half dose challenge at a similar level as 
they did to chronic full dose risperidone, suggesting an increase in behavioural responsivity to this 
drug on re-exposure. Importantly this apparent sensitivity to CAR suppression after drug washout 
was not confounded by age-related alterations in escape failures and crossings, which were almost 
exactly the same in both age groups. This finding is in agreement with a recent study in which rats 
treated as adolescents with risperidone for 5 days were reported to show a sensitization-like CAR 
response, i.e. an increase in behavioural sensitivity, to a challenge dose of this APD as adults (Qiao 
et al. 2014a). The selective behavioural sensitivity in rats treated as adolescents is made more 
notable by the longer drug-washout period in our study (60 days vs. 15 days in adults). Moreover, 
our supplementary data showing that drug wash-out period had no effect on an animal’s ability to 
retain or relearn the avoidance response in the behavioural paradigm employed argue against the 
possibility that rats exposed to risperidone in adolescence were starting from any different baseline. 
Although sensitization to risperidone in a CAR paradigm has also been reported in adult rats (Gao 
and Li 2013), this behavioural response was not observed in my study. Variations in our 
experimental design such as the dose (1.3 mg/kg vs. 1 mg/kg), route (IP vs. SC), duration of 
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exposure (21 vs. 5 days), age of CAR training (adolescent vs. adult) and nature of CAR paradigms 
(CS-US test vs. CS-only test) may explain our inability to show this in chronically treated adults. 
With respect to haloperidol and clozapine treatment in Experiment 1A, the challenge dose of 
haloperidol (0.025 mg/kg) suppressed CAR to a level approximately 50% of that seen in all age-
matched controls. This dose is approximately equivalent to the reported ED50 dose of haloperidol 
for CAR suppression (Natesan et al. 2007). This suggests that no significant increase in behavioural 
sensitivity to haloperidol was induced at any ages after drug washout. Since this second part of our 
study was designed to assess long-term sensitization to prior APD exposure, the question of 
whether clozapine tolerance persisted after drug-washout could not be addressed due to the use of a 
lower (7.5 mg/kg), not higher, clozapine dose as a challenge dose. A challenge with the same (15 
mg/kg) or a higher dose would be required to assess this in future studies. 
3.4.3. Brain structural outcome and neural metabolism with chronic APD treatment 
Chronic 21-day APD administration in both adolescents and adults produced no long-term effect on 
any brain structure examined, possibly because the duration of treatment was insufficient to induce 
structural changes. Reduction in whole brain and cortical volumes in adult SD rats has been 
reported to occur after 8 weeks of continuous APD treatment via osmotic minipumps but not after 4 
weeks (Vernon et al. 2011). Although differences in route of administration (osmotic minipumps in 
the study by Vernon et al. and IP in the current study) may impede a direct comparison of the 
findings, it appears that an extended duration of treatment may be required to induce brain structural 
changes. Unfortunately any treatment duration longer than 5 weeks would have exceeded the 
duration of adolescence in rats making it impossible to parse adolescent exposure-specific effects. 
Still, it remains plausible that ultra-structural changes such as alterations in the dendritic spines can 
occur (Frost et al. 2010; Milstein et al. 2013).  
My findings contrast with those of Piontkewitz and colleagues who reported that adolescent 
treatment with 1.2 mg/kg risperidone for 14 days led to reduction in adult whole brain volume at 
PND120 (Piontkewitz et al. 2011). Differences in experimental factors including rat strains (SD vs. 
Wistar), prenatal handling exposure in the latter’s study and adolescent exposure to CAR training in 
the current study may have confounded comparison. In any case I interpret an absence of any long-
term changes in brain volumes in our 21-day risperidone regimen as an indication that my particular 
regimen may be less toxic then others previously used. 
The limitations in interpretation of structural outcomes should also be acknowledged. In this study, 
manual segmentation of brain regions was performed. This methodology has certain drawbacks: (1) 
only the regions that have been defined a priori can be analysed; (2) volumetric analysis of brain 
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regions such as the NAc will be difficult to be achieved reliably; (3) manual segmentation is less 
sensitive to detect smaller changes in brain volume. Therefore, the use of automated analysis such 
as voxel-based or deformation-based morphometry (VBM or DBM, for example, see (Lau et al. 
2008)) may be able to detect voxel-wise changes in brain structure. A recent study in adult SD rats 
utilized tensor-based morphometry (TBM) analysis of structural MRI data and showed that chronic 
8-week treatment with haloperidol and olanzapine induced inward and outward displacement of 
dorsal hippocampus respectively while hippocampal volume was not altered (Crum et al. 2016). 
The use of VBM, DBM or TBM in addition to volumetric analysis will help address the question as 
to whether adolescent APD treatment can induce similar changes in brain morphometry. Another 
limitation is a possible role of the drug-free interval in determining structural outcomes. In adult 
rats, increases in striatal volume and decreases in whole brain volume have been reported to 
normalize after 8 weeks of drug-free interval (Vernon et al. 2012). Therefore, a more thorough 
investigation with longitudinal assessment with adequate sample size is still required to determine 
brain structural changes with adolescent APD treatment.    
A recent preclinical study suggested that treatment with the atypical APD olanzapine in adolescence 
could alter the baseline levels of glutamate and GABA in the NAc at adulthood (Xu et al. 2015). 
Therefore, in Experiment 1B, I examined the levels of these neural metabolites and NAA in the 
NAc of mature rats that had been treated with risperidone in adolescence or adulthood. No 
significant alteration in the levels of accumbal metabolites was observed. It appears that long-term 
changes in levels of GABA and glutamate in the NAc depend on the type of APD and possibly the 
route of administration (IP injection in the current study vs via drinking water in Xu’s study). 
3.4.4. Neurochemistry after a drug-free interval 
The NAc is a major locus of APD-induced CAR impairment (Wadenberg et al. 1990b). 
Dopaminergic neurotransmission primarily within the NAc (McCullough et al. 1993; Oleson et al. 
2012) has also been reported to play a critical role in CAR behaviour. Also given the well-known 
regulation of dopamine by serotonergic systems (Di Giovanni et al. 2008; Di Matteo et al. 2008; 
Navailles and De Deurwaerdère 2011) and the high affinities of risperidone for 5HT2A receptors 
(Schotte et al. 1996) I elected to examine gene expression of dopaminergic markers and 5HT2A 
receptors in the NAc. Here I revealed a significant downregulation in gene expression of 5HT2A 
receptors and COMT selectively in rats chronically exposed to risperidone as adolescents.  
Decreased 5HT2A receptors have been reported in different brain regions shortly after termination of 
chronic treatment with atypical APDs such as olanzapine, risperidone and clozapine in both adult 
(Lian et al. 2013; Tarazi et al. 2002; Yadav et al. 2011) and adolescent animals (Choi et al. 2010b). 
Our findings extend this literature by demonstrating that reductions in 5HT2A receptors in the NAc 
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can occur long after a drug withdrawal from adolescent treatment. Changes in both mRNA and 
protein levels of COMT have been reported in the frontal cortex of adult animals 24 hours after 
withdrawal from chronic 21-28 day treatment with atypical APDs such as risperidone, olanzapine, 
clozapine and aripiprazole. The direction of change is inconsistent, with reports of both up- (Chen 
and Chen 2007; Cheng et al. 2008) and down-regulated (Fatemi and Folsom 2007; Fatemi et al. 
2012) levels. To the best of my knowledge COMT expression in the NAc tissues after APD 
withdrawal has not been examined. Here, I showed that COMT was downregulated in rats with 
adolescent risperidone exposure even after two months of drug-free period. 
What is the functional significance of decreased expression of 5HT2A receptors and COMT in the 
NAc? Blockade of 5HT2A receptors by a selective 5HT2A antagonist MDL100907 has no effect on 
CAR performance by itself. However, MDL100907 can enhance the CAR-suppressive effects of 
both raclopride and haloperidol, which are potent D2 receptor antagonists (Wadenberg et al. 2001a; 
Wadenberg et al. 1998a). The co-administration of MDL100907 with such potent DA blocking 
agents recreates the pharmacology of risperidone. Therefore the selective reduction in NAc 5HT2A 
receptors in the adolescent risperidone-exposed animals may phenocopy the effects of 5HT2A 
receptor blockade thus enhancing CAR suppression on re-exposure to this APD. 
COMT and monoamine oxidase A and B (MAO-A and MAO-B) are enzymes involved in the 
degradation of mono-amine neurotransmitters such as dopamine, epinephreine and norepiphrenine. 
Given reports that APD-induced downregulation of COMT mRNA levels is accompanied by 
decreased protein levels (Fatemi and Folsom 2007), it is presumed that NAc COMT protein will 
also be downregulated in our animals. Such a condition may lead to compromised DA turnover in 
the NAc although we are wary of such speculation given mono-amine oxidase levels are normal. In 
any case, given that one outcome of 5HT2Aactivation is increased dopamine synthesis and release 
(Navailles and De Deurwaerdère 2011), I speculate this reduction in COMT may be a compensatory 
process in an attempt to maintain normal NAc DA levels as 5HT2A receptor function is presumably 
impaired in adolescents exposed to risperidone. Measurement of monoamines and their metabolites 
by high-performance liquid chromatography (HPLC) along with an assessment of COMT 
functional activity in the NAc from these animals is therefore now warranted (See Chapter 5). 
In summary, the findings of Experiment 1 show that the adolescent brain is highly susceptible to 
risperidone, with this atypical APD being capable of inducing long-standing changes in behaviour 
and neurochemistry in the NAc. However, the findings should still be interpreted in the context of 
certain limitations. First, I have examined CAR as the sole behavioural read-out of risperidone’s 
effects on integrated brain function. Other behavioural tests examining cognitive function, decision-
making and risk-taking, the ability to learn a complicated task, reward function, challenge with 
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other psychomimetic drugs or 5HT2A-dependent behavioural tests such as 5HT2A-agonist induced 
head shake behaviour (Canal and Morgan 2012; Halberstadt and Geyer 2013) may produce 
complimentary results. Second, to keep final CAR testing age constant in all groups by necessity, 
the duration of drug washout period varied. It remains unanswered whether a longer drug-free 
interval in adult exposure groups may have produced a similar behavioural and neurochemical 
outcome as in adolescent exposure group. This provided a future direction for Chapter 5 to examine 
risperidone-induced neurobiological outcomes after an equivalent drug-free interval. Third, other 
important regions such as PFC, striatum and VTA have not been examined for changes in 
neurochemistry. It is unknown whether changes in 5HT2A and COMT in the NAc of rats with 
adolescent risperidone exposure are compensatory to neurotransmission changes in these regions. 
 
 
  
 
 
 
 
 
 
 
 
 
Chapter 4. A comparative examination of risperidone-
induced cataleptic responses in adolescents and adults 
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4.1. Introduction 
In Chapter 3, I showed that chronic administration of risperidone induced a significantly lower level 
of escape failures in adolescents than in adults. This finding suggested two possibilities: (1) neural 
adaptation changes during chronic risperidone treatment are different in adolescents and adults and 
(2) APD-induced escape failures in the CAR paradigm (total failure to respond to both conditioned 
stimulus (white noise) and unconditioned stimulus (foot-shock)) possibly reflect cataleptic 
responses (Wadenberg 2010). Catalepsy in rodents represents as the state in which the animal 
remains or fails to correct an unusual posture for an extended duration (Sanberg et al. 1988; 
Wadenberg 1996). Therefore, in Chapter 3, I speculated that a progressive increase in cataleptic 
response developed after repeated risperidone treatment in adults, but this developed at a lower 
level when the same treatment regime was used in adolescents. 
Supporting this hypothesis, a progressive increase in cataleptic responses in adult rats has been 
reported with repeated treatment with low dose haloperidol, a typical APD, despite the lack of such 
a response at the beginning of treatment (Banasikowski and Beninger 2012a; Pezarro Schimmel et 
al. 2015; Schmidt et al. 1999). Another study has also reported that the cataleptic responses of 
adolescent male rats progressed at a lower rate than adults during repeated treatment with 
haloperidol (Wiley and Evans 2008). The findings by Wiley and Evans again suggested a different 
rate of neural adaptative changes in adolescents in response to ongoing repeated APD treatment. 
Wiley and Evans also reported that repeated treatment with the atypical APD clozapine could also 
progressively induce catalepsy in both adolescents and adults; however there was no differential 
age-dependent effect with clozapine, suggesting that the behavioural outcomes could vary with the 
receptor affinity profiles of the APD. However, this study did not investigate neurochemical 
changes that could underlie differential cataleptic responses at these two ages. Therefore, the neural 
mechanism(s) that predispose(s) adolescents to lower a cataleptic response to APDs is still 
unknown. Moreover, it is still unknown whether chronic treatment with risperidone, another 
atypical APD with different neurotransmitter receptor affinity profiles (Schotte et al. 1996), could 
induce a differential pattern of catalepsy in adolescents and adults.  
In rodents, APD-induced cataleptic response models the potential for extrapyramidal side effects 
(EPS) in humans such as akinesia and rigidity (Hoffman and Donovan 1995; Porsolt et al. 2010). 
Doses of APDs exceeding 80% striatal dopamine receptor blockade can induce EPS in humans 
(Kapur et al. 2000) and cataleptic responses in rodents (Natesan et al. 2008; Natesan et al. 2006a; 
Wadenberg et al. 2000; Wadenberg et al. 2001b). The cataleptic response in rodents is examined 
with either a horizontal bar or grid test (Sanberg et al. 1988; Wadenberg 1996).  
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The striatum has been reported to be the major brain region associated with APD-induced catalepsy 
(Ossowska et al. 1990; Yoshida et al. 1994). A progressive increase in haloperidol-induced 
catalepsy in adults has also been linked to spike frequency of medium spiny neurons in the striatum 
(Frank and Schmidt 2004). However, the adolescent striatum is undergoing important maturation 
changes, especially in the dopaminergic systems with changes in both presynaptic activity 
(Matthews et al. 2013; Stamford 1989) and postsynaptic receptors (Tarazi and Baldessarini 2000; 
Tarazi et al. 1999; Teicher et al. 1995). Consequently, chronic APD-induced dopaminergic 
blockade may not have as much effect on the adolescent striatum as on the adult striatum. This may 
be an underlying neural mechanism for the differential cataleptic responses induced in adolescents 
and adults by APDs. Alternately, chronic risperidone treatment may actively alter maturation within 
the adolescent striatum and consequently alter behavioural responses to this APD. To answer these 
questions, no study to date has thoroughly examined longitudinal course of behavioural response 
with repeated risperidone treatment in adolescents, in comparison with the same regimen in adults.  
Here in Chapter 4, I aimed to address whether chronic risperidone induces a differential progression 
of catalepsy in adolescents compared with adults and to understand what neural mechanisms 
underlie such outcomes. I hypothesized that (1) cataleptic responses induced by chronic risperidone 
treatment are lower in adolescents than in adults and (2) risperidone-induced increases in dopamine 
neurotransmission in the immature adolescent striatum underlie a lower cataleptic vulnerability in 
adolescents.  
4.2. Materials and methods 
4.2.1. Subjects 
Male SD rats arrived at the animal facility either on PND 28 (n= 24 for adolescent cohort) or PND 
70 (for adult cohort, n = 24) (n = 12 per drug group for a given age. One rat assigned to the 
adolescent control group died before the start of experiments, thus giving n = 11 for this group. Rats 
from the same drug and age groups were pair-housed in Macrolon cages (39 cm x 23.5 cm x 16 cm) 
with Sani chip bedding (Able Scientific) and wire lids in a temperature (21 ± 1 °C) and lighting 
(lights on at 06:00 h and off at 18:00 h) controlled room. All rats were given ad libitum access to 
food and water throughout the whole experiment. Behavioural tests were conducted during the light 
phase of the diurnal cycle. 
4.2.2. Experimental design 
Rats were treated with 1.3 mg/kg risperidone or vehicle (IP) for 22 continuous days either as 
adolescents (PND35-PND56) or as adults (PND80-PND101) (Figure 4-1). On Day 1, 3, 5, 7, 10 and 
17 of chronic treatment, rats were examined for cataleptic response 1 h after injection using the 
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horizontal bar test. This time point was chosen to match the time after drug administration in which 
escape failures were observed in the CAR in Chapter 3. Immediately after termination of cataleptic 
test, rats were placed in the locomotor chambers for recording of locomotor activity for 30 min. At 
24 h after the last injection i.e. Day 23 of experiment, all rats were sacrificed with an overdose of 
phenobarbitone (Lethabarb) and brain tissues collected in liquid nitrogen, coded and stored at -80 
C until use. 
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Figure 4-1 Timeline of the catalepsy experiment. Rats treated with risperidone or vehicle either as adolescents (PND35-PND56) or adults (PND80-PND101) were 
tested for cataleptic responses (CAT) and locomotor activity (Loco) at 1 h after injection at Day 1, 3, 5, 7, 10 and 17 of treatment. At 24 h after the last injection i.e. 
at Day 23 of experiment, right and left striatal tissues were collected for HPLC and real-time PCR respectively. 
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4.2.2.1 Bar test for catalepsy 
The horizontal bar test was performed using a chamber (35 cm x 20 cm x 25 cm), comprising a grid 
floor and a horizontal bar (1 cm in diameter) with adjustable height (10 cm for adolescents and 13 
cm for adults) (See details in Chapter 2, Section 2.3). At 1 h after injection with vehicle or 
risperidone, rats were placed individually into bar apparatus. Both forepaws of rats were gently 
placed on the horizontal bar and the time rats stayed with both forepaws on the bar was video-
recorded. If rats voluntarily removed their paws from the bar, they were placed back on to the bar 
after a waiting time of 10 s. Each rat was examined for a maximum duration of 180 s or a maximum 
of 12 trials (12 times of placing the forepaws on the bar). Videos were coded and analysed in Media 
Player Classic Home video viewer. Analyst was blind to treatment. The duration rats stayed with 
their forepaws (time on-bar) was noted in millisecond resolution. The average duration of time on-
bar out of the total number of trials in each test was calculated for each animal. 
4.2.2.2 Open field test (OFT) for locomotor activity 
Risperidone-induced suppression of spontaneous locomotor activity was tested in four black 
Plexiglas locomotor activity chambers (45 cm x 45 cm x 30 cm). The chambers were equipped with 
Activity Monitor (MedAssociates). Immediately after catalepsy test (which took approximately 5 
min per rat) i.e. ~ 65 min after injection with risperidone or vehicle, rats were individually placed in 
the locomotor chambers and locomotor activity was examined for a total of 30 min in terms of total 
distance travelled (cm).  
4.2.2.3 HPLC of striatal tissues 
At 24 h after the last injection, all rats were euthanised and their striatal tissues collected and stored 
at -80 ˚C until use. Briefly, the right hemisphere striatum was quickly weighed (wet weight) and 
homogenised on ice in a minimum volume of 0.1 ml of 0.1M perchloric acid and 50 mg/ml 
deoxyepinephrine (internal standard for catecholamines), using ultrasonicator probe (Vibra-Cell, 
Sonics & Materials, Inc. CT.). After centrifugation at 13,000 rpm for 5 minutes, supernatant from 
each sample was collected and filtered through 0.2 µm nylon filter. Next, 10 µl of each sample was 
injected into a HPLC system (See details in Chapter 2)  and dopamine, serotonin (5HT), 
noradrenaline and their metabolites (dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
(HVA), 3-methoxytyrarmine (3-MT) and 5-hydroxyindoleacetic acid (5-HIAA)) and measured. 
Data were processed offline with Chemstation software (Rev B.01.03, Agilent Technologies, Inc. 
CA). The amount of catecholamines and their metabolites were expressed as pg/mg wet tissue, after 
correction for the dilution. 
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4.2.2.4 RT-PCR of striatal tissues 
Briefly, total RNA was extracted from each left striatal hemisphere sample using QIAzol and 
RNeasy Mini Kit (Qiagen, Australia). For each sample, 1 g of RNA per 21 μl reaction was 
reverse-transcribed to cDNA with SuperScript IV First-Strand Synthesis System (Invitrogen). RT-
PCR was performed in 12 µl reaction using a Roche LightCycler 480 (Roche Diagnostics, 
Australia), using a SYBR Green method in 384-well plates. Relative expression of the target genes 
normalized to that of endogenous control GAPDH was calculated following the published method 
(Schmittgen and Livak 2008). All PCR experiments were performed twice. Gene expression data 
was only considered if significant changes were observed in both repeats. PCR experiments were 
performed with adolescent and adult groups in the same PCR plate along with a universal control 
sample in each plate. The 2-∆Ct values of each sample normalized to that of the universal control. 
This allowed the whole cohort to be compared across-age groups.  
4.2.3. Statistical analysis 
All data were expressed as mean ± standard error of the mean (SEM). Catalepsy data (time on bar) 
were log-transformed for normalization. Behavioural data were analyzed with repeated measures 
two-way (age x drug) analysis of variance (ANOVA) followed by posthoc Dunnett’s tests. Due to a 
technical problem with the controlling computer, locomotor data from 3 adolescent control animals 
at Day 3 were lost, thus giving n = 8 for this particular time point. HPLC and real-time PCR data 
were analysed with two-way ANOVA followed by post hoc Dunnett’s tests. Pearson’s correlation 
analysis was used to determine the relationship between neurochemical and behavioural data. 
Statistical significance was defined as p< 0.05. 
4.3. Results 
4.3.1. Cataleptic responses in adolescents vs adults during chronic risperidone treatment 
As shown in Figure 4-2, cataleptic responses progressively increased in both adults and adolescents 
treated with risperidone from Day 1 to Day 17 of chronic treatment, but not in controls. Starting 
from Day 5, a differential cataleptic outcome was observed; the levels of cataleptic responses were 
lower in adolescents than in adults [2-way repeated measures ANOVA: significant main effects of 
Day (F5, 200 = 23.628), Drug (F1,40 = 96.635), Day x Drug interaction (F5,200 = 7.823), all p < 0.001; 
but no significant main effects of Age (F1,40 = 1.186), Age x Drug (F1,40 = 1.517), Day x Age (F5,200 
= 0.837) or Day x Age x Drug interaction (F5,200 = 1.346), all p> 0.05].  
Further examination at individual testing days showed that risperidone-treated adolescents had 
significantly lower cataleptic response than their adult counterparts (p= 0.047) at Day 10 [2-way 
ANOVA: significant main effects of Drug (F1,43 = 96.572, p < 0.001) and Age (F1,43) = 4.082, p = 
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0.05) but no Age x Drug interaction (F1,43 = 2.023, p = 0.162)]. The differences in cataleptic 
responses between risperidone-treated adolescents and adults approached statistical significance (p 
= 0.082) at Day 5 [2-way ANOVA: significant main effects of Drug (F1,43 = 102.177, p < 0.001) 
and Age x Drug interaction (F1,43 = 5.241, p = 0.027; no main effect of Age (F1,43 = 0.648, p = 
0.425)]. No significant difference in cataleptic responses was observed at other test days. Vehicle-
treated adolescents and adults did not show any differences in the time-on bar.  
These data support the hypothesis that, with ongoing chronic risperidone treatment, the time course 
of behavioural responses in adolescents is different from that of adults and the adolescents develop 
lower catalepsy than adults. 
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Figure 4-2 Risperidone-induced cataleptic responses were lower in adolescents than in adults. Data 
expressed mean ± SEM. n = 12 per drug for a given age except n = 11 for adolescent CON. *** p < 0.001 
RIS vs CON; * p < 0.05 for adolescent RIS vs adult RIS; # p = 0.08 for adolescent RIS vs adult RIS. CON – 
vehicle-treated controls; RIS – risperidone-treated group;  
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4.3.2. Locomotor activity in adolescents vs adults during chronic risperidone treatment 
Risperidone suppressed locomotor activity in both adolescents and adults starting from Day 1 of 
administration (Figure 4-3). Again, apparent differences in risperidone-induced locomotor 
suppression were observed in adolescents and adults [2-way repeated measures ANOVA: 
significant main effects of Drug (F1,40 = 147.071 , p < 0.001 ) and Day (F5,200 = 5.061, p <0.001); 
Age x Drug (F1,40 = 4.021, p = 0.052); no main effects of Age (F1,40 = 0.173, p = 0.680); Day x Age 
(F5,200 = 2.112, p = 0.065); Day x Drug (F5,200 = 0.574, p = 0.720); Day x Age x Drug (F5,200 = 
0.500, p = 0.776)]. 
Further examination at individual test days confirmed that risperidone-treated animals from both 
adolescent and adult cohorts had significantly lower locomotor activity than their corresponding 
controls (p < 0.001 for all days). Two-way ANOVA at individual test days showed a significant 
main effect of age x drug interaction at Day 17 (F1,43 = 5.953, p = 0.019). However, the differences 
in locomotor activity between risperidone-treated adolescents and adults did not reach the statistical 
threshold of post-hoc tests (all p > 0.1).  
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Figure 4-3 Chronic risperidone-induced suppression of locomotor activity in adolescents and adults. Data 
expressed mean ± SEM. n = 12 per drug for a given age except n = 11 for adolescent CON. *** p < 0.001 
RIS vs CON; CON – vehicle-treated controls; RIS – risperidone-treated group; 
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4.3.3. Changes in striatal monoamines and metabolites with chronic risperidone treatment 
in adolescents vs adults 
One day after termination of chronic 22-day treatment, risperidone-induced changes in striatal 
monoamines (dopamine, 5HT and noradrenaline) and their metabolites (DOPAC, HVA, 3MT and 
5HIAA) were examined.  
Among monoamines (Figure 4-4), no significant alterations were observed for both dopamine [2-
way ANOVA: no significant main effect of Age, Drug or Age x Drug interaction, all F < 1.9, all p > 
0.1) and noradrenaline [2-way ANOVA: no significant main effects of Age, Drug and Age x Drug 
interaction, all F < 3.1 all p > 0.08].  However, significant differences in 5HT levels were observed 
between adolescent and adult cohorts [2-way ANOVA: significant main effect of Age (F1,43 = 
8.007, p = 0.007) but no main effect of Drug (F1,43 = 1.770) or Age x Drug interaction (F1,43 = 
0.499), both p > 0.1). 
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Figure 4-4 Changes in levels of striatal monoamines with chronic risperidone treatment in adolescence or adulthood. Striatal levels of (a) dopamine (b) 
noradrenaline (NA) and (c) 5HT are shown for both adolescents and adults. Data expressed mean ± SEM. n = 12 per drug for a given age except n = 11 for 
adolescent CON. ** p < 0.01 adolescent cohorts vs adult cohorts; CON – vehicle-treated controls; NA – noradrenaline; RIS – risperidone-treated group;
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Increases in striatal 5HIAA, the main metabolite of 5HT, followed the increases observed in 5HT. 
The adolescent cohorts had significantly higher 5HIAA than adult cohorts [2-way ANOVA: 
significant main effects of Age (F1,43= 8.232, p = 0.006); no main effect of Drug (F1,43 = 1.455) or 
Age x Drug interaction (F1,43 = 2.170), both p > 0.1].  
The adolescent risperidone group appeared to show higher levels of dopamine metabolites: DOPAC 
[2-way ANOVA: significant main effects of Age x Drug interaction (F1,43 = 4.601, p = 0.038) but 
no main effect of Age or Drug, both F< 1.7 and p > 0.1]; HVA [2-way ANOVA: significant main 
effects of Age x Drug interaction (F1,43= 5.870, p = 0.020) but no main effect of Age or Drug, both 
F < 1.7 and p > 0.1]; 3MT [2-way ANOVA: significant main effects of Age x Drug interaction 
(F1,43 = 5.906, p = 0.019) and Drug (F1,43 = 4.562, p = 0.038); but not main effect of Age (F1,43 = 
2.820, p = 0.10]. On further analysis, the adolescent risperidone group had significant higher levels 
of DOPAC (p < 0.05) and 3MT (p = 0.007), compared to adolescent controls. In addition, 
risperidone-treated adolescent rats had higher levels of 3MT than their adult counterparts and adult 
controls (both p < 0.05). Striatal HVA levels were not statistically different among different groups. 
Turnover rate of dopamine and 5HT was also examined by comparison of ratios between DOPAC 
or HVA and dopamine and between 5HIAA and 5HT respectively. However, no significant 
difference was observed among different groups.  
Taken together, these findings of increased dopamine metabolites in risperidone treated adolescents 
suggested that changes in dopaminergic neurotransmission on a background of higher 5HT and 
5HIAA might contribute to some underlying neural mechanism for their diminished cataleptic 
responses. 
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(c)         (d) 
  
Figure 4-5 Changes in levels of striatal monoaminergic metabolites following chronic risperidone treatment in adolescents or adults. Striatal levels of (a) 5HIAA (b) 
DOPAC, (c) 3MT and (d) HVA are shown for both adolescents and adults. Data expressed mean ± SEM. n = 12 per drug for a given age except n = 11 for 
adolescent CON. * p < 0.05 for adolescent RIS vs other treatment group; ** p < 0.01 for adolescent RIS vs other treatment group and for adolescent cohorts vs 
adult cohorts; 3MT – 3-Methoxytyramine;5HIAA – 5-Hydroxyindoleacetic acid; CON – vehicle-treated controls; DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – 
homovanillic acid; RIS – risperidone-treated group;  
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4.3.4. Relationship between striatal dopamine metabolites and cataleptic responses at Day 
17 
Interestingly, in adolescents treated with risperidone, the levels of the striatal dopamine metabolites: 
DOPAC (r = -0.728, p = 0.007) and HVA (r = -0.631, p = 0.028) negatively correlated with the 
cataleptic responses at Day 17, which was the time of behavioural testing most proximal to that of 
neurochemical examination (Figure 4-6(a) and (b)). This finding was again selective to adolescent 
risperidone treatment. No correlation was found in either adult risperidone treated animals or 
control groups (Figure 4-6(c) and (d)). In adolescent controls, a positive correlation between 
cataleptic scores and striatal DOPAC only (r = 0.6256, p = 0.040) was observed.  
In addition, striatal dopamine levels positively correlated with both DOPAC (r = 0.818, p = 0.001) 
and HVA (r = 0.622, p = 0.031) in adolescent risperidone group and only with DOPAC in their 
controls (r = 0.643, p = 0.033). This suggested that in this age group, striatal dopamine availability 
was closely linked to the levels of dopamine metabolites. However, in adult groups, no correlation 
was observed between striatal dopamine and its metabolites levels (r = -0.194 to 0.425, all p> 0.1). 
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(c)        (d) 
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Figure 4-6 Correlation between striatal dopamine metabolites and cataleptic responses at Day 17 in adolescents and adults.(a) Striatal dopamine metabolites 
negatively correlated with cataleptic responses in adolescent rats treated with risperidone. (b) In adolescent controls, only striatal DOPAC levels correlated with 
cataleptic responses but this was in the reverse direction. Adult rats treated with (c) risperidone or (d) vehicle did not show any significant correlation between 
striatal dopamine metabolites and cataleptic responses.   
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4.3.5. Risperidone-induced changes in dopaminergic receptors and metabolizing enzymes in 
adolescents and adults 
Next I examined whether dopamine receptor expression in the adolescent striatum was altered by 
chronic risperidone treatment. As shown in Figure 4-7 (a and b), no significant alterations in D2 and 
D1 receptor mRNA levels were observed in both adolescents and adults (2-way ANOVA for D1: no 
significant main effect of Age, Drug or Age x Drug interaction, all F < 2, p > 0.1; 2-way ANOVA 
for D2: no significant main effect of Age or Drug (both F < 2, p > 0.1) or Age x Drug interaction 
(F1,43 = 3.311, p = 0.076).   
Given the findings of increased striatal dopamine metabolites in risperidone-treated adolescents, the 
expression of dopamine-metabolizing enzymes was also examined. As described in Figure 4-7 (c 
and d), no significant alterations of COMT and MAO-A was observed in both adolescents and 
adults (2-way ANOVA: no significant main effects of Age, Drug, or Age x Drug interaction for 
both COMT and MAO-A, all F < 2.1, all p >0.15).   
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(c)            (d) 
     
Figure 4-7 Risperidone induced no alteration in gene expression of dopamine receptors and dopamine-metabolizing enzymes in adolescents and adults.No 
significant alteration was observed in gene expression of (a) D2 and (b) D1 receptors, (c) COMT and (d) MAO-A with risperidone treatment in adolescence or 
adulthood. Data expressed mean ± SEM. n = 12 per drug for a given age except n = 11 for adolescent CON. CON – vehicle-treated controls; COMT – catechol-o-
methyl transferase; MAO-A – monoamine oxidase A 
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4.4. Discussion 
The main findings of Chapter 4 were: (1) compared to adults, adolescents developed a lower 
progression of cataleptic responses during chronic risperidone treatment; (2) striatal levels of 
dopamine metabolites namely DOPAC and 3MT were elevated selectively in rats treated with 
risperidone in adolescence; (3) a relationship between striatal dopamine metabolite levels and 
cataleptic responses was identified in adolescents treated with risperidone. 
4.4.1. Differential cataleptic responses induced in adolescents and adults 
As predicted, risperidone induced an increasing level of cataleptic responses in both adolescents and 
adults from Day 1 to Day 17 of chronic treatment. The cataleptic responses in adolescents and 
adults were almost indistinguishable at the beginning of treatment. However, starting from Day 5, 
adolescents showed lower levels of cataleptic responses than adults and this difference in cataleptic 
responses became significant at Day 10. These findings are consistent with a previous preclinical 
report which showed a lower rate of progression of cataleptic responses in male adolescent rats 
compared with male adults during 10-day treatment with a typical APD haloperidol (Wiley and 
Evans 2008). These data explain the lower levels of escape failures in risperidone treated 
adolescents relative to adults during CAR testing during chronic treatment in Chapter 3. These data 
further support the hypothesis in Chapter 3 that disruption of avoidance responses by chronic 
risperidone in the CAR paradigm is partly contributed to by escape failures/cataleptic responses. 
Moreover, it is still unknown whether the observed outcome in catalepsy persists after a drug-free 
interval or whether the adolescents are more vulnerable to long-term catalepsy than adults. 
Following up on these questions, I examined long-term cataleptic response in rats treated with 
risperidone in adolescence or adulthood in (See Chapter 5). 
Several studies have consistently shown that, in adult rats, repeated treatment with haloperidol, a 
typical APD with high affinity for dopamine D2 receptors, induces a progressive increase in 
catalepsy, a behavioural response often referred to as ‘catalepsy sensitization’ (Banasikowski and 
Beninger 2012a; Banasikowski and Beninger 2012b; Frank and Schmidt 2004; Klein and Schmidt 
2003; Lanis and Schmidt 2001; Pezarro Schimmel et al. 2015; Riedinger et al. 2011; Schmidt et al. 
1999).These studies have also suggested a link between haloperidol-induced catalepsy sensitization 
and extra-pyramidal side-effects in humans such as akinesia and rigidity. Haloperidol-induced 
catalepsy sensitization in adult rats has also been explained through the phenomenon of 
conditioning i.e. repeated pairing of haloperidol-induced decreased dopaminergic activity and bar 
testing environment (Klein and Schmidt 2003; Schmidt et al. 1999), or inverse incentive learning 
(Pezarro Schimmel et al. 2015). Within this framework, the repeated pairing of haloperidol-induced 
hypodopaminergia and catalepsy test environment in adult rats has been proposed to lead to 
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conditioning effects and catalepsy sensitization. This idea was also supported by lack of catalepsy 
sensitization in the rats from these prior studies that underwent the same number of both daily 
haloperidol injections and catalepsy tests but only when the haloperidol injection was given after 
catalepsy test i.e. no pairing of hypodopaminergia with context. Here, I have extended this literature 
by demonstrating that repeated treatment with risperidone, an atypical APD with high affinity for 
both D2 receptors and 5HT2A receptors (Schotte et al. 1996), also induces a sensitization-like 
cataleptic response in adults but at a lower level in adolescents as chronic treatment progresses. The 
findings of lower catalepsy progression in adolescents during chronic treatment with haloperidol 
(Wiley and Evans 2008) and risperidone (Current study) indicate that the adolescent brain is rather 
different from the adult brain in short-term behavioural responses to the same APD regimen.  
Consistent with a lower catalepsy sensitization in adolescents in this study, locomotor sensitization 
to repeated treatment with psychostimulants has also been reported to be lower in adolescents, 
compared to adults – this lower locomotor sensitization in adolescents has been reported with 
cocaine (Collins and Izenwasser 2002; Frantz et al. 2007), nicotine (Collins and Izenwasser 2004), 
∆9-tetrahydrocannabinol (∆9-THC), 3,4-methylenedioxymethamphetamine (MDMA) and ketamine 
(Wiley et al. 2008a) (but see (Schramm-Sapyta et al. 2009). What neural mechanism(s) mediate(s) 
lower sensitivity of adolescents to APD-induced catalepsy sensitization or psychostimulant-induced 
locomotor sensitization? Although still not thoroughly understood, some experimenters have 
implicated the role of neural changes in dopaminergic system in the striatum (Laviola et al. 2001) 
and dopaminergic and serotonergic systems in the striatum and the NAc (Collins and Izenwasser 
2002). Here at least with risperidone-induced catalepsy sensitization, I speculated that 
neurotransmission changes in the striatum would mediate differential cataleptic responses in 
adolescents and adults (See below).   
   
4.4.2. Striatal neurochemical changes in adolescents and adults following chronic 
risperidone treatment 
The striatum is the major brain region associated with APD-induced catalepsy (Ossowska et al. 
1990; Yoshida et al. 1994); Blockade of >80% striatal dopamine receptors in the striatum by high 
doses of APDs induces cataleptic responses (Natesan et al. 2007; 2008; Natesan et al. 2006a; 
Wadenberg et al. 2000; Wadenberg et al. 2001b). Additionally spike frequency of the medium spiny 
neurons in the striatum increases with the development of haloperidol-induced catalepsy 
sensitization (Frank and Schmidt 2004). The adolescent striatum however is still maturing (See 
Chapter 6 for detailed discussion). The adolescent striatum has reduced presynaptic dopamine 
availability (Matthews et al. 2013; Stamford 1989) and a higher number of dopamine receptors 
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which are subsequently pruned to lower levels in the adult (Tarazi and Baldessarini 2000; Tarazi et 
al. 1999; Teicher et al. 1995). Therefore, I hypothesized that the striatum would be the brain region 
associated with differential cataleptic responses in adolescents and adults.  
Here, I showed that striatal levels of DOPAC and 3MT, metabolites of dopamine, were elevated 
selectively in risperidone-treated adolescents. More importantly, the levels of striatal dopaminergic 
metabolites (DOPAC and HVA) negatively correlated with the cataleptic responses at Day 17, 
which was the most proximal period to the time of neurochemical examination. Again this was 
selective to risperidone-treated adolescents. However, I did not observe any risperidone-induced 
alterations in the gene expression of dopamine-metabolizing enzymes, COMT and MAO-A.  
What is the mechanistic link between risperidone-induced catalepsy and observed neurochemical 
changes in striatum? An increase in dopaminergic metabolites may reflect an increase in either 
turnover or availability of dopamine. Turnover of dopamine could be increased by elevated levels 
of dopamine-metabolizing enzymes (COMT, MAO-A and MAO-B) or their enzymatic activity. 
Given these enzymes were unaltered at least at the level of gene expression, the observed increase 
in dopaminergic metabolites would not suggest increased metabolism. Instead, increased dopamine 
metabolites could result from increased availability of dopamine itself in the system. This 
hypothesis was supported by a tight positive correlation between the levels of dopamine and those 
of DOPAC and HVA in risperidone-treated adolescents. Tentatively I suggest that risperidone-
treated adolescent rats had an increase in dopamine availability, which consequently could 
overcome catalepsy-inducing effect of dopaminergic blockade by risperidone. However, I did not 
observe a significant elevation of dopamine in these rats. Still this finding does not exclude the 
possibility of increased dopamine availability during behaviour. Examination of dopamine release 
using a technique such as microdialysis would better address this issue.  
Lower progression of risperidone-induced cataleptic responses in adolescents may also be 
contributed to by changes in other neurotransmitter systems such as 5HT. For instance, increasing 
5HT activity is known to counteract catalepsy induced by haloperidol or other dopaminergic 
antagonists (Elliott et al. 1990; Hicks 1990; Wadenberg and Ahlenius 1995; Wadenberg and 
Hillegaart 1995; Wadenberg et al. 1999). The finding that adolescents had a higher level of 5HT 
and 5HIAA than adults suggests that this may be one reason why adolescents experience lower 
APD-induced catalepsy. 
In addition to changes in dopaminergic and 5HT systems discussed above, risperidone-induced 
alterations in other neurotransmitter systems such GABA and glutamate may also play a role in 
determining cataleptic responses in adolescents. For example, it has been reported that 
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administration of NMDA or AMPA antagonists immediately after cataleptic tests can reduce 
haloperidol-induced catalepsy sensitization (Riedinger et al. 2011). Therefore, further investigations 
into changes in glutamatergic systems may also be warranted. Another outstanding question is 
related to a potential role of age-related pharmacokinetic factors in differential cataleptic responses. 
Examination of serum levels of risperidone and its metabolite 6-hydroxyrisperidone can also 
provide more information as to whether a comparable level of drug concentration is achieved in 
adolescents and adults. I also observed no change in dopamine receptor expression. A more 
sensitive technique such as radioligand binding which can also give a read-out of functional 
receptor activity may provide more information on risperidone-induced changes in dopamine 
receptors (Moran-Gates et al. 2007).  
To sum up, here in Chapter 4, I showed that chronic risperidone induced a lower progression of 
catalepsy in adolescent rats, compared to adult rats. Accompanying this behavioural outcome, 
risperidone-treated adolescents had elevated levels of striatal dopamine metabolites, which 
correlated negatively with their cataleptic response at Day 17 of chronic treatment. I propose that 
increased availability of striatal dopamine as suggested by increased dopamine metabolite levels 
was a potential mechanism for lower cataleptic levels in adolescents. Together, the findings provide 
further support that the adolescent brain differs from the adult brain in short-term behavioural and 
neurochemical responses to chronic treatment with risperidone.  
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5.1. Introduction 
N-acetylaspartate (NAA), a well-studied molecule in neuropsychiatric diseases (Moffett et al. 
2007), is synthesized from acetyl coenzyme-A and aspartate by n-acetyltransferase 8 (NAT8L) or 
NAA synthase (Niwa et al. 2007), which is mainly located in mitochondria of neurons (Patel and 
Clark 1979). Therefore, NAA is mainly of neuronal origin and changes in NAA levels are thought 
to reflect neuronal function, viability or density (See review by (Rae 2014)). While NAA changes 
have been observed in different regions of schizophrenic patients (See systematic reviews and meta-
analyses by (Kraguljac et al. 2012; Steen et al. 2005)), potential confounds of APD treatment on 
these observations are still in debate; some studies have reported an increase or correction of NAA 
levels with APD treatment (Bertolino et al. 2001; Fannon et al. 2003; Szulc et al. 2005; Szulc et al. 
2013); other studies have observed no significant changes with APDs (Bustillo et al. 2008; Bustillo 
et al. 2010). Examination of NAA levels with APD treatment in ‘normal’ rodents without 
psychopathological effects can help address this issue.  
NAA findings from preclinical APD studies in adult rats have also been inconsistent with studies 
reporting increases (Harte et al. 2005; McLoughlin et al. 2009) or no change (Bustillo et al. 2006; 
Bustillo et al. 2004; Lindquist et al. 2011) in different brain regions following chronic APD 
treatment. On-drug changes in NAA levels, that is, changes after an injection of APD and time 
course profiles of these changes, have not been investigated in an existing study. My preliminary 
data from a pilot experiment (Appendix C) suggested that acute administration of 1.3 mg/kg 
risperidone could induce differential changes in NAA levels in the NAc of adolescents and adults; 
accumbal NAA levels were observed to increase only in adolescents approximately 20-25 min after 
risperidone administration. This preliminary finding raises the following questions: (1) Does 
risperidone treatment induce an increase in NAA in the NAc selectively in the adolescents? (2) 
How does the NAA level in the NAc change from acute (Day 1) to chronic (Day 22) risperidone 
treatment in adolescents or adults? Thus, to answer these questions in this Chapter, I utilized a 
translationally relevant technique named proton magnetic resonance spectroscopy (1H MRS), which 
enables in vivo measurement of brain metabolites (Agarwal and Renshaw 2012; Michaelis et al. 
2009). On 1H MRS spectrum, NAA is detected as a peak at 2.008 ppm (See review (Rae 2014)). In 
this Chapter, I aimed to address limitations in the pilot 1H MRS experiment by using a larger 
sample size and a more optimized 1H MRS acquisition technique. In addition to NAA, I also aimed 
to investigate other detectable metabolites such as glutamate, glutamine and GABA given their 
well-known roles in both metabolism and neurotransmission (Rae 2014).  
In Chapter 4, adolescents were observed to develop lower levels of catalepsy compared to adults, 
during chronic treatment with risperidone. This finding raises another question as to whether the 
Chapter 5 
 140 
observed differential short-term cataleptic responses in adolescents and adults can persist after a 
drug-free interval. Given that long-term cataleptic response induced by adolescent risperidone 
treatment has not been investigated thoroughly in the literature, one aim of Chapter 5 was to 
investigate the nature of cataleptic outcome induced by risperidone treatment in adolescence or 
adulthood.   
As introduced in Chapter 1 and 3, conditioned avoidance response (CAR) is the behavioural test 
widely used in screening of novel compounds with APD potential (Wadenberg 2010; Wadenberg 
and Hicks 1999). In addition, the ability to acquire the CAR is frequently investigated in studies of 
fear and anxiety (for example, see (Choi et al. 2010a; Lázaro-Muñoz et al. 2010)). In Chapter 3, all 
rats from adolescent and adult cohorts received CAR training up to a criterion of ≥70% avoidance 
during early adolescence (PND30-PND34). Given that the CAR is resistant to extinction (See 
reviews by (Kapur et al. 2006; Moutoussis et al. 2007)), these rats re-acquired the CAR in 
adulthood (PND117) rapidly with only one session of retraining (See Chapter 3, Section 3.3.2.2.2.). 
However, it is still unknown whether learning of the CAR at adulthood can be altered by prior 
adolescent risperidone treatment in previously untrained rats. In a recent preclinical study, 
adolescent olanzapine treatment was shown to decrease the rate of learning to the criterion in a 
delayed non-match to sample task and increase context-dependent freezing in adulthood (Milstein 
et al. 2013). While this data suggests a possible long-term deficit in learning a particular task, it was 
still unanswered whether this deficit was selective to adolescent treatment given a lack of 
comparison age group. In addition, the existing preclinical studies in rodents have investigated 
acquisition of the CAR in adults only during chronic treatment with risperidone (Castellano et al. 
2009; Drago et al. 1997). No study to date has examined the long-term effect of adolescent 
risperidone treatment on first-time CAR learning. Therefore, in the current chapter, I aimed to 
address the question on the impact of adolescent risperidone treatment on CAR learning at maturity. 
Another outstanding question in Chapter 3 is related to the role of drug washout period in 
determining long-term behavioural and neurochemical outcomes. Different drug washout periods in 
adolescent and adult cohorts (60 vs 14 days respectively) in Chapter 3 could possibly have 
contributed to the differential behavioural and neurochemical outcomes observed at the time of 
assessment. Indeed, the existing literature has suggested that the interval between termination of 
drug treatment and behavioural and/or neurochemical assessment influences outcome measures 
[See review by (Spear 2007)]. Therefore, in this Chapter, I aimed to investigate whether any 
differential long-term behavioural/neurochemical outcomes could still be induced in adulthood 
following an equivalent drug-free interval from chronic risperidone treatment either as adolescents 
or adults. 
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To summarise, the aims of the experiment in Chapter 5 are as follows:  
(1) To examine whether chronic risperidone treatment induces differential changes in NAA levels 
of the NAc in adolescents and adults; 
(2) To examine whether differential cataleptic responses seen in adolescents and adults during 
chronic treatment (Chapter 4) persist after a drug-free interval;  
(3) To examine whether prior chronic risperidone treatment affects CAR acquisition at adulthood in 
animals who have not previously been trained;  
(4) To examine whether the drug-free interval is a factor in sensitized CAR suppression in rats with 
adolescent risperidone exposure (Chapter 3);  
(5) To examine long-term neurochemical changes in the striatum and the NAc after a drug-free 
interval from chronic risperidone treatment.  
 
5.2. Materials and methods 
5.2.1. Subjects 
Male SD rats arrived at the animal facility either on PND 28 (n= 24 for adolescent cohort) or PND 
70 (for adult cohort, n = 24) (n = 12 per risperidone/vehicle treatment for a given age). Rats from 
the same drug and age groups were pair-housed in Macrolon cages with Sani chip bedding (Able 
Scientific) and wire lids in a temperature (21 ± 1 °C) and lighting (lights on at 6:00 h and off at 
18:00 h controlled room. All rats were given ad libitum access to food and water throughout the 
whole experiment. Imaging and behavioural tests were conducted during the light phase of the 
diurnal cycle. 
5.2.2. Experimental design 
The timeline of the experiment is shown in Figure 5-1. Rats received once-daily IP injections of 1.3 
mg/kg risperidone or vehicle for 22 days either during adolescence (PND36-PND57) or adulthood 
(PND80-PND100). This is the same risperidone treatment protocol as used in all previous 
experiments in Chapter 3 and Chapter 4. At Day 1 and Day 22 of chronic treatment, 1H MRS scans 
were performed on all rats at both baseline (prior to drug administration) and after administration of 
risperidone or vehicle. After an equivalent drug-free interval of 36 days (PND91 and PND135 
respectively for adolescent and adult cohorts), a challenge dose of 1.3 mg/kg risperidone was 
administered to all rats (both risperidone and vehicle-treated) from both age groups and their long-
term cataleptic responses were examined. Four days after the catalepsy test (PND95 or PND139 
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respectively for adolescent and adult cohorts), all rats were examined for their ability to acquire the 
CAR over 7 days of training. At least 2 days after CAR training, saphenous blood samples (~100-
150 µl) were obtained from all rats at baseline conditions (under mild restraint only). After an 
interval of four days, rats were given a CAR challenge session and saphenous blood samples were 
obtained 5-10 min after the end of this CAR session. One day after blood sample collection with 
CAR challenge, all rats were culled and their brain tissues collected. One adult control rat died 
suddenly while resting during the drug-free interval, thus giving n = 11 for this particular group.  
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Figure 5-1 Timeline of the final experiment  Rats were treated for 22 days with either risperidone or vehicle during (a) adolescence (from PND36 to PND57) or (b) 
adulthood (from PND80 to PND101). At Day 1 and Day 22 of chronic treatment, 1H MRS scans were performed at baseline and after administration of 1.3 mg/kg 
risperidone or vehicle. After a 36-day drug washout period, long-term behavioural outcomes (catalepsy, locomotion and CAR) were assessed along with 
examination of plasma corticosterone levels and neurochemical assays of regional brain tissues. CAR – conditioned avoidance response; CAT+Loco – horizontal 
bar test for catalepsy + open field test for locomotor activity; CORT – plasma corticosterone;   
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5.2.2.1 1H MRS scans with risperidone challenge 
At Day 1 and Day 22 of chronic risperidone treatment, 1H MRS spectra were obtained from each rat 
at both baseline (prior to drug administration) and after administration of 1.3 mg/kg risperidone or 
vehicle remotely through an IP cannula and attached tubing.  
After induction of anaesthesia with 5% isoflurane, each rat received an IP catheterization using 18G 
cannula and PE50 tubing (Fisher Scientific). After mounting of the rat on the animal bed of 9.4T 
MRI scanner, anaesthesia was maintained at 1.5-1.7% isoflurane and O2 flow rate of 1.2 L/min. 
Axial and sagittal anatomical scans were obtained for localization of the voxel bilaterally over the 
NAc (6 x 2 x 2 mm3). A smaller voxel size (5.5 x 1.8 x 2 mm3) was used at Day 1 scans of 
adolescent cohorts to accommodate a smaller NAc size. After minimizing magnetic field 
inhomogeneity with B0 map acquisition, first, second and third order shimming was carried out 
with MAPSHIM. Following acquisition of a reference non-suppressed water spectrum, a baseline 
water-suppressed 1H MRS spectrum was obtained from the voxel placed bilaterally on the NAc 
using PRESS sequence (TE = 9.9 ms; TR = 2500 ms; averages = 356; repetition = 1, time taken = ~ 
14.5 min). 
Immediately after the baseline scan, fifteen time course 1H MRS spectra were obtained from the 
same voxel with either risperidone or vehicle challenge using the same PRESS sequence with the 
following modifications: averages = 96 (cf. 356 in the baseline scan), time taken for each scan = ~ 4 
min (cf. 14.5 min in the baseline scan) and automated local frequency adjustment in between 15 
scans. As shown in Figure 5-2, a saline injection was remotely administered IP immediately after 
completion of the first time course 1H MRS scan to assess the effect of injection on neuronal 
metabolism. Next, an injection of risperidone or vehicle was given after the fourth scan and changes 
in accumbal metabolites were examined for the next 11 scans i.e. approximately for another 44 min.  
All 1H MRS data were processed at TOPSPIN and analysed in LCModel (version 6.3-1J) software 
(Provencher 1993), using the reference basis sets with the same data acquisition parameter. 
Metabolites with Cramer-Rao Lower bound (CRLB) or %SD > 20 were rejected from the analysis 
unless otherwise stated. The concentration of individual metabolites was expressed as a ratio to total 
creatine (Cr + PCr) following the guidelines in the LCModel manual. 
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Figure 5-2 Timeline of 1H MRS data acquisition during chronic risperidone treatment in adolescence or adulthood  At Day 1 and Day 22 of chronic treatment, 1H 
MRS spectra were obtained from the voxel bilaterally placed over the nucleus accumbens of vehicle- or risperidone-treated rats from adolescent or adult cohorts. 
First, a baseline scan was performed to obtain the levels of neural metabolites before drug administration. Next 15 1H MRS spectra were obtained, with saline 
injection immediately after completion of the first scan (Green arrow) and risperidone or vehicle injection after the fourth scan (Red arrow).    
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5.2.2.2 Bar test for catalepsy 
After a lengthy drug-free interval of 36 days (PND91 for adolescent treatment group and PND135 
for adult treatment group), the cataleptic response to a challenge dose of 1.3 mg/kg risperidone (IP) 
was examined in both risperidone- and vehicle-treated rats from both age groups. At 1 h after 
injection, their cataleptic response was examined with the horizontal bar test (for details, see 
Chapter 2, Section 2.4). Both forepaws of the rats were placed on the bar and the time rats stayed 
with both forepaws on the bar was video-recorded. Each rat was examined for a maximum duration 
of 180 s or a maximum of 12 trials (12 times of placing the forepaws on the bar). Videos were 
coded, that is, analyst was blind to treatment and analysed in Media Player Classic Home video 
viewer. The average duration an animal spent with both forepaws on the bar out of the total number 
of trials in each test was calculated for each animal. 
5.2.2.3 Open field test for locomotor activity 
Immediately after the catalepsy test i.e. approximately 65 min after injection, long-term locomotor 
response to the same challenge with risperidone was examined in four black Plexiglas locomotor 
activity chambers (for details, see Chapter 2, Section 2.5). Rats were individually placed in the 
locomotor chambers and locomotor activity was examined for a total of 30 min in terms of total 
distance travelled (cm).  
5.2.2.4 CAR training 
After a 4-day drug washout period after the catalepsy test, all rats were trained for the CAR with 40 
continuous trials per session per day for 7 days. At each training session, after 10-min habituation to 
the CAR boxes, rats received 40 trials of CS (80 dB white noise) for 10 s, followed by pairing with 
US (0.6 mA foot-shock) as described previously in Chapter 2 and 3. As before, avoidance 
(movement of the rat into the other chamber during 10 s CS-only presentation), escape (crossing 
during the next 10 s of presentation of the CS paired with the US) and escape failure (failure to 
make a crossing during the entire 20 s period) were recorded. The inter-trial interval varied 
randomly from 20 to 40 seconds (Natesan et al. 2006b; Wadenberg et al. 2001b). Avoidance, escape 
and escape failures were calculated as the percentage out of the total trials in the session. Motor 
activity was recorded as the number of chamber crossings. 
5.2.2.5 Plasma corticosterone assay  
At a minimum of 2-day interval from the CAR training, two saphenous blood samples were 
collected from each rat using 23 G needles: one at baseline (under mild restraint) and another after a 
challenge CAR session. There was an interval of 4 days in between two samples. Plasma samples 
were stored at -20˚C until use. Plasma corticosterone levels were determined by an in-house liquid 
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chromatography tandem mass spectroscopy (LC-MS/MS). The system consisted of a Shimadzu 
Nexera® UPLC system with a Phenomenex Kinetex® 1.7u XB-C18 100Å (50x2.1mm) column 
attached to an ABSciex QTrap-5500® triple-quadrupole mass spectrometer. Briefly, in 96-well 
plates, 20 µl of plasma samples and standards were mixed with 10 µl each of internal standards 
(500 nM corticosterone-[²H4] in 1:1 acetonitrile : water) and 10 µl of 1M ZnSO4 and 600 µl of 
extraction solvents (9:1 ethyl-acetate : acetonitrile). After centrifugation at 500 rpm for 20 min, 500 
µl each of sample mixture was transferred to another clean 96-well plate, evaporated to dryness at 
55˚C for 20 min in the vacuum concentrator and reconstituted in 50 µl of 1:1 methanol : water. 20 
µl sample extract was then injected in a 384-well plate and assayed overnight. A gradient elution 
method at 0.5mL/min was used with the mobile phases A= 0.1% aqueous formic acid and B= 0.1% 
formic acid in 9:1 acetonitrile : water. The mixture was increased from 50%B to 95%B over 2 min, 
held at 95%B for 0.5 min and then returned to 50%B for 1 min.  This resulted in a retention time of 
1.2 min. The mass-spectrometer detection was by way of positive-mode, scheduled multiple 
reaction monitoring with electrospray ionisation. The mass spectrometer parameters were as 
follows: for corticosterone: m/z= 247.1 → 329.1, declustering potential (DP) =100V, exit potential 
(CXP) =12, collision energy (CE) = 23V; for corticosterone-[2H4]: m/z= 351.1 → 333.0, DP=100, 
CXP=15, CE=23. Calibration standards over the range 1000 – 10nM and quality controls at three 
levels were prepared in stripped plasma. Differential quality control samples were prepared by 
spiking rat serum with 75nM of corticosterone. A ±15% acceptance criterion was applied to all 
quality controls. 
5.2.2.6 HPLC measurements of monoamines and metabolites  
At 24 h after saphenous blood sample collection with CAR challenge session, all rats were 
euthanised and their striatal and the NAc tissues (Paxinos and Watson 2005) collected and stored at 
-80 ˚C until use. Briefly, striatal tissues (right hemisphere) and the NAc (bilateral) were quickly 
weighed (wet weight) and homogenised on ice in a minimum volume of 0.1 ml of 0.1M perchloric 
acid and 50 mg/ml deoxyepinephrine (internal standard for catecholamines), using ultrasonicator 
probe (Vibra-Cell, Sonics & Materials, Inc. CT.). After centrifugation at 13,000 rpm for 5 minutes, 
supernatant from each sample was collected and filtered through 0.2 µm nylon filter. Next, 10 µl of 
each sample was injected into a HPLC system (See details in Chapter 2)  and dopamine, serotonin 
(5HT), noradrenaline and their metabolites (dihydroxyphenylacetic acid (DOPAC), homovanillic 
acid (HVA), 3-methoxytyrarmine (3-MT) and 5-hydroxyindoleacetic acid (5-HIAA)) and 
measured. Data were processed offline with Chemstation software (Rev B.01.03, Agilent 
Technologies, Inc. CA). The amount of catecholamines and their metabolites were expressed as 
pg/mg wet tissue, after correction for the dilution. 
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5.2.3. Statistical analysis 
All data are expressed as mean ± SEM unless otherwise stated. 1H MRS, CAR training and plasma 
corticosterone data were analysed with repeated measures two-way (Age x Drug) ANOVA. Data 
from catalepsy and locomotor tests, plasma corticosterone assays (baseline and CAR challenge as 
separate analyses) and HPLC assays were analysed with two-way ANOVA followed by Tukey’s 
post hoc tests. For CAR training data, survival curve analysis was performed using Kaplan-Meir 
technique and log-rank (Mantel-Cox) test as described previously (Kesby et al. 2015). Pearson’s 
Chi-Square analyses were performed to compare the failure rates of CAR learning in different 
treatment groups. Correlation between behavioural and neurochemical data was examined using 
Pearson’s correlation analysis. Statistical significance was defined at p < 0.05.  
5.3. Results 
5.3.1. The effect of chronic risperidone on NAA and other metabolites in the NAc 
Accumbal NAA could be reliably measured from all rats with 1H MRS (mean ± SEM of NAA 
CRLB – 7.48 ± 0.05). Other metabolites such as glutamate, glutamine, glutathione (GSH), taurine 
and GABA could also be reliably measured with CRLB of 7.25 ± 0.04, 12.61 ± 0.07, 15.28 ± 0.08, 
8.90 ± 0.06 and 18.16 ± 0.11 respectively in the brains of these rats using 1H MRS.  
At both Day 1 and Day 22, chronic risperidone treatment did not appear to alter the levels of NAA 
or other metabolites in the NAc in both adolescent and adult cohorts. Levels of almost all the 
detectable metabolites decreased over the course of the study (significant main effect of Time (p < 
0.001) on repeated measures two-way ANOVA; no significant main effect of Time, Time x Drug, 
Time x Drug x Age or Age x Drug interaction, all F < 3, p > 0.05; Details of statistical analysis 
results reported in two tables in Appendix D). Changes in NAA and glutamate levels with 
risperidone or vehicle challenge at Day 1 and Day 22 of chronic treatment in adolescence or 
adulthood are shown in Figure 5-3 and 5-4 respectively. Other metabolites are reported in the two 
tables in Appendix D. Varying the analysis by examining (1) an average metabolite level from 
blocks of 4 (time 1-4, 5-8, 9-12 and 13-15) to increase the statistical power, (2) % change from 
levels at baseline or (3) % change from levels at time 1 or average levels before vehicle or 
risperidone administration (average of time blocks 1-4) did not show any significant change in the 
levels of all detectable metabolites in the NAc. Examination of baseline levels of metabolites only 
also did not reveal any significant difference between risperidone-treated and control rats in both 
age groups (all F < 3, p > 0.05). Therefore NAA and other metabolites that were measurable with 
1H MRS were not altered in the NAc by either risperidone treatment regardless of the age of animal.   
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 (a) (i)           (a) (ii) 
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(b) (i)            (b) (ii) 
  
Figure 5-3 Levels of n-acetylaspartate (NAA) in the NAc with risperidone treatment in adolescence or adulthood.  Changes in NAA in the NAc (at baseline and after 
risperidone or administration) at (a)(i) Day 1 and (b)(i) Day 22 of chronic treatment are shown. [Analysis as time blocks of 4 is shown in subfigure (a)(ii) and 
(b)(ii]). No significant change in NAA was observed at either day in both adolescent and adult cohorts. Green arrow shows the time of saline injection and red 
arrow risperidone or vehicle injection. Data are expressed as mean ± SEM. n = 12 per drug for a given age; Adoles – adolescent; BL – baseline; CON – vehicle-
treated control; RIS – risperidone-treated; VEH – vehicle injection.   
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 (a)(i)              (a) (ii) 
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(b)(i)              (b) (ii) 
     
Figure 5-4 Levels of glutamate (Glu) in the NAc with risperidone treatment in adolescence or adulthood.  Changes in glutamate in the NAc (at baseline and after 
risperidone or administration) at (a)(i) Day 1 and (b)(i) Day 22 of chronic are shown. [Analysis as time blocks of 4 is shown in subfigure (a)(ii) and (b)(ii)]. No 
significant change in glutamate was observed at either day in both adolescent and adult cohorts. Green arrow shows the time of saline injection and red arrow 
risperidone or vehicle injection. Data are expressed as mean ± SEM. n = 12 per drug for a given age; Adoles – adolescent; BL – baseline; CON – vehicle-treated 
control; RIS – risperidone-treated; VEH – vehicle injection  
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5.3.2. Long-term cataleptic response and locomotor activity after a drug-free interval 
After a drug-free interval of 36 days, all rats from both age groups received a challenge dose of 1.3 
mg/kg risperidone IP and long-term cataleptic response was examined. This dose of risperidone 
produced a small degree of catalepsy in all animals, with all groups showing an average time-on bar 
of at least 4-5 s. As shown in Figure 5-5(a), this challenge dose of risperidone induced a significant 
increase in level of cataleptic response in rats previously treated with this APD in adulthood [two-
way ANOVA: significant main effect of Age (F1,43 = 4.254, p = 0.045), Drug (F1,43 = 18.733, p < 
0.001), Age x Drug interaction (F1,43 = 5.186, p = 0.028)]. Post hoc tests further confirmed that 
adult risperidone group stayed longer on the bar than both their vehicle-treated control group and 
adolescent risperidone- and vehicle-treated groups (all p < 0.05). This cataleptic outcome after a 
lengthy drug-free interval is consistent with the finding during chronic treatment in Chapter 4: in 
that rats treated with risperidone in adolescence, had lower cataleptic response than those treated in 
adulthood. 
Locomotor activity immediately after the catalepsy test is shown in Figure 5-5(b). Two-way 
ANOVA showed a significant main effect of Age x Drug interaction (F1,43 = 5.509, p = 0.024) 
without any significant main effect of Age or Drug (both F < 0.6, p > 0.4). However, post hoc tests 
did not show any significant difference among the four treatment groups. Therefore, it was 
concluded that long-term locomotor response to risperidone was not altered by prior treatment in 
adolescence or adulthood. 
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 (a)            (b) 
        
Figure 5-5 Long-term cataleptic response and locomotor suppression induced by a challenge dose of risperidone.(a) Rats treated previously in adulthood showed a 
significant increase in cataleptic response. Risperidone-induced catalepsy was determined as the mean time (s) the rat stayed with both forepaws on the bar. (b) 
Long-term locomotor response to a challenge dose of risperidone in rats previously treated in adolescence or adulthood is shown as total distance travelled during 
30 min of open field test. Data expressed as mean ± SEM. n = 12 per drug for a given age except n = 11 for adult CON; Adol – adolescent; CON – vehicle –treated 
controls; RIS – risperidone-treated rats; * p < 0.05, *** p < 0.001 
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5.3.3. CAR acquisition after a lengthy drug-free interval  
Four days after the catalepsy test, all rats were trained for CAR. The overall avoidance performance 
of individual groups over 7 days of CAR training is shown in Figure 5-6(a). As expected, the 
avoidance performance of the majority of rats improved as the training progressed. Notably, the 
adolescent cohorts showed a slower rate of CAR learning than adult cohorts. This apparent 
difference seemed to be driven by the adolescent risperidone group that showed the slowest rate of 
CAR acquisition [repeated measures two-way ANOVA: significant main effects of Day (F6,258 = 
47.059, p < 0.001) and Age (F1,43 = 4.955, p = 0.031) but no significant main effect of Drug, Age x 
Drug, Day x Age or Day x Age x Drug  (all F < 3, all p > 0.05)].  
Escapes and chamber crossings are shown in Figure 5-6 (b) and (c) respectively. As expected from 
the avoidance data, adolescent risperidone group showed the highest levels of escapes among the 
four groups [repeated measures two-way ANOVA: significant main effect of Day (F6,258 = 49.196, 
p < 0.001) and Age (F1,43 = 5.134, p = 0.029), Day x Age (F6,258 = 2.564, p = 0.020) but no 
significant main effect of Drug, Age x Drug, or Day x Age x Drug  (all F < 3, all p > 0.05)]. As the 
avoidance levels improved across training days, chamber crossings also became higher; again 
adolescent cohorts had lower chamber crossings than adult cohorts [repeated measures two-way 
ANOVA: significant main effects of Day (F6,258 = 8.985, p < 0.001) and Age (F1,43 = 4.4.482, p = 
0.040) but no significant main effect of Drug, Age x Drug, Day x Age or Day x Age x Drug  (all F 
< 1.5, all p > 0.05)]. However, none of the four groups showed a significant level of escape failures 
(Table 5-1). 
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 (a) 
 
 (b) 
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 (c) 
 
Figure 5-6 Acquisition of the CAR in rats treated with risperidone or vehicle in adolescence or adulthood. 
(a) % avoidance (b) %escape and (c) number of chamber crossings are shown for rats treated with 
risperidone or vehicle in adolescence or adulthood. All data expressed as mean ± SEM. n = 12 per drug for 
a given age except n = 11 for adult CON; * p < 0.05 Adol cohorts VS adult cohorts. Adol – adolescent; CAR 
– conditioned avoidance response; CON – control; RIS – risperidone 
 
Table 5-1 Escape failures during 7-day CAR training  
Age Drug 
Days of CAR training 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 
Adolescent 
RIS 0 ± 1.25 0 ± 0 0 ± 0.31 0 ± 0  0 ± 1.56 0 ± 0.31 0 ± 0  
CON 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0.63 0 ± 0 
Adult  
RIS 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
CON 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0 
Data are expressed as median ± semi-interquartile range. n = 12 per drug for a given age except n 
= 11 for adult CON; CON – vehicle-treated control rats; RIS – risperidone-treated rats; 
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Since there was such a disparity in learning between groups, I re-examined CAR acquisition using 
survival curve analysis. In order to do this, an avoidance criterion needed to be set. A minimum 
criterion of 40% avoidance was chosen primarily as this allowed the inclusion of all groups 
(Adolescent risperidone group’s performance was ~40% on day 7 (Figure 5-6(a)). As can be 
observed in survival curves in Figure 5-7, the majority of rats from the adult risperidone and control 
groups and the adolescent control group reached this criterion by Day 3 or 4 of CAR training. 
However, only 41.7% of rats from adolescent risperidone group reached this criterion by the last 
day (Day 7) of CAR training. When the performance was compared across different groups, 
significantly more rats from the adolescent risperidone group (58.3%) failed to reach the criterion, 
compared to the adolescent controls (16.7%) (χ2 = 3.929, p = 0.047); adult controls (18.2%) (χ2 = 
5.243, p = 0.022). Differences between rats that had prior adolescent risperidone treatment and 
those with prior adult risperidone treatment did not reach the defined statistical significance (χ2 = 
3.379, p = 0.066). Adult risperidone group also did not differ from adult controls (χ2 = 0.791, p = 
0.374).   
Since such a small (5 out of 12) number of animals from the adolescent risperidone group could 
successfully acquire the CAR, there was an inadequate sample size to achieve statistical power for 
further CAR tests. Therefore I chose not to examine their long-term behavioural response to 
risperidone challenge in the CAR paradigm in order to investigate whether the drug-free interval is 
a factor in sensitized CAR suppression in rats with adolescent risperidone exposure (Chapter 3).     
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Figure 5-7 Survival curves for rats reaching a criterion of 40% avoidance across 7 days of CAR training  A 
significantly lower proportion of rats treated with risperidone in adolescence failed to reach the criterion at 
the end of 7-day training period. Adol – adolescent; CAR – conditioned avoidance response; CON – control; 
RIS – risperidone  
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5.3.4. Plasma corticosterone levels at baseline and after a challenge CAR session  
The finding of a lower CAR acquisition rate with prior adolescent risperidone exposure raised a 
question on the role of stress and involvement of hypothalamic-pituitary-adrenal (HPA) axis. 
Indeed, low avoidance rats, that is, those that show lower ability to acquire the CAR, have been 
shown to be ‘more reactive’ or ‘hyperemotional’ to stressful conditions compared to high avoidance 
rats, for example, more freezing to white noise stress and higher levels of plasma corticosterone 
under baseline conditions and stressful events (Steimer and Driscoll 2005; Uvnäs-Moberg et al. 
1999). Therefore, plasma corticosterone levels were examined in all rats at baseline (only mild 
restraint, at a minimum of 2 days after CAR training) and immediately after a challenge CAR 
session. At baseline, no significant differences in plasma corticosterone levels were observed 
among four treatment groups (two-way ANOVA: no significant main effect of Age, Drug or Age x 
Drug interaction, all F < 2.9, all p > 0.05) (Figure 5-8). As expected, after a challenge CAR session, 
plasma corticosterone levels became significantly elevated; however, these levels were not different 
among groups (repeated measures two-way ANOVA: a significant main effect of Sample Type 
(F1,43 = 34.648, p < 0.001; no significant main effects of Sample Type x age, Sample Type x Drug, 
Sample Type x Age x Drug, Age, Drug or Age x Drug interaction, all F < 3.3, p > 0.07). 
Furthermore, plasma corticosterone levels of CAR learners, i.e. rats that successfully acquired the 
CAR, did not differ significantly from those of non-learners.  
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Figure 5-8 Plasma corticosterone levels in rats previously treated with risperidone or vehicle as adolescents or adults.  Plasma corticosterone levels were measured 
from saphenous blood samples collected at baseline and shortly after a challenge CAR session, with an interval of 4 days in between. *** p < 0.001 levels at  
baseline vs levels after CAR. Data are expressed as mean ± SEM. n = 12 per drug group for a given age. Adol – adolescent; CON – vehicle treated controls; RIS – 
risperidone-treated rats; 
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5.3.5. Levels of monoamines and their metabolites in the striatum and the NAc 
One day after saphenous blood sample collection, all rats were euthanised and regional brain tissues 
[the striatum and the NAc (Paxinos and Watson 2005)] collected for HPLC assay of 
catecholamines. Dopamine and its metabolites (DOPAC, HVA and 3MT) in the striatum and the 
NAc were of particular interest given their roles in catalepsy and CAR performance respectively.   
Levels of monoamines (dopamine, 5HT and noradrenaline) and their metabolites in the striatum and 
the NAc are shown in Table 5-2 and 5-3 respectively. Risperidone treatment in adolescence or 
adulthood did not induce any significant changes in the levels of monoamines and their metabolites 
in both striatum and NAc (all F < 2.35, p > 0.05). Two-way ANOVA of ratios between striatal 
5HIAA and 5HT revealed a significant main effect of Age x Drug interaction (F1,43 = 4.89, p = 
0.032) with no main effect of Age and Drug (both F < 1.2, p > 0.05). However, post-hoc tests did 
not show any significant difference among the four groups. Examination of the ratios between 
dopamine and its metabolites also did not show any significant difference among four groups. Next 
correlation analysis was performed to identify any relationship between neurochemical data 
(catecholamines and their metabolites in the striatum or the NAc) and behavioural data (catalepsy, 
locomotion and CAR). However, no significant correlation between any measures was observed for 
any treatment group.    
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Table 5-2 Levels of catecholamines and their metabolites in the striatum of rats treated with risperidone in adolescence or adulthood 
Age group 
Drug 
group 
Striatal monoamines and their metabolites (pg/mg tissue) (mean ± SEM) 
Dopamine DOPAC HVA 3MT 5HT 5HIAA NA 
Adolescent 
RIS 5174.30 ± 218.49 1159.88 ± 61.76 538.92 ± 56.01 210.93 ± 9.71 248.25 ± 12.16  308.53 ± 8.76 70.14 ± 9.86 
CON 4692.98 ± 482.85 1021.87 ± 103.35  507.39 ± 52.52  191.51 ± 22.14  220.94 ± 19.97  265.01 ± 24.80  64.12 ± 17.02 
Adult 
RIS 5193.43 ± 234.55  1120.70 ± 59.11 492.99 ± 67.39  203.86 ± 13.01  270.08 ± 13.97  292.88 ± 20.08  56.29 ± 5.31 
CON 5199.19 ± 213.01 1184.95 ± 81.55 451.12 ± 54.84 203.11 ± 17.47  245.88 ± 20.64  303.72 ± 17.05  59.55 ± 8.47 
F values 
from  
Two-way 
ANOVA$ 
Age 0.71 0.62 0.77 0.02 1.91 0.38 0.68 
Drug 0.58 0.22 0.40 0.39 2.31 0.76 0.02 
Age x 
Drug  
0.61 1.66 0.01 0.33 0.01 2.11 0.17 
All data are shown as mean ± SEM. n = 12 per drug for a given age except n = 11 for adult CON. $All comparisons are F1,43, p > 0.05; 3MT – 3-
Methoxytyramine; 5HIAA – 5-Hydroxyindoleacetic acid; 5HT – 5-hydroxytryptamine or serotonin; Adoles – adolescent; CON – vehicle-treated 
control rats; DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – Homovanillic acid; NA – noradrenaline; RIS – risperidone-treated rats; 
 
 
 
 
 
 
164 
Chapter 5 
 165 
Table 5-3 Levels of catecholamines and their metabolites in the NAc of rats treated with risperidone in adolescence or adulthood 
Age group Drug 
group 
Accumbal monoamines and their metabolites (pg/mg tissue) (mean ± SEM) 
Dopamine DOPAC HVA 3MT 5HT 5HIAA NA 
Adolescent 
RIS 4219.97 ± 325.82 1014.85 ± 70.82 509.89 ± 56.15  143.06 ± 15.08 349.22 ± 32.18  266.60 ± 28.84 155.79 ± 32.59 
CON 3746.39 ± 297.30  856.07 ± 59.04 394.24 ± 26.66  143.99 ± 14.78 350.95 ± 16.88  291.22 ± 13.18  142.81 ± 18.44 
Adult 
RIS 4217.13 ± 202.37  970.44 ± 132.90  429.77 ± 32.80  148.69 ± 17.72  402.34 ± 22.36 309.98 ± 12.65  138.51 ± 13.71 
CON 4571.42 ± 329.10  1065.81 ± 74.67  430.48 ± 26.53 170.82 ± 17.27 374.79 ± 31.60 271.18 ± 16.38 103.62 ± 10.82 
F values 
from  
Two-way 
ANOVA$ 
Age 1.98 0.85 0.33 1.00 2.13 0.38 1.93 
Drug 0.04 0.13 2.29 0.50 0.24 0.14 1.39 
Age x 
Drug  
2.010 2.00 2.34 0.43 0.31 2.77 0.29 
All data are shown as mean ± SEM. n = 12 per drug for a given age except n = 11 for adult CON. n = 11 for NA levels of Adoles RIS given one sample 
did not have a reliably detectable level of NA. $All comparisons are F1,43 p > 0.05; 3MT – 3-Methoxytyramine; 5HIAA – 5-Hydroxyindoleacetic acid; 
5HT – 5-hydroxytryptamine or serotonin; Adoles – adolescent; CON – vehicle-treated control rats; DOPAC – 3,4-Dihydroxyphenylacetic acid; HVA – 
Homovanillic acid; NA – noradrenaline; RIS – risperidone-treated rats; 
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5.4. Discussion 
In this Chapter, I investigated chronic risperidone treatment in adolescents and adults with regards 
to the short-term effects on NAA and other metabolites in the NAc and long-term behavioural 
(catalepsy, locomotion and CAR acquisition) and neurochemical changes (in the striatum and the 
NAc). I showed that, at both Day 1 and Day 22, chronic risperidone treatment did not alter 
accumbal levels of NAA or other metabolites in both adolescents and adults. More importantly, I 
showed that after an equivalent drug-free interval, rats treated with risperidone in adolescence had a 
lower cataleptic response to a challenge dose. These same rats with prior adolescent risperidone 
exposure were also observed to have a retarded ability to acquire the CAR in adulthood. However, 
no long-term alterations in levels of plasma corticosterone or monoamines and their metabolites in 
the striatum and the NAc were observed.  
5.4.1. On-drug changes in metabolites of the NAc during chronic treatment  
To investigate whether chronic risperidone treatment could differentially affect accumbal NAA 
levels in adolescents and adults, the NAc was examined with 1H MRS at baseline and after 
risperidone administration at Day 1 and Day 22. Along with NAA, other metabolites such as 
glutamate and GSH were also examined. The NAc was chosen given it is the major site for 
adolescent remodelling changes in dopaminergic and glutamatergic systems (Benoit-Marand and 
O'Donnell 2008; Huppe-Gourgues and O'Donnell 2012; Mathews et al. 2009; Matthews et al. 2013; 
Tarazi and Baldessarini 2000; Tarazi et al. 1998) and given the reported long-term changes in 
GABA and glutamate with adolescent olanzapine treatment (Xu et al. 2015).  
In both clinical and preclinical literature, the effects of APDs on NAA have been inconsistent. For 
instance, preclinical studies in rats have reported a region-dependent increase (Harte et al. 2005; 
McLoughlin et al. 2009) or no change (Bustillo et al. 2006; Bustillo et al. 2004; Lindquist et al. 
2011) in NAA levels following chronic APD treatment. Discrepancy in findings of APDs’ effect on 
NAA may be partly due to heterogeneity in experimental methodologies used in these studies such 
as route and dosing of APDs (oral vs subcutaneous injections) and method of assessment (HPLC Vs 
1H MRS). Still no study to date has examined on-drug changes in NAA with risperidone challenge. 
Here, I showed that in the NAc, chronic risperidone treatment did not alter baseline and on-drug 
NAA levels in both adolescents and adults. Lack of any significant effect of risperidone on NAA in 
my animals without neurobiological pathology could suggest that NAA changes observed in 
schizophrenic patients are probably due to psychopathological condition per se, with minimal 
confounds of the effects of chronic APD treatment. Indeed, recent clinical findings indicate that 
region-specific reductions in NAA occur only in chronic schizophrenia rather than at-risk stage 
(Brugger et al. 2011; Liemburg et al. 2016), thus suggesting a close relationship between 
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progression of illness and NAA changes. Another recent preclinical study in rodent model of 
schizophrenia has also reported a biphasic change in NAA level with MIA (Vernon et al. 2015), 
thus further supporting the possibility that NAA changes are due to psychopathological changes 
rather than due to effects of APDs.    
Given NAA is regarded as a marker of neuronal viability, function and density (See review by (Rae 
2014)) and synthesized almost exclusively in neuronal mitochondria (Niwa et al. 2007; Patel and 
Clark 1979), the outcome of risperidone treatment on these aspects still needs to be investigated 
with other techniques. Discrepancies in NAA findings between my previous pilot 1H MRS 
experiment and the current experiment may be due to experimental differences in 1H MRS data 
acquisition. During a single 1 h long continuous scan in pilot experiment (Appendix C), drifting of 
the water peak was observed and this affected the quality of spectra obtained and consequently 
reliability (high CRLB) in quantification of metabolites. In the current experiment, 15 separate 1H 
MRS scans (each 4 min long) were performed with automated local frequency adjustment to 
compensate for drifting of water peak. This technique provided a better spectral quality and a more 
reliable quantification of metabolites. Difference in pharmacokinetics as a result of different routes 
of administration in pilot experiment (SC) and the current study (IP) may also play a role in the 
final outcomes observed. Perhaps, also the small sample size in the pilot experiment suffered from a 
winner’s curse phenomenon (Button et al. 2013).     
1H MRS measures all the available pool of metabolites within the specified voxel, i.e. both 
extracellular and intracellular levels as well as both neuronal and glial levels. Therefore, given there 
was no significant alteration in other metabolites such as glutamate, glutamine, GABA and GSH I 
conclude that risperidone did not alter the metabolism of neurons or glia in the NAc. However, it is 
still possible that risperidone could differentially affect neurotransmission in GABA-ergic or 
glutamatergic systems in adolescents and adults, which can be investigated more thoroughly with 
other techniques such as electrophysiology or microdialysis. In this study, 1H MRS levels of 
metabolites were measured only from the NAc. Changes in other brain regions are still to be 
investigated.   
A consistent change in 1H MRS data observed in all groups was a progressive reduction in the 
levels of most metabolites, most pronounced with NAA and glutamate, across scan time-points. 
Perhaps this reduction could be due to suppression of brain metabolism by isoflurane anaesthesia, 
which can produce potential confounds the neural metabolites examined (Boretius et al. 2013; 
Herring et al. 2009; Liachenko et al. 1999; Stover et al. 2004). Imaging 1H MRS on awake fully 
conscious rats may perhaps provide a better physiological measure of accumbal metabolite levels. 
Another limitation in interpretation of 1H MRS findings is the localization of the voxel bilaterally 
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over the NAc following the published method in the literature (Xu et al. 2015). It is yet to be 
investigated whether there is any contamination of signal, although expected to be minimal, from 
anterior commissure and the intervening regions such as medial septal nucleus.  
5.4.2. Long-term behavioural outcomes  
In the current Chapter, I showed that prior chronic risperidone treatment induced long-term 
behavioural effects in catalepsy and CAR. These differed depending on whether treatment was 
administered to rats either as adolescents or adults.  
5.4.2.1. Catalepsy and locomotion  
When examined after a lengthy drug-free interval, a challenge dose of risperidone induced a robust 
cataleptic response selectively in rats previously treated with this APD as adults. Rats with prior 
adolescent risperidone treatment or controls with prior vehicle treatment did not show a significant 
level of catalepsy. In Chapter 4, a lower level of risperidone-induced cataleptic responses was 
observed in adolescents, compared to adults during ongoing treatment. Furthermore, it was 
speculated that incomplete wiring status of the adolescent striatum (Matthews et al. 2013; Teicher et 
al. 1995) would mediate a diminished cataleptic response in adolescents. Again, here in Chapter 5, 
after a drug-free interval, rats with prior adolescent risperidone treatment were observed to have a 
lower level of catalepsy to a challenge dose, compared to those with prior adult risperidone 
treatment. Therefore, it seemed that some aspect of the lower potential for rats with adolescent 
risperidone treatment to develop catalepsy persisted even after a drug-free interval. The underlying 
neurobiological basis for this intriguing finding remains unknown. Given that risperidone-induced 
locomotor suppression did not significantly differ among the four treatment groups, the observed 
long-term change appeared to be specific to catalepsy only. This finding also suggested differential 
long-term effects of risperidone on the striatum compared to the NAc since catalepsy is mainly 
striatum-dependent (Ossowska et al. 1990; Wadenberg et al. 2001b; Yoshida et al. 1994) and 
locomotion NAc-dependent (Beninger 1983; Kelly et al. 1975; Staton and Solomon 1984). (See 
chapter 6 for detailed discussion). 
Although several investigators have examined on-drug cataleptic behaviour with acute or chronic 
APD treatment, long-term outcomes in catalepsy are less frequently explored. To date, the long-
term cataleptic effect of chronic adolescent haloperidol treatment has only been examined in mice 
(Ushijima et al. 1995). This adolescent haloperidol treatment induced a decreased cataleptic 
response (tolerance) in the short-term (1 and 3 days of drug washout) but an increased cataleptic 
response in the long term (15 and 21 days of drug washout) to a challenge dose of this APD. 
Together, the findings in the study by Ushijima and colleagues and my current results suggest that 
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long-term cataleptic outcome of adolescent APD treatment can vary with the type of APDs 
examined and the species utilized.  
5.4.2.2. Acquisition of the CAR  
When rats were trained to acquire the CAR, differential outcomes were observed depending on the 
history of prior risperidone treatment. Rats from the adolescent cohorts showed a slower rate of 
CAR learning. In particular, rats previously treated with risperidone in adolescence were observed 
to have a retarded ability to acquire the CAR, compared with other treatment cohorts. Only a 
limited number of rats from the adolescent risperidone cohort successfully acquired the CAR. This 
low rate of successful CAR acquisition (~41% to reach a criterion of 40% avoidance) following 
adolescent risperidone treatment was in sharp contrast with the reported rate of CAR acquisition 
(~75-80% to reach a criterion of ≥70% avoidance) in the literature (Choi et al. 2010a) as well as 
those rates (~75-80% to reach a criterion of ≥70% avoidance) observed in Chapter 3. This outcome 
resulted in an inadequate sample size to study CAR suppression by risperidone challenge; 
consequently, the fourth aim of this Chapter to determine the role of drug-free interval in sensitized 
CAR suppression could not be achieved.  
The majority of preclinical studies that investigate CAR in chronic APD treated animals examine 
suppression of already acquired CAR by APD treatment in adolescents (Chou et al. 2015; Gao and 
Li 2014; Qiao et al. 2014a; Qiao et al. 2013; Qiao et al. 2014b; Shu et al. 2014b) or adults (Gao and 
Li 2013; Natesan et al. 2007; 2008; Natesan et al. 2006a; Samaha et al. 2007; Wadenberg et al. 
2000). Similarly, in Chapter 3, I examined suppression of the already acquired CAR by risperidone 
treatment in adolescence or adulthood. All rats in Chapter 3 had a prior history of successful CAR 
acquisition from PND30 to PND34 and therefore, re-acquired the CAR in adulthood as rapidly as 
within 1 day of retraining regardless of age or drug groups. This is consistent with previous reports 
that CAR is a persistent behaviour (see reviews by (Kapur et al. 2006; Moutoussis et al. 2007)) and 
that CAR re-acquisition is not altered by prior APD treatment (Qiao et al. 2013; Qiao et al. 2014b; 
Shu et al. 2014b). 
Unlike the widely studied suppression of previously acquired CAR, there are only a limited number 
of studies have examined the acquisition of CAR in previously untrained rats after a drug-free 
interval from chronic APD treatment. To the best of my knowledge, no study has examined CAR 
acquisition after a lengthy drug-free interval from either adolescent or adult risperidone treatment. 
In adult rats, CAR acquisition has been reported to be unaltered at shortly after termination of 
chronic risperidone treatment (Drago et al. 1997). Here, I showed that, after a lengthy drug-free 
interval, adult risperidone treatment did not alter CAR learning. Another study has also investigated 
CAR acquisition during a lengthy risperidone treatment that began in adolescence (Castellano et al. 
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2009); this study also reported no deficits in CAR acquisition. However, Castellano et al. treated 
rats with risperidone for an extended duration (>90 days) from adolescence to adulthood, which 
vastly exceeded duration of adolescence (See Chapter 1). Therefore, the authors’ finding may not be 
specific to adolescent exposure.  
Learning of the CAR has been hypothesized to be a two-step process [for example, see (Cain and 
LeDoux 2008; Choi et al. 2010a)]: (1) Rats have to form an association between the CS and the US 
(white noise and mild foot-shock respectively in this experiment) through Pavlovian conditioning; 
in other words, fear is conditioned to the CS (Oleson and Cheer 2013). (2) Rats learn to perform an 
instrumental avoidance response (crossing into the other chamber) to avoid the foot-shock through 
the fear aroused by the presence of CS itself. Low avoidance rats have also been reported to be 
freezing (‘fear conditioned’) instead of making an instrumental avoidance response (Choi et al. 
2010a; Lázaro-Muñoz et al. 2010). Moreover, low avoidance rat strains have also been reported to 
‘more reactive’ to stress, with higher levels of stress hormones of HPA axis such as corticosteroids 
(Akieda-Asai et al. 2011; Ohta et al. 1999; Steimer and Driscoll 2005; Uvnäs-Moberg et al. 1999). 
Therefore, I next examined plasma corticosterone levels in all rats at baseline and shortly after a 
challenge CAR session. CAR challenge increased plasma corticosterone levels significantly from 
baseline levels, indicating that this CAR challenge was a stressful event. However, plasma 
corticosterone levels were not different among the four treatment groups at both baseline and after 
CAR. While examination of plasma adrenocorticotrophic hormones (ACTH) or corticotrophin 
releasing hormones (CRH) (Akieda-Asai et al. 2011; Ohta et al. 1999) may be complimentary, the 
current finding with plasma corticosterone levels suggested that impaired CAR learning in rats with 
adolescent risperidone exposure was less likely due to altered response to stress or stress-related 
reactions from CAR training. Still, freezing response cannot be ruled out. Indeed, the existing 
literature has shown that adult rats with prior adolescent olanzapine have heightened freezing to 
context and impaired fear extinction (Milstein et al. 2013). Further examination of freezing 
behaviour, for example, in fear-conditioning or during CAR acquisition is now required. 
5.4.3. Long-term neurochemical outcomes  
Next, I continued to examine neurochemical changes in rats with prior adolescent or adult 
risperidone treatment. Given the striatum is often implicated in the cataleptic response to APDs 
(Ossowska et al. 1990; Wadenberg et al. 2000; Wadenberg et al. 2001b; Yoshida et al. 1994), this 
brain region may be responsible for the observed long-term differential cataleptic responses. I also 
wanted to examine whether short-term increases in striatal dopamine metabolites in risperidone-
treated adolescents (Chapter 4) persisted after a lengthy drug-free interval. Mesolimbic 
dopaminergic system plays a major role in acquisition of the CAR (Fantin and Bottecchia 1984; 
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Koob et al. 1984; Oleson et al. 2012; Ramirez et al. 2015; Shumake et al. 2010). This mesolimbic 
dopaminergic activity, in the NAc in particular, is thought to modulate motivational circuits and 
provide incentive value to neutral stimuli such as white noise or tone (CS) (Oleson and Cheer 
2013). Therefore, I hypothesized that differential outcomes in catalepsy and CAR acquisition were 
mediated by neurochemical changes in the striatum and the NAc respectively. To test this 
hypothesis, I examined monoamines and their metabolites in these two brain regions.  
Here, I showed that levels of dopamine, 5HT and their metabolites in both striatum and NAc as 
examined with ex vivo HPLC were not altered by prior risperidone treatment regardless of the age 
of prior exposure. Also, no significant relationship was observed between catalepsy, locomotion or 
CAR learning and monoamines or their metabolites. This finding does not rule out dynamic 
alterations in dopaminergic or serotoninergic neurotransmission in the striatum and the NAc, that 
may be occuring during a behaviour. This obviously would require techniques such as dialysis or 
voltammetry to address.  
Therefore, an outstanding question in this Chapter is which neural mechanism(s) underlie(s) 
differential long-term behavioural responses in the catalepsy and the CAR acquisition in 
risperidone-treated rats. With regards to catalepsy, neurochemical changes in presynaptic 
dopaminergic regions such as substantia nigra (SNr) in addition to terminal regions such as the 
striatum may perhaps underlie differential cataleptic response observed in this study. For instance, 
chronic haloperidol treatment in adult rats has been reported to induce a long-lasting 
downregulation (up to 4 weeks) in TH immunoreactivity in the SNr (Levinson et al. 1998). It is still 
unknown whether TH immunoreactivity in the midbrain can be altered by risperidone treatment 
selectively in adults or adolescents or both. Moreover, in adult rodents, chronic APD treatment can 
decrease the number of spontaneously firing neurons in SNr or VTA or both, a condition referred to 
as ‘depolarization block’ (Chiodo and Bunney 1983; Gill et al. 2014; Grace et al. 1997). These 
authors have also proposed a relationship between depolarization block of dopaminergic neurons 
and extrapyramidal side effects (EPS) of APDs. This is relevant because the adolescent midbrain 
dopaminergic neurons fire faster than their adult counterparts (McCutcheon et al. 2012; 
McCutcheon and Marinelli 2009) and no study has to date compared midbrain dopaminergic neuron 
activity following risperidone treatment in adolescence or adulthood.    
Successful acquisition of the CAR has been related to neural activity in multiple brain regions such 
as the NAc (Oleson et al. 2012), the VTA (Shumake et al. 2010), the PFC (Stark et al. 1999) and the 
amygdala (Choi et al. 2010a; Darvas et al. 2011; Lázaro-Muñoz et al. 2010), the striatum (Darvas et 
al. 2011; Dombrowski et al. 2013). Connections between the NAc and the amygdala (Ramirez et al. 
2015) or between the PFC and the amygdala (Moscarello and LeDoux 2013) are also important for 
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CAR acquisition. Rats that fail to acquire CAR are known to be freezing (Pavlovian ‘fear 
conditioned’ instead of making an instrumental avoidance). This freezing response is mediated by 
neural activity in central amygdala nuclei (CeA) (Choi et al. 2010a; Lázaro-Muñoz et al. 2010). 
Lesioning of CeA (Choi et al. 2010a) or suppression of CeA activity by cortical input from the PFC 
(Moscarello and LeDoux 2013) suppresses CeA-mediated freezing and significantly improves the 
CAR. In addition, electrical stimulation of the VTA can improve avoidance acquisition whereas 
stimulation of lateral habenula can decrease it (Shumake et al. 2010). Therefore, a complex 
interplay between multiple brain regions is involved in the CAR acquisition. Nonetheless, the NAc 
appears to have the most central role in CAR acquisition since this brain region modulates 
motivational circuits and serves as an integrative centre of inputs from the VTA, the amygdala, the 
PFC and the hippocampus (Humphries and Prescott 2010). For instance, examination of the NAc 
with voltammetry has shown differential patterns of dopamine release in the NAc during avoidance 
(increased release) and escape (decreased release) responses during a CAR session or during 
freezing (decreased release) responses in the fear conditioning (Oleson et al. 2012). The resultant 
changes in dopamine concentration have been hypothesized to modulate inputs from other brain 
regions and produce a final behavioural response (Oleson and Cheer 2013). Therefore, examination 
of dopamine signalling in the NAc in a behaving animal will provide further insight into 
risperidone-induced neurotransmission changes. Moreover, changes in the brain regions such as the 
amygdala, the PFC or the VTA that provide inputs to the NAc still need to be examined in rats with 
prior adolescent risperidone exposure. These aspects will be discussed in more detail in Chapter 6. 
A limitation in interpretation of CAR learning deficits in this experiment is that all rats received 
isoflurane during adolescence. While detrimental neurocognitive outcomes of isoflurane exposure 
have been reported in neonatal (Jevtovic-Todorovic et al. 2003; Lee et al. 2014), adult (Liu et al. 
2014) or aged (Callaway et al. 2015) rodents, no study to date has specifically examined the effects 
of adolescent isoflurane exposure. However, given that vehicle-treated control rats with the same 
isoflurane exposure and handling history did not show a similar degree of deficits, this caveat would 
seem unlikely to be relevant.     
To sum up, in Chapter 5, chronic risperidone treatment in adolescence was examined for short-term 
changes in accumbal NAA and other metabolites and long-term behavioural and neurochemical 
changes. As in the previous chapters, the outcomes with adolescent risperidone treatment were 
directly compared with those of adult treatment. The current 22-day risperidone regimen did not 
alter the levels of NAA or other metabolites in the NAc in both age groups, suggesting no 
differential age-dependent effect on accumbal metabolism during chronic treatment. After a lengthy 
drug-free interval, this risperidone treatment induced a long-term increase in cataleptic response 
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only in rats with prior adult risperidone exposure. By contrast, prior risperidone treatment in 
adolescence impaired the CAR acquisition in adulthood again after a lengthy washout period. 
However, no changes in ex vivo levels of monoamines or their metabolites were observed in the 
striatum and the NAc in both age groups. Further examination of risperidone-induced 
neurochemical or neurophysiological changes is still required to identify underlying neural 
mechanism(s) of differential long-term behavioural outcomes in catalepsy and CAR. Taken 
together, the findings of Chapter 5 provide further support to the hypothesis that the adolescent 
brain differs from the adult brain in the response to chronic risperidone treatment.     
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6.1. Introduction 
Over the last twenty years, prescription of APDs to children and adolescents has increased 
dramatically (as much as 5-6 fold) in several different countries (Kalverdijk et al. 2008; Olfson et 
al. 2006; Olfson et al. 2012; Ronsley et al. 2013; Song and Guo 2013). Consequently, the global 
increase in prescription of APDs to adolescents in clinical settings has raised concerns about its 
neurobiological consequences (Ben Amor 2012; Patel et al. 2005; Ronsley et al. 2015; Vitiello et al. 
2009). To address whether such concerns are warranted, the effects of APD treatment on adolescent 
brain neurochemistry and brain function need to be examined. In clinical research, long-term 
assessment of behavioural and neurochemical changes as a result of adolescent APD prescription 
can be achieved with certain psychometric tests and imaging modalities such as MRI, 1H MRS or 
positron emission tomography (PET). However, such studies are costly, difficult to perform and 
require time scales outside the remit of most funding bodies.  
Neurobehavioural maturation processes are highly conserved between species (Spear 2000; 2007). 
In addition, a transition period equivalent to human adolescence has been identified in rodents, 
based on physical, pubertal and neurobehavioural changes (Brenhouse and Andersen 2011; 
McCutcheon and Marinelli 2009; Schneider 2013; Spear 2000; 2007). This enables us to model 
adolescent APD treatment in laboratory rodents and investigate the resultant neurobiological 
changes. Experimental settings, for example, the age at the start of treatment or duration of 
treatment can be well-controlled in preclinical APD studies. Moreover, invasive neurochemical 
assays, which are not feasible clinically, can also be achieved in the preclinical APD studies. In 
particular, studies can be strictly controlled to assess long or short-term outcomes either on or off 
drug in a timely manner in rodent studies. Furthermore, use of translationally relevant assessments 
in experimental adolescent rodents, for example, MRI or 1H MRS, as has been done in the current 
thesis, can be reverse-translated back to the clinic.  
While still limited in number, existing preclinical studies have attempted to identify short-term 
behavioural and neurochemical effects of adolescent APD treatment [for example, (Choi et al. 
2009; Lian et al. 2016; Moran-Gates et al. 2007; Wiley 2008; Wiley and Evans 2008)]. A few 
preclinical studies over the past five years have also started to examine long-term neurobiological 
consequences of adolescent treatment with atypical APDs (De Santis et al. 2016; Milstein et al. 
2013; Qiao et al. 2013; Vinish et al. 2013). For example, adolescent treatment with olanzapine has 
been shown to induce long-term deficits in behaviour in adulthood, such as alterations in working 
memory, fear conditioning, reward behaviour (to amphetamine) and anxiety/depression-related 
behaviour, as well as changes in neurotransmission in the NAc, and dendritic spine pruning in other 
major brain regions (Brooks et al. 2016; De Santis et al. 2016; Milstein et al. 2013; Xu et al. 2015). 
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However, the fact that adolescent APD treatment in these existing studies was not examined 
together with a comparison age group (Fuhrmann et al. 2015; Spear 2007) raises the question 
whether or not the reported findings are specific only to the adolescent animals.  
To address such issues, the experiments in this thesis have examined chronic 22-day risperidone 
administration in adolescent rats (PND36-PND56/57) and compared this with outcomes from the 
same exposure in adulthood (PND80-PND100/101). Risperidone was selected for detailed 
examination given this atypical APD is most commonly prescribed to adolescents (Hollingworth et 
al. 2013; Olfson et al. 2006; Olfson et al. 2012). The findings of the current thesis have added to the 
growing literature on adolescent APD exposure by demonstrating short- and long-term 
neurobiological consequences either in behaviour or neurochemistry selective to adolescent APD 
exposure.  
In this thesis, behavioural outcomes of adolescent APD treatment were examined with two 
behavioural tests, namely CAR and horizontal bar test for catalepsy. These two behavioural tests 
were chosen because they are widely used in the assessment of APDs or compounds with APD 
potential (Porsolt et al. 2010; Wadenberg 2010). Here, I showed that behaviours in chronic 
risperidone treated animals were highly dependent on age of exposure:- (1) Long-term alterations in 
the acquisition of the CAR and sensitized suppression of CAR were observed in rats treated with 
risperidone in adolescence compared with adults. (2) Long- and short-term alterations in cataleptic 
response were observed in rats treated with risperidone in adulthood compared with adolescence. 
Accompanying alterations in neurochemistry were also observed in brain regions associated with 
these behaviours. In the following sections, differential behavioural outcomes in CAR and catalepsy 
are discussed. Given that MRI and 1H MRS data and possible reasons for negative findings have 
been discussed in greater details in Chapter 3 and Chapter 5 respectively, these will not be repeated 
in the current chapter.   
 
6.2. CAR: A further introduction on circuits involved  
The CAR is a behavioural paradigm which is widely used not only in studies of APDs (as early as 
1950s (Cook and Weidley 1957)) but also in the studies of fear and anxiety (Lovibond et al. 2008). 
The CAR paradigm in rodents is most often performed in a chamber with two compartments which 
are separated with a door or a hurdle (See Chapter 2, Section 2.3.1.). Investigators have focused on 
two aspects of CAR: acquisition in untrained rats or expression of a previously acquired CAR after 
some intervention or time period. 
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Acquisition of the CAR is considered to be a two-step process. First, rats undergo Pavlovian 
conditioning from repeated pairing of CS (white noise, tone or light) and US (foot-shock), by 
learning that the CS is followed by the US (formation of CS-US associations). This Pavlovian 
conditioning leads to a freezing response. Second, rats learn to perform an instrumental avoidance 
response (crossing into the other chamber) instead of freezing, in order to avoid the foot-shock.  
As summarised in Figure 6-1, acquisition of CAR is influenced by neural activity in distinct brain 
regions such as the NAc (Oleson et al. 2012), the VTA (Shumake et al. 2010), the PFC (Stark et al. 
1999) and the amygdala (Choi et al. 2010a; Darvas et al. 2011; Lázaro-Muñoz et al. 2010). 
Connectivity between these regions is critical to perform a CAR, for example, between the NAc and 
the amygdala (Ramirez et al. 2015) or between the PFC and the amygdala (Moscarello and LeDoux 
2013). CS-US associations are formed in the lateral nucleus of the amygdala (LA) (Sah et al. 2003). 
Lesioning of the LA therefore impairs CAR acquisition (Choi et al. 2010a; Lázaro-Muñoz et al. 
2010). When CS information is relayed from the basal nucleus of the amygdala (BA) to the NAc, 
active ‘defensive’ responses (avoidance response in the case of CAR) are produced (Ramirez et al. 
2015). If CS information is processed through the central amygdala nucleus (CeA) this leads to 
Pavlovian responses (freezing) and acts against acquisition of CAR (Choi et al. 2010a; Lázaro-
Muñoz et al. 2010). Suppression of the CeA activity improves CAR learning and this is thought to 
be mediated by cortical input from the PFC (infralimbic region) (Moscarello and LeDoux 2013) or 
recurrent connections between the NAc and the PFC (Ramirez et al. 2015) through the cortico-
striato-thalamic loop (Sesack and Grace 2010) (Figure 6-1). 
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Figure 6-1 Neural pathways and brain regions involved in acquisition of conditioned avoidance response (CAR) Information of CS and US is relayed from the 
sensory systems to the lateral nucleus (LA) of the amygdala. The LA projects to the basal nucleus (BA) which projects to both central amygdala nucleus (CeA) and 
the nucleus accumbens (NAc). The NAc is central to mediating an instrumental avoidance response whereas the CeA mediates freezing response. The projections 
from the prefrontal cortex (PFC, infralimbic region) to the CeA suppress CeA-mediated freezing reactions and promote avoidance response. Stimulation of the 
ventral tegmental area (VTA), that provides dopaminergic innervation to the NAc, also improves CAR acquisition. CS – conditioned stimulus; DRN – dorsal raphe 
nuclei; LHb – lateral habenula; MRN – medial raphe nuclei; SNr – substantia nigra; US – unconditioned stimulus;   
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Despite an involvement of such a complex interplay between multiple brain regions in the 
acquisition of the CAR, dopamine signalling within the NAc appears to be the final common 
pathway in conditioned avoidance behaviour (Oleson and Cheer 2013). The NAc modulates 
motivational circuits, serves as an integrative centre of inputs from the VTA, the amygdala, the PFC 
and the hippocampus, and produces a final behavioural output (Humphries and Prescott 2010; 
Mogenson et al. 1980). Increases in dopamine release in the NAc are accompanied by avoidance 
responses (McCullough et al. 1993; Oleson et al. 2012) whereas local depletion of dopamine in the 
NAc (McCullough et al. 1993) or lesioning of the NAc (and the striatum) (Koob et al. 1984) 
impairs CAR acquisition. In addition, electrical stimulation of the VTA, which provides 
dopaminergic input to the NAc (Elsworth and Roth 2009), can improve CAR acquisition (Shumake 
et al. 2010). By contrast, stimulation of the lateral habenula (LHb), which inhibits 90% of midbrain 
dopamine neurons (Ji and Shepard 2007), can disrupt CAR acquisition (Shumake et al. 2010).  
Suppression of avoidance without affecting escape responses is a behavioural effect selective to 
APDs especially with acute administration (Arnt 1982; Wadenberg 2010; Wadenberg and Hicks 
1999). It is thought that APDs achieve this selective suppression of CAR mainly through the 
blockade of dopamine neurotransmission in the NAc (Wadenberg 2010; Wadenberg and Hicks 
1999). Local administration of dopamine antagonists into the NAc suppresses CAR in a manner 
analogous to acute systemic administration of APDs (Wadenberg et al. 1990b). At the same time, 
APD-induced suppression of avoidance also correlates tightly with the occupancy of dopamine D2 
receptors (Natesan et al. 2007; 2008; Wadenberg et al. 2000; Wadenberg et al. 2001b) (Figure 6-2). 
Suppression of the CAR is therefore considered a robust behavioural readout of APD action 
(Wadenberg 2010; Wadenberg and Hicks 1999).  
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Figure 6-2 Schematic diagram of APD-induced suppression of CAR through blockade of dopamine 
neurotransmission in the nucleus accumbens (NAc)  In normal rats (without APD treatment), increases in 
the dopamine release are accompanied by avoidance responses (CAR) and decreases by escape responses. 
In rats treated with APDs, dopamine neurotransmission in the NAc is blocked leading to suppression of CAR 
without affecting escape responses.  
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6.3. Risperidone-induced changes in CAR: adolescents vs adults 
In this thesis, using CAR, I examined behavioural changes induced by risperidone treatment in 
adolescents and adults both during chronic treatment and after a drug-free interval. Depending on 
the timing and method (suppression or acquisition) of assessment, risperidone induced changes in 
CAR differed between adolescents and adults. During ongoing chronic treatment, suppression of 
previously acquired CAR was assessed (Chapter 3). At this time point of assessment, the 
adolescents experienced fewer escape failures than the adults. After a drug-free interval, both 
suppression of already acquired CAR in previously trained rats and acquisition of the CAR in 
untrained rats were assessed. At this time point of assessment, rats with prior adolescent risperidone 
exposure were more sensitive to CAR suppression by a challenge dose of this APD, compared to 
those with prior adult risperidone exposure (Chapter 3). Moreover, after a drug-free interval, rats 
with prior adolescent risperidone exposure showed a retarded capability to acquire the CAR 
(Chapter 5).  
6.3.1. Risperidone-induced suppression of previously acquired CAR    
The majority of studies investigating repeated APD treatment have examined suppression of the 
CAR in well-trained adolescent or adult rats (for example, (Gao and Li 2014; Li et al. 2007; Li et al. 
2010; Qiao et al. 2013; Samaha et al. 2007)). Similar to these studies, in Chapter 3, I studied 
suppression of the CAR with chronic APD treatment in adolescents and adults. The experimental 
features that distinguished my study from the existing reports are: (1) I directly compared 
adolescent and adult treatment [cf. examination of only one age group in the existing studies, for 
example, (Gao and Li 2014; Li et al. 2007; Qiao et al. 2013)]; (2) I used CS-US CAR tests unlike 
the existing studies of adolescent APD treatment that utilized CS-only CAR tests [for example, 
(Qiao et al. 2014a; Shu et al. 2014a; Shu et al. 2014b) but see (Gao and Li 2014)].  
In the first part of Chapter 3, I examined three APDs (risperidone, clozapine and haloperidol) 
whereas in the second part, I continued to examine risperidone only. Rats were given the same 
handling history including CAR training, the only variable being the age at which APD treatment 
was administered. I showed in both adolescents and adults that risperidone and haloperidol 
suppressed the CAR during chronic treatment (Day 17) whereas clozapine no longer blocked the 
CAR (tolerance). These findings in Chapter 3 are consistent with the reported CAR outcomes of 
these APDs in adolescents (Qiao et al. 2014a; Qiao et al. 2013) and adults (Li et al. 2007; Li et al. 
2010). Importantly, I identified an important age-dependent outcome – adolescents were less 
susceptible to risperidone-induced escape failures than adults during chronic treatment (See the next 
section for detailed discussion).  
Chapter 6 
 182 
After a drug-free interval, when these animals were re-challenged with half of the APD dose they 
previously received, differential outcomes in CAR were identified depending on the age windows 
of prior risperidone treatment. Rats treated with risperidone in adolescence were observed to be 
more sensitive to CAR suppression by this APD challenge compared with those treated in 
adulthood. This finding suggests a sensitization-like CAR suppression in rats with adolescent 
risperidone exposure, as has been reported in the literature (Qiao et al. 2014a). However, no 
differential effect on escape failure or locomotor responses was observed. This finding selective to 
the suppression of CAR without any effect on escape failures further suggested that the adolescent 
risperidone treatment preferentially affected the NAc, not the striatum (See the next section for 
further discussion).  
As discussed earlier, the NAc is the major brain region associated with APD-induced suppression of 
CAR. Therefore, the NAc was the brain region I examined for neurochemical correlates (Chapters 3 
and 5). Among the dopaminergic and serotonergic markers examined I observed a significant 
downregulation of 5HT2A receptor and COMT mRNA in rats previously treated with risperidone in 
adolescence (Chapter 3). Decreasing 5HT2A receptor activity experimentally by administration of a 
selective 5HT2A antagonist can potentiate suppression of CAR by dopamine antagonists 
(Wadenberg et al. 2001a). Therefore, I speculate that a decreased 5HT2A receptor activity would 
potentiate the effect of dopaminergic receptor blockade by risperidone and therefore lead to 
increased (or ‘sensitized’) CAR suppression by the challenge dose of this APD in these rats. This 
hypothesis needs to be examined in future studies.  
Another aspect of stimulation of the 5HT2A receptor is increased dopamine synthesis and release 
(Navailles and De Deurwaerdère 2011). Therefore, I speculate that an alternate consequence of 
decreased 5HT2A receptor levels in rats with adolescent risperidone exposure would be decreased 
dopamine availability. A reduction in COMT, a major catabolic enzyme for dopamine, in the NAc 
could represent a compensatory mechanism to decreased dopamine availability. Therefore, I 
examined the levels of dopamine and its metabolites in another cohort of rats treated with the same 
adolescent risperidone regimen (Chapter 5). However, no significant alterations in dopamine, 5HT 
and their metabolites were observed in the NAc. While this finding contradicts this hypothesis, 
dynamic changes in dopamine availability may still occur for the following reasons: (1) The net 
functional outcome of 5HT2A receptors are state-dependent; so it is only under activated conditions 
(e.g. in response to a pharmacological agent) that the activity of 5HT2A receptor may regulate 
dopamine release (Porras et al. 2002; Schmidt et al. 1992) or behaviour (e.g. CAR) (Wadenberg et 
al. 2001a; Wadenberg et al. 1998a). (2) Ex vivo HPLC measurement of all the available pools of 
neurotransmitters and their metabolites may not reflect dynamic changes in synaptic levels as occur 
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during a behavioural performance. Further examination, for example, with microdialysis under a 
pharmacological challenge (for example, with risperidone itself or dopamine agonist) may assess 
functional outcomes of downregulated 5HT2A receptor levels on dopamine neurotransmission.   
 
 
Figure 6-3 Long-term changes in CAR and alterations in neurotransmission in the nucleus accumbens (NAc) 
of rats with prior risperidone exposure in adolescence or adulthood. Downregulation of 5HT2A receptors in 
the NAc is hypothesized to potentiate CAR suppression by dopamine-blocking effects of half dose risperidone 
challenge in rats with prior adolescent risperidone treatment. Escape failures induced by risperidone 
challenge were minimal in both age groups.    
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6.3.2. Risperidone-induced deficits in acquisition of CAR  
Following seminal works and influential reviews by Wadenberg and colleagues (for examples, see 
(Wadenberg et al. 1990b; Wadenberg et al. 1998b; Wadenberg 2010; Wadenberg and Hicks 1999; 
Wadenberg et al. 2001b)), the majority of preclinical APD studies either in adolescent or adult rats 
that utilize CAR examined the suppression of previously acquired CAR in well-trained rats. 
Wadenberg and colleagues also recommended a selective inclusion of well-trained rats in order to 
avoid the potential confounds of freezing behaviour in the interpretation of the findings (Wadenberg 
and Hicks 1999). By contrast, only a limited number of studies have investigated the effect of 
chronic APD treatment on the acquisition of CAR in previously untrained rats. These existing 
studies (adult animals only) investigated CAR acquisition only during repeated or chronic treatment 
[for example, see (Aguilar et al. 1997; Drago et al. 1997; Li et al. 2004)]. To the best of my 
knowledge, no existing study has examined CAR acquisition after a drug-free interval from either 
adolescent or adult treatment with APDs.  
Since the acquisition of CAR involves a co-ordinated interplay between multiple brain regions (See 
Section 6.2.), examination of CAR acquisition can provide a mechanistic insight into co-ordinated 
brain function and behaviour. Moreover, the ability to acquire CAR may also serve as an index of 
learning and memory or anxiety and fear behaviour. Therefore, in Chapter 5, rats with prior 
risperidone exposure as adolescents or adults were trained for CAR for 7 days and their ability to 
acquire CAR was examined. I show rats previously treated with risperidone as adolescents have a 
retarded ability to acquire the CAR, compared to similarly treated adults. Given that the NAc is the 
final common pathway to CAR acquisition, I hypothesized that neurochemical changes in this brain 
region would correlate with this observed acquisition deficit in animals exposed to risperidone as 
adolescents. To test this hypothesis, I examined monoamine levels in the NAc at the conclusion of 
the experiment. This ex vivo neurochemical examination did not identify any significant alterations 
in baseline pool of monoamines (Dopamine, 5HT and noradrenaline) and their metabolites in the 
NAc regardless of prior treatment history. Nonetheless, this finding does not exclude alterations in 
dynamic neurotransmission that happens during a behavioural performance in these rats as 
previously mentioned.  
Examination of neural activity in specific region(s), for example, in the NAc with voltammetry or 
electrophysiology in a behaving animal, could provide insight into the dynamic nature of 
neurochemical changes in the NAc. Increases in dopamine release in the NAc are observed during 
avoidance when examined either with voltammetry (Oleson et al. 2012) or microdialysis 
(McCullough et al. 1993). By contrast, decreases in dopamine release in the NAc are accompanied 
by escape responses (Oleson et al. 2012). These alterations in the accumbal dopamine release are 
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thought to be due to different computation and encoding of the CS and the US by dopaminergic 
neurons which modulates incentive-motivational circuitry (Oleson and Cheer 2013). Therefore, a 
more detailed analysis of dopaminergic input in the NAc by voltammetry or electrophysiology will 
provide mechanistic insight into risperidone-induced deficits in CAR learning.  
While the NAc serves as the final output pathway to CAR, other brain regions that closely interact 
with the NAc should also be further examined. As discussed earlier, neural activity in the VTA that 
provides dopaminergic input to the NAc, strongly influences CAR acquisition (Shumake et al. 
2010). During adolescence, dopaminergic neurons in the VTA undergo major changes in 
electrophysiological properties (for example, firing rate) (McCutcheon et al. 2012; McCutcheon and 
Marinelli 2009) whereas afferent inputs to the VTA from other regions are still incomplete 
(Yetnikoff et al. 2014). It is still unknown how adolescent risperidone treatment can affect these 
maturation changes. In adults, 21-day APD treatment can reduce the activity of dopaminergic 
neurons (a state referred to as ‘depolarization block’) in the VTA or the SNr or both, depending on 
the drug type (Chiodo and Bunney 1983; Grace et al. 1997). Recently, this finding has been 
extended to adult offspring of a neurodevelopmental model of schizophrenia (Gill et al. 2014; 
Valenti et al. 2011). However, VTA neurophysiology has yet to be examined in adolescent 
risperidone treatment. Investigation of both short- and long-term changes in the VTA and the 
influence of these changes on the behaviour is therefore required.   
Risperidone-induced changes in distinct amygdala nuclei may also play important roles in CAR 
learning. As introduced previously, amygdala nuclei such as the LA, the BA and the CeA and their 
connections with the NAc or the PFC are important in CAR acquisition (Choi et al. 2010a; Lázaro-
Muñoz et al. 2010; Moscarello and LeDoux 2013; Ramirez et al. 2015). Acute administration of 
APDs in adult rodents is known to induce neuronal activation in the amygdala nuclei (Cohen et al. 
2003; Park et al. 2011; Rebec et al. 1983; Takashi et al. 1983; Zhao and Li 2012). Chronic 
risperidone treatment in adults can also induce neurochemical changes in the amygdala nuclei [for 
example, see (Terry Jr et al. 2005)]. Yet, the current knowledge of adolescent risperidone treatment 
on the amygdala is rather limited. In adults, acute administration of APDs increases levels of 
dopamine and its metabolites in the amygdala but chronic administration induces tolerance to this 
effect (Essig and Kilpatrick 1991; Kurachi et al. 1995; Kurachi et al. 1994; Takashi et al. 1983). It is 
still unknown whether similar outcomes can be induced by risperidone treatment in adolescents or 
which neurotransmitter systems (glutamate, GABA, 5HT or dopamine) are targeted by this 
treatment.   
Serotonergic pathways that have a close interaction with the dopaminergic system are also actively 
involved in the (associative) learning process (Cools et al. 2008; Harvey 2003; Olvera-Cortes et al. 
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2008). Downregulation of 5HT2A receptors in the NAc was observed in another cohort of rats with 
the same adolescent risperidone treatment (Chapter 3). It is still unknown whether this 
downregulation of 5HT2A receptors has played a role in inducing CAR acquisition deficits. 
Therefore, the role of 5HT systems in the acquisition of the CAR also requires investigation. 
To sum up, the acquisition of CAR is a complex process involving multiple brain regions. 
Subsequent investigations of the neural mechanism(s) that underlie CAR learning deficits in rats 
with adolescent risperidone treatment will require use of techniques to assess neurochemistry and 
neurophysiology in one or more brain regions such as the NAc in behaving animals. Another 
outstanding question is whether impaired CAR acquisition represents a deficit in general learning 
ability as a consequence of risperidone exposure in adolescence. Rats treated with olanzapine as 
adolescents have also been reported to require longer time to reach a defined criterion when 
examined in delayed non-match to sample task in adulthood (Milstein et al. 2013). Together, the 
findings in the study of Milstein et al. and in the current thesis raise a hypothesis that APD 
treatment in adolescence can induce long-term deficits in learning in adulthood. Further 
investigations of learning and memory are therefore required.    
6.4. Risperidone-induced changes in catalepsy: adolescents vs adults 
Catalepsy is defined as an inability to correct an unusual posture (Sanberg et al. 1988). In 
preclinical studies, catalepsy is examined with either a horizontal bar test or grid test (Porsolt et al. 
2010; Sanberg et al. 1988). APDs are known to induce catalepsy at high (‘supra-therapeutic’) doses 
which occupy >80% striatal dopamine D2 receptors (Wadenberg et al. 2000; Wadenberg et al. 
2001b). When given repeatedly in adult rats, low doses of haloperidol which acutely do not induce 
catalepsy, also induce a progressive increase in this behavioural response (Banasikowski and 
Beninger 2012a; Schmidt et al. 1999).  
At therapeutically relevant doses that occupy 60-80% dopamine D2 receptors, APDs are known to 
inhibit CAR selectively without affecting escape responses (no escape failures) (Natesan et al. 
2008; Wadenberg 2010; Wadenberg and Hicks 1999; Wadenberg et al. 2001b). The dose of 
risperidone used in this study should achieve a dopamine D2 occupancy of approximately 80% 
(Wadenberg et al. 2001b). I have shown that the acute administration of this dose of risperidone did 
not induce a significant number of escape failures in adults (See Pilot Experiment, Chapter 3, 
Section 3.2). However, with repeated injections during chronic treatment, a significant level of 
escape failures became apparent only in adults (Chapter 3). Although not well-understood, APD-
induced escape failures are thought to be due to the development of motor or extrapyramidal side 
effects from high striatal D2 receptor blockade (Shannon et al. 1999; Wadenberg 2010). Therefore, 
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I hypothesized the following: Escape failures observed in adult rats would be due to a progressive 
increase in catalepsy with repeated injections during chronic risperidone treatment. Adolescent rats 
would experience lower cataleptic responses and therefore lower escape failures during the same 
treatment. Indeed, supporting my hypothesis, the existing literature shows that the cataleptic 
responses in adults are higher than those in adolescents during 10-day repeated treatment with 
haloperidol (Wiley and Evans 2008).  
To examine these hypotheses, rats were treated for 22 days with risperidone either as adolescents or 
adults (Chapter 4). Cataleptic and locomotor responses were examined longitudinally from Day 1 to 
Day 17 of chronic treatment. Consistent with the reported findings of haloperidol treatment (Wiley 
and Evans 2008), a lower progression of cataleptic responses was observed in risperidone-treated 
adolescents, compared to similarly treated adult rats. Moreover, these changes in catalepsy were 
consistent with the findings in Chapter 3 in which I showed that adolescents developed lower levels 
of escape failures than adults during chronic risperidone treatment. This provides further support to 
the hypothesis that the observed escape failures in risperidone treated adults are due to cataleptic 
responses (Wadenberg 2010). This finding also further suggested that cataleptic responses might 
have partially contributed to CAR suppression at least in adults. By contrast, no differential effect 
on locomotion was observed in adolescents and adults. Given that catalepsy is mainly striatum-
dependent (Ossowska et al. 1990; Yoshida et al. 1994) and locomotion mainly NAc-dependent 
(Beninger 1983; Kelly et al. 1975), this finding further suggested that striatum-dependent 
behavioural changes (catalepsy and escape failures) became more prominent with repeated 
risperidone injections in adults whereas the adolescents treated with the same risperidone regime 
were less sensitive to these behaviour changes (Figure 6-4). 
The outstanding question therefore is: ‘Why are adolescent rats less sensitive to striatum-dependent 
behavioural outcomes than adult rats? The adolescent striatum is still immature with ongoing 
multiple remodelling processes, for example, in presynaptic dopaminergic innervation (Mathews et 
al. 2009; Matthews et al. 2013; Naneix et al. 2012; Stamford 1989), and dopaminergic (Andersen et 
al. 2000; Naneix et al. 2012; Tarazi and Baldessarini 2000; Tarazi et al. 1998; 1999; Teicher et al. 
1995) and endocannabinoid receptors (de Fonseca et al. 1993; Klugmann et al. 2011). Therefore, I 
hypothesized that incomplete wiring of the adolescent striatum would contribute lower striatum-
dependent behavioural outcomes in these rats (See the next section for further discussion).  
Thus, I elected to examine the neurochemistry of the striatum from rats treated with risperidone in 
adolescence or adulthood in Chapter 4. Striatal dopamine metabolites were observed to be elevated 
selectively in risperidone-treated adolescent rats. Interestingly, a negative correlation between 
striatal dopamine metabolites and cataleptic responses were observed in risperidone-treated 
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adolescent rats. I speculate that increased striatal dopamine metabolites reflect increased dopamine 
availability in adolescents which in turn is able to counter the hypodopaminergia produced by 
risperidone. This could act to produce a lower cataleptic response. However, striatal dopamine 
levels were observed to be normal in these rats, at least at the time of ex vivo neurochemical 
examination. Still this finding does not exclude a possibility of increased dopamine availability in 
behaving rats. Therefore, further investigations are still required to support this hypothesis. 
Examination of baseline and/or stimulated dopamine release in the striatum with microdialysis, 
activity of midbrain dopaminergic neurons with electrophysiology [for example, (Grace et al. 
1997)] or TH expression in midbrain neurons with immunohistochemistry [for example, (Levinson 
et al. 1998)] will enable a more accurate assessment of risperidone-induced changes in 
dopaminergic activity. 
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Figure 6-4 Schematic diagram of observed changes in cataleptic behaviour and its contribution to escape 
failures in the CAR tests during chronic risperidone treatment in adolescent or adult rats.  (a) In adult rats, 
repeated risperidone induced a significant increase in catalepsy and escape failures, striatum-dependent 
behaviours. These behaviours would contribute to drug-induced CAR suppression observed in these rats. (b) 
In adolescent rats, given incomplete wiring of the striatum, repeated risperidone treatment did not induce a 
significant increase in catalepsy and escape failures to a level observed in adults. CAR suppression in 
adolescents would therefore be due to action mainly on the NAc.  
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Following up on short-term cataleptic outcomes (Chapter 4), I next examined long-term cataleptic 
outcomes in another cohort of animals in Chapter 5. Rats treated with risperidone or vehicle for 22 
days in either adolescence or adulthood underwent an equivalent drug-free interval. Then all rats 
received a challenge of risperidone at the same dose they previously received during chronic 
treatment and their cataleptic behaviour was examined. Remarkably, rats with prior adult 
risperidone exposure were observed to have a robust sensitization-like cataleptic response. This was 
not observed in those animals with adolescent risperidone exposure. These findings further 
suggested that, even after drug-free interval, rats treated with risperidone in adolescence were still 
less sensitive to striatum-dependent behavioural changes.  
However, when the striatal tissues were examined with HPLC, no significant alterations in baseline 
levels of monoamines and their metabolites were observed (Chapter 5). One caveat to the 
interpretation of this data is that ex vivo HPLC measurements of all available monoamines and their 
metabolites in both extracellular and intracellular pools do not reflect dynamic neurotransmission 
changes that occur under the influence of an APD or during behavioural performance. Another 
caveat is that neurotransmitter content was performed after 7 days of CAR training, not 
immediately after catalepsy testing. Neurochemical examination at a more proximal time point, for 
example, immediately after bar test, may perhaps provide a better insight into neurotransmission 
changes responsible for catalepsy while reducing any other possible confounds, for example, from 
CAR training. 
Investigation of changes in the neural activity or neurochemistry in the presynaptic regions, for 
example, the substantia nigra, may also provide further mechanistic insight into long-term cataleptic 
response. In adults, APD-induced downregulation of TH levels in the SNr has been observed to last 
up to 4 weeks and this has been proposed to be one mechanism for extrapyramidal effects like 
catalepsy (Levinson et al. 1998). This may perhaps be a mechanism for differential catalepsy 
sensitization in rats with adolescent or adult risperidone exposure. Moreover, in adult rodents, 
chronic treatment with APDs can decrease the number of spontaneously firing neurons in SNr or 
VTA or both, a condition referred to as ‘depolarization block’ (Chiodo and Bunney 1983; Gill et al. 
2014; Grace et al. 1997). These authors have also proposed a relationship between depolarization 
block of dopaminergic neurons and cataleptic potential of APDs. Therefore, further examination of 
midbrain dopaminergic activity is now required. 
In addition to dopaminergic systems, changes in other neurotransmitter systems should also be 
investigated. For example, glutamatergic antagonists have been reported to reduce haloperidol-
induced catalepsy sensitization (Riedinger et al. 2011). In particular, glutamatergic 
neurotransmission in the inferior colliculus appears to have an important role at least in haloperidol-
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induced catalepsy (Medeiros et al. 2014; Melo et al. 2010). The neural mechanisms mediating 
risperidone-induced catalepsy sensitization remain unknown and further investigations are therefore 
required to better understand the neurobiological underpinnings of differential cataleptic outcomes 
with risperidone treatment in adolescence or adulthood.  
6.5. Risperidone-induced behavioural changes in adolescents vs adults: A synthesis  
Together, the findings in the preceding three chapters have provided insights into the 
neurobiological effects of chronic adolescent risperidone treatment. Risperidone treatment in 
adolescence was found to preferentially affect CAR – both suppression in previously trained rats 
and acquisition in untrained rats. This outcome became evident after a drug-free interval. By 
contrast, risperidone treatment in adulthood preferentially affected catalepsy both during chronic 
treatment and after a lengthy drug-free interval (See Section 6.7. for discussion on limitations in 
interpretation of these findings). As discussed in earlier sections, neurotransmission in the NAc is 
pivotal in both acquisition and suppression of the CAR. By contrast, catalepsy and escape failures 
are mainly mediated by the striatum. Therefore, I propose that two distinct brain regions, the NAc 
and the striatum, are respectively involved in age-dependent outcomes in CAR and catalepsy. 
Differences in the effects of risperidone on the NAc and the striatum in adolescents may be related 
to relative maturation status of these two regions. Here I speculate that due to a less mature wiring 
state of the striatum, the adolescents are therefore less sensitive to risperidone-induced catalepsy 
(and escape failures), which are mainly striatum-dependent. In adolescents, presynaptic 
dopaminergic innervation of the striatum, as identified by TH levels, is still incomplete (Matthews 
et al. 2013). This may explain why the adolescent striatum has lower levels of dopamine release 
both at baseline (Naneix et al. 2012) and after stimulation (Matthews et al. 2013; Stamford 1989) 
compared to adults. Consistent with this, adolescent rats show lower levels of striatum-mediated 
stereotypic fine movements in response to acute amphetamine (Matthews et al. 2013). The 
adolescent striatum has also been observed to have higher dopamine turnover than the adult 
striatum (Naneix et al. 2012). On the other hand, TH innervation of the adolescent NAc is relatively 
mature (Matthews et al. 2013) (but see (Mathews et al. 2009) and dopamine release in the 
adolescent NAc was comparable to that in the adult NAc at both baseline and after amphetamine 
stimulation (Matthews et al. 2013). Dopamine turnover in the NAc is also similar in adolescents and 
adults (Naneix et al. 2012). Moreover, dopamine receptor changes in the striatum and the NAc also 
differ. During adolescence, dopamine receptors reach peak levels in the striatum, followed by 
pruning to adult levels but these changes in dopamine receptors are not seen in the adolescent NAc 
(Naneix et al. 2012; Teicher et al. 1995) (but see (Tarazi et al. 1998)). Moreover, task-evoked 
neural activity of the adolescent striatum in operant chambers is different from that of the adult 
Chapter 6 
 193 
striatum, suggesting differential processing of stimuli in the striatum of adolescents and adults 
(Simon and Moghaddam 2015; Sturman and Moghaddam 2012). Therefore, it is plausible that 
differences in the wiring status of the NAc and striatum in the adolescents lead to differential effects 
of risperidone on these two brain regions and consequently produce differential effects on CAR and 
catalepsy.  
The outstanding question is: ‘Given a relatively more mature state of the NAc, why are adolescents 
more sensitive to changes in CAR, which is dependent on this brain region?’ Although presynaptic 
dopaminergic innervation of the adolescent NAc has reached a relatively mature status, the levels of 
dopamine transporters in the NAc are lower in adolescents than in adults (Matthews et al. 2013). 
Also, the functional status of NAc medium spiny neurons (MSNs) at the level of integration of 
glutamatergic and dopaminergic inputs has not reached full maturity (Benoit-Marand and O'Donnell 
2008; Huppe-Gourgues and O'Donnell 2012; Huppé-Gourgues and O'Donnell 2012). For example, 
dopamine D2 receptor-mediated modulation of cortically evoked excitatory postsynaptic potentials 
(EPSPs) in the accumbal MSNs changes from a suppressive effect in adolescents to a potentiating 
effect in adults (Benoit-Marand and O'Donnell 2008). Such functional maturation in the NAc can be 
arrested at the adolescent state by olanzapine treatment in adolescence (Brooks et al. 2016). 
Therefore, it is plausible that adolescent risperidone treatment has also altered or arrested the 
functional maturation of MSNs in the NAc and therefore produced changes in the CAR.   
In the literature on addiction, locomotor sensitization is well-established with exposure to 
psychoactive or rewarding agents, for example, amphetamine [See review by (Vanderschuren and 
Kalivas 2000)]. In this thesis, sensitization-like responses in CAR and catalepsy were observed in 
rats with prior adolescent or adult risperidone exposure respectively. These findings raise the 
following questions: (1) Does risperidone induce behavioural sensitization like psychostimulants?  
(2) What mechanisms are common and what are different with regards to risperidone-induced 
behavioural sensitization (in CAR and catalepsy) and psychostimulant-induced locomotor 
sensitization? (3) How do mechanisms of risperidone-induced sensitization differ in adolescents and 
adults? 
Behavioural sensitization is a progressive increase in a particular behavioural effect with repeated 
treatment with a drug and an enhanced response in this behaviour on re-exposure to this drug 
(Vanderschuren and Kalivas 2000). The findings of my thesis, together with those in the existing 
literature strongly suggest that APDs can produce behavioural sensitization. Here I showed 
risperidone-induced sensitization in CAR suppression and catalepsy, consistent with the reported 
findings in these two behaviours induced by repeated treatment with risperidone or other APDs 
such as haloperidol and olanzapine (for example, (Banasikowski and Beninger 2012b; Li et al. 
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2007; Qiao et al. 2014a; Schmidt et al. 1999)). In addition to CAR and catalepsy, APD-induced 
sensitization responses have also been demonstrated in other behaviours such as vacuous chewing 
movements (an index of APD-induced tardive dyskinesia in rodents) (Turrone et al. 2003; Turrone 
et al. 2005), suppression of PCP-induced hyperlocomotion (Shu et al. 2014a; Sun et al. 2009) and 
suppression of lever presses for reward (Trevitt et al. 1998; Varvel et al. 2002). Given the evidence 
supporting the phenomenon of ‘APD-induced behavioural sensitization’, another question is related 
to the neural mechanism(s) involved.   
In locomotor sensitization to psychostimulants, such as amphetamine, two distinct stages are well-
recognized: induction (repeated treatment) and expression (rechallenge). Different brain regions 
(the NAc, the PFC or the VTA) and neurotransmitter systems (dopamine or glutamate) are involved 
at these different stages (Vanderschuren and Kalivas 2000). It is still unclear whether sensitization 
to risperidone in either CAR or catalepsy operates according to similar mechanisms as found in 
locomotor sensitization to psychostimulants. The existing studies have shown that induction and 
expression stages also exist in APD sensitization in  CAR (for example, (Qiao et al. 2013)) or 
catalepsy (for example, (Klein and Schmidt 2003)) [Also see review by (Li 2016)]. However, unlike 
well-studied locomotor sensitization to psychostimulants, the roles of different brain regions or 
neurotransmitter systems in sensitisation to APDs are far less well understood.  
At least in adult APD treatment, an increase in D2 receptor activity, as indicated by heightened 
locomotor responses to quinpirole, is thought to mediate sensitized responses in CAR suppression 
(which was not observed in this thesis) (Gao and Li 2013; Li 2016). However, the locus of this 
increased D2 activity (whether in the striatum, the NAc or other brain region) is still unknown. This 
D2-mediated mechanism appears be less likely in sensitization in adolescent APD treatment. 
Heightened locomotor responses to quinpirole were not observed in animals that were treated as 
adolescents with risperidone (1 mg/kg/day for 5 days) (Qiao et al. 2014a) or haloperidol (0.05 or 
0.25 mg/kg/day) (Gao and Li 2014) despite sensitized CAR suppression responses. Furthermore, a 
recent study did not find a quantitative change in D2 receptor protein levels in striatum, PFC and 
hippocampus of adult rats expressing sensitized CAR responses after adolescent asenapine 
treatment (Shu et al. 2014b). Here I showed that, at least in rats with prior adolescent risperidone 
exposure, 5HT2A receptors in the NAc may be involved in sensitized CAR suppression. Further 
investigations are still required to better understand neurobiological underpinnings of APD-induced 
sensitization in CAR. 
With regards to haloperidol-induced catalepsy sensitization in adults, different roles of dopamine 
receptors have been identified at different phases. In the induction phase, normal function of D1 
receptors is required (Banasikowski and Beninger 2012a) whereas D3 receptors are involved in 
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expression phase (Banasikowski and Beninger 2012b). Antagonism at NMDA or AMPA receptors 
has also been shown to lower the rate of catalepsy sensitization during induction phase in adults 
(Riedinger et al. 2011). However, it is still unknown whether similar mechanisms operate in 
adolescents and adults with regards to catalepsy sensitization. My findings of differential catalepsy 
sensitization both during chronic treatment and after a drug-free interval strongly suggest that 
neural mechanisms differ in the two age groups.  
At the broader level, how does the adolescent brain handle risperidone-induced neurobiological 
changes? Do risperidone-induced changes modify normal adolescent remodelling processes? The 
findings of this thesis, together with the reports in the literature, strongly suggest that normal 
maturation processes of the adolescent brain can be modified by adolescent APD treatment. For 
example, adolescent olanzapine treatment has been reported to alter dendritic spine pruning in a 
region-specific manner (Milstein et al. 2013). The findings of this thesis also suggested 
modification of adolescent maturation in the striatum. During normal development, dopamine 
metabolite levels in the striatum reach a peak around PND30 and fall to adult level by PND45 
(Naneix et al. 2012). My findings in Chapter 4 indicated a possible alteration of this striatal 
maturation process by adolescent risperidone treatment as these rats still showed elevated levels of 
dopamine metabolites even at PND58. This finding raised a possibility of a protracted or arrested 
maturation of the striatum as a result of adolescent risperidone treatment. A similar ‘protracted’ 
maturation status has been identified in the activity of MSNs in the NAc after adolescent olanzapine 
treatment (Brooks et al. 2016). Moreover, neural adaptations during the drug-free interval also seem 
to play a role due to the following observations: (1) The observed short-term elevations in the 
striatal dopamine metabolites did not persist after a drug-free interval in rats with adolescent 
risperidone treatment. (2) Rats treated with risperidone in adolescence became more sensitive to 
changes in CAR (suppression or acquisition) after a drug-free interval. Therefore, a more thorough 
longitudinal assessment is still required to better understand the effects of risperidone on the 
adolescent brain remodelling.           
6.6. Risperidone-induced neurobiological changes in adolescents: Translation back 
to the clinic?  
Through a comparative examination of risperidone treatment in adolescent and adult rats, I showed 
that the adolescent and the adult brains have significant differences in behavioural and 
neurochemical responses to this APD regimen (See Section 6.7. for discussion on limitations in 
interpretation of these findings). This provides supporting evidence that neurobiological 
consequences of APDs on the adolescent brain cannot be extrapolated directly from the existing 
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findings in adults. This further suggests that a more thorough understanding of the effects of APDs 
on the adolescent brain is required.  
In this thesis, I used CAR and bar test for catalepsy to probe risperidone-induced alterations in brain 
function and behaviour in adolescent and adult rats. A direct reverse-translation of observed 
behavioural changes in these two paradigms will not be feasible due to low face validity of these 
behaviours (Porsolt et al. 2010; Wadenberg and Hicks 1999) and low construct validity given the 
use of ‘neurodevelopmentally normal’ animals. However, my findings still have important clinical 
implications. Failure to acquire CAR in rats with adolescent risperidone exposure may perhaps 
represent an alteration in anxiety/fear status. Or this deficit in CAR acquisition may also suggest a 
deficit in general learning capability or cognitive performance, which needs to be further 
investigated. Sensitization-like responses in either CAR suppression or catalepsy after risperidone 
also indicate some long-term alteration in brain function. At the same time, these findings raise two 
questions: (1) Do APD-induced sensitized responses exist in the clinic? (2) What are the 
implications of APD-induced sensitization?    
Psychotic symptoms in schizophrenic patients are thought to be due aberrant assignment of salience 
to normal stimuli by increased dopaminergic neurotransmission (Kapur 2003). By blocking 
dopaminergic neurotransmission, APDs are thought to reduce aberrant salience assignment and 
therefore psychosis (Kapur et al. 2006). In preclinical studies with CAR, the CS provides animals a 
motivational salience (to make an avoidance response) through dopaminergic neurotransmission in 
the NAc and APDs block this salience through dopaminergic blockade (Li et al. 2004). CAR 
suppression by APDs in rodents is therefore thought to be equivalent to APD-induced suppression 
of psychotic symptoms in schizophrenic patients (Kapur et al. 2006). In schizophrenic patients, 
APD treatment rapidly induces symptom reduction within 24 h of treatment (Kapur et al. 2005) and 
this symptom reduction progressively increases (over a duration of several weeks) as this treatment 
continues (Agid et al. 2003; Leucht et al. 2005) (Figure 6-5(a)). Similarly in preclinical studies in 
rodents, CAR suppression also progressively increases with repeated APD treatment (over a 
duration of several days) (Li et al. 2007; Samaha et al. 2008). In the clinic, patients treated with 
APDs especially with typical APDs can develop a syndrome of EPS called tardive dyskinesia (TD) 
and APD-induced TD progressively increases over time [See review (Waln and Jankovic 2013)]. 
Similarly in preclinical studies including the current thesis, cataleptic responses, an index of EPS, 
progressive increase with repeated APD treatment (Banasikowski and Beninger 2012a; Pezarro 
Schimmel et al. 2015; Schmidt et al. 1999; Wiley and Evans 2008) (Figure 6-5). Therefore, a 
progressive increase in symptom reduction or side effects observed in APD-treated patients has 
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been hypothesized to be analogous to the phenomenon of APD sensitization (CAR or catalepsy) 
seen in rodents (Li 2016).  
If the phenomenon of ‘APD sensitization’ does exist in the clinic, what are the implications? In 
sensitization to a drug, a behavioural response becomes increased on subsequent exposure to the 
same drug (drug challenge as examined here) or to another drug (via ‘cross-sensitization’). In 
addition, a specific behavioural response can also become decreased on subsequent exposure to 
another drug (via ‘cross-tolerance’). These outcomes will have important clinical implications, for 
instance, an adolescent patient who develops a sensitization to risperidone may become ‘cross-
tolerant’ to clozapine if he/she needs a switch in APD type. The same patient may also require 
lower doses if the same APD treatment needs to be repeated for other behavioural symptoms. This 
same patient may also become ‘cross-sensitized’ to a psychostimulant and therefore more prone to 
addiction. A recent preclinical study using developmental MAM model has provided evidence for 
APD-induced cross-tolerance by demonstrating that MAM rats treated previously with haloperidol 
did not respond to novel agent 5 GABAA positive allosteric modulator (Gill et al. 2014).  In the 
clinical settings, a drug challenge to examine a sensitization response, as has been done here in this 
thesis or preclinical studies, will not be feasible due ethical issues. Currently, neuroimaging 
paradigms translated from rodent CAR experiments are available to study the effects of APDs, for 
example, in healthy volunteers (Bolstad et al. 2015). Perhaps such kinds of neuroimaging studies 
may enable detection of risperidone-induced sensitization responses in the clinic. 
Another potential implication is related to the finding of lower cataleptic sensitization, a striatum-
dependent behaviour, in adolescent rats. Although a lower rate of catalepsy sensitization may 
simply be interpreted as a possibility of lower progression of EPS in patients, I speculate on the 
possibility of further clinical implications related to striatal function. Here, in this preclinical study, 
I suggest that chronic risperidone produces less effect on the adolescent striatum than it does on the 
adult striatum. In patients (often around the age of late-adolescence or young adulthood) at risk for 
development of schizophrenia, striatal dopamine synthesis capacity is increased and this increase 
tightly correlates with transition to full-blown psychosis (Howes et al. 2011; Howes et al. 2009). 
However, the outcomes of clinical trials on early intervention with APDs to prevent this transition 
in these at-risk individuals have been disappointing (Amos 2014; Preti et al. 2014; Stafford et al. 
2013). Lack of effects of APDs in these individuals may be due the fact that APDs are not exerting 
the required action on the striatum as shown in this study.         
In addition to behaviour tests, I also used invasive ex vivo neurochemical assessments, which 
clearly are not feasible in the clinical studies. Using these neurochemical assays, I here showed 
short-term increases in striatal dopamine metabolites and long-term reduction in accumbal levels of 
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5HT2A receptor and COMT selectively in rats with adolescent risperidone exposure. Together with 
my behavioural findings this strongly suggests neurotransmission in the adolescent brain is 
persistently altered by prior risperidone exposure. How these neurochemical changes can be 
translated to the clinic, for example, the impact on neurobehavioural or neurocognitive outcomes is 
still to be investigated. 
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Figure 6-5 Time course of a progressive increase in APD effect (APD-induced sensitization) in both patients and in rodents  (a) Schematic diagram shows that in 
schizophrenic patients, symptom reduction is observed within 24 h of APD administration (Kapur et al. 2005) and this symptom reduction, that is, drug effect, 
progressively increases over time i.e. sensitization [See details in (Agid et al. 2003; Leucht et al. 2005)]. (b) In male rats studied in this thesis, risperidone induced a 
small degree of catalepsy with the first dose (Day 1) and this cataleptic response, that is, drug effect, progressively increased over time, i.e. sensitization (Data 
reported in Chapter 4).   
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6.7. Limitations and future directions 
While the three experiments in this thesis have examined short- and long-term behavioural and 
neurochemical changes induced by adolescent risperidone treatment, a few areas still need to be 
addressed. In my experiments, I used daily IP injections as the route of administration. However, as 
highlighted by (Kapur et al. 2003), this route may not be clinically relevant due to short half-life of 
APDs in rats which metabolize these drugs faster. Moreover, stress from repeated handling and 
injections may also have some confounds on the observed findings such as sensitized CAR 
suppression. Supporting this speculation, SC injections of a lower dose of haloperidol in adolescent 
rats have been reported to induce a more robust sensitized CAR suppression, compared to 
continuous administration of a higher dose of this APD via osmotic minipumps (Gao and Li 2014). 
Recent preclinical studies of adolescent APD treatment have attempted to achieve a more clinically 
comparable pharmacokinetic profiles through the use of oral administration via cookie dough (three 
times a day) (De Santis et al. 2016; Lian et al. 2015; Lian et al. 2016) or drinking water (Milstein et 
al. 2013; Vinish et al. 2013; Xu et al. 2015). Yet, only in one of these studies, plasma concentration 
of APD achieved was examined (Milstein et al. 2013). It is still unknown whether oral 
administration can induce similar behavioural and neurochemical outcomes as IPD injections. 
Therefore, a comparative examination of different routes of administration of risperidone in 
adolescent rats (IP Vs. drinking water Vs. cookie dough Vs osmotic minipumps) will provide an 
important insight to this phenomenon.       
Due to differences in body size and composition between adolescent and adult rats, it is possible 
that pharmacokinetic factors (Spear 2007), such as relative absorption and distribution of 
risperidone in different body compartments may be different and any differences in 
pharmacokinetic factors could contribute to differential outcomes in adolescents and adults rats. In 
this thesis, I used the same dose of risperidone based on body weight but I did not examine plasma 
and brain tissue level of risperidone achieved in both age groups to address this issue. Therefore, it 
is highly recommended to examine the levels achieved in both plasma and brain during chronic 
treatment as well as after a drug-free interval. For example, in adult rats, haloperidol and 
risperidone are detectable in whole brain tissues even after a 14-day drug-free interval from chronic 
treatment although plasma levels were no longer detectable (Terry Jr et al. 2007a). Moreover, it is 
still to be examined whether this same dose can achieve the same level of dopamine receptor 
occupancy in adolescents and adults. This is relevant since the adolescent striatum is known to have 
higher levels of dopamine receptors (Tarazi and Baldessarini 2000; Teicher et al. 1995).         
I selected behavioural assessments based on well-validated behavioural tests (CAR and catalepsy) 
which are specific and sensitive to APDs’ action. The effects of APDs on other behavioural 
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domains, for example, cognition (Llorente-Berzal et al. 2012) or learning are still not well 
understood. Further examination of risperidone-induced outcomes in behavioural tests of cognition, 
learning and memory, such as novel object recognition and Morris Water Maze, will complement 
the current findings of learning deficits in CAR.    
The clinical reports are now revealing that APD prescription is increasing not only in adolescents 
but also in children (Olfson et al. 2006; Olfson et al. 2012; Rettew et al. 2015; Ronsley et al. 2013). 
In this thesis I focussed on risperidone treatment only in adolescents. Therefore, a comparative 
examination of atypical APD treatment in juvenile and adolescent rats along with adult cohorts will 
enable identification of critical windows for specific therapeutic or detrimental outcomes. 
Adolescence in rats is often considered to have three stages: early (PND23-PND34), mid (PND34-
PND46) and late (PND46-PND59) (Burke and Miczek 2014; Tirelli et al. 2003). In this thesis, I 
examined risperidone treatment starting from mid-adolescence (PND35-PND56). It is still to be 
investigated which stage of adolescence is the most critical window for inducing a certain 
behavioural or neurochemical outcome.  
In my studies, I only utilized male animals given the scope of the studies. Gender differences in 
neural outcomes of adolescent APD treatment are still to be investigated. A recent study has 
elegantly demonstrated the need for inclusion of both males and females, by showing long-term 
differential behavioural outcomes in male and female rats treated with the same APD regimens in 
adolescence (De Santis et al. 2016). Future studies should therefore investigate sex-dependent 
outcomes of adolescent APD treatment. 
 Moreover, only ‘neurodevelopmentally normal’ adolescent rats were used in this thesis to identify 
neurobiological consequences specific to risperidone treatment. This use of ‘normal animals’ may 
not fully reflect the clinical scenario of APD prescription in adolescent patients with 
‘neurodevelopmentally altered’ brain. Examination of adolescent risperidone treatment in rodent 
models of neuropsychiatric disorders [for example, (Piontkewitz et al. 2012; Zhu et al. 2014)] may 
complement the findings of the current thesis. It is still unknown how APD-induced sensitization 
can affect behavioural deficits in animal models of neuropsychiatric disorders. At least, sensitized 
CAR suppression has also been reported with adolescent olanzapine treatment in MIA model (Chou 
et al. 2015). These authors proposed that although the magnitude and temporal pattern of this 
sensitized CAR response in MIA animals was similar that seen in ‘normal’ adolescent rats with 
olanzapine treatment, underlying neural mechanism(s), at least in hippocampal cell proliferation or 
survival, would be different (Chou et al. 2015). Examination of APD-induced sensitization in rodent 
models of neuropsychiatric disorders is therefore another possible future direction.     
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In this thesis, 1H MRS examination was performed under isoflurane anaesthesia. Therefore potential 
confounds of the effects of isoflurane anaesthesia on the observed metabolites levels cannot be 
excluded. Imaging in awake rodents may perhaps provide a better measurement of brain 
metabolites. In addition, the impact of isoflurane on the adolescent brain maturation is still not 
known. Deficits in CAR acquisition in rats with adolescent risperidone exposure may perhaps be 
partially due to the effects of isoflurane and this still need to be investigated. Another limitation of 
the current thesis is that 1H MRS examination was focussed on the NAc. Changes in metabolites 
other brain regions, for example, the PFC, still need to be examined.  
An outstanding question that needs to be addressed from Chapter 3 is whether different drug-free 
intervals in adolescent and adult cohorts lead to differential behavioural responses in CAR 
(sensitized suppression) and neurochemistry (5HT2A receptor downregulation) selective to 
adolescents. Although I intended to examine the role of drug-free interval in Chapter 5, this aim was 
not achieved given a retarded learning of the CAR in adolescent risperidone cohort. Therefore, a 
more thorough examination of behavioural and neurochemical outcomes after the same drug 
washout period in adolescent and adult cohorts is still required.  
The functional consequences of 5HT2A receptor downregulation in the NAc in rats with adolescent 
risperidone treatment are still known. Given involvement of 5HT receptors in associative learning 
(Harvey 2003), investigation of the role of 5HT2A receptor downregulation in the CAR learning is 
also warranted in rats with adolescent risperidone treatment. As thoroughly reviewed elsewhere 
(Zhang and Stackman 2015), 5HT2A receptors are strongly involved in behaviours such as novel 
object recognition and spatial cognition in addition to major neuropsychiatric disorders including 
depression, schizophrenia and Alzheimer’s disease. Therefore, functional significance of 5HT2A 
receptor downregulation in other behaviours apart from the CAR is also yet to be explored. 
Ex vivo neurochemical assessments in this thesis focussed on dopamine-enriched brain regions such 
as the striatum and the NAc. In vivo assessments of neural signalling, for example, with 
microdialysis, voltammetry or electrophysiology, in behaving animals (for instance, (McCullough 
et al. 1993; Oleson et al. 2012; Sturman and Moghaddam 2012)) will enable identification of 
neurotransmission changes relevant to impaired CAR acquisition or catalepsy sensitization. 
Examination of the PFC, midbrain dopaminergic regions (VTA and SNr) or amygdala will provide 
further mechanistic insights into these behavioural changes. For instance, the firing rate of 
dopaminergic neurons in the adolescent VTA is higher, compared to the adult VTA counterparts 
(McCutcheon et al. 2012; McCutcheon and Marinelli 2009). The effects of adolescent risperidone 
treatment on these VTA neurons are still unknown. Changes in VTA neurons may perhaps underlie 
risperidone-induced deficits in CAR acquisition or sensitized CAR suppression. In addition to 
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changes in dopaminergic and serotonergic systems, APD-induced changes in the endocannabinoid 
systems should also be investigated. Given a report that short-term endocannabinoid CB1 signalling 
could be altered by adolescent APD treatment in a drug- and sex-dependent manner (Wiley et al. 
2008b), examination of CB1 receptor changes with adolescent risperidone treatment could be 
another promising direction in the future..  
6.8. Conclusion  
To conclude, using adolescent male SD rats, this thesis has examined short- and long-term 
neurobiological outcomes of adolescent risperidone treatment in comparison with the same 
treatment regime in adults. I used CAR and catalepsy tests, which are sensitive and specific for the 
actions of APDs on brain function. Along with these behavioural assessments, clinically relevant 
examination with MRI and 1H MRS and end-point neurochemical assays of the striatum and the 
NAc were performed. Through these assessments in this thesis, age-dependent behavioural 
outcomes were observed to be induced by the same risperidone treatment – In adolescent rats, the 
CAR was more preferentially affected by risperidone treatment while the outcomes in the catalepsy 
(and escape failures) are less prominent, compared to adults. Accompanying these behavioural 
changes, short-term elevations in dopamine metabolites in the striatum and long-term 
downregulation of 5HT2A receptor and COMT in the NAc were observed selectively with 
adolescent risperidone treatment. No short-term alteration in NAc metabolites or long-term change 
in brain structure was observed with the current risperidone regimen in adolescents and adults. My 
findings provide supporting evidence that the adolescent brain differs markedly from the adult brain 
in response to risperidone. In short, findings from this thesis plainly indicate that adolescents are not 
‘little adults’ and that adolescent APD prescription practices cannot just be extrapolated from adult 
findings or guidelines. Given risperidone is the most commonly prescribed atypical APD to 
adolescents, these findings may prove clinically relevant, providing new directions for clinical 
research on the outcomes of APD treatment in adolescents. These preclinical findings could help 
shape future clinical trials which will more extensively examine the neurobiological outcomes of 
adolescent APD prescription. 
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Appendix A – Primer information  
Information on the primers used in RT-PCR experiments  
Target Gene 
NCBI 
reference 
sequence 
Forward Primer Reverse Primer 
Product 
Size 
(bp) 
GAPDH NM_017008.4 ATCCTGCACCACCAACTGCT GGGCCATCCACAGTCTTCTG 123 
Dopamine D1 NM_012546.2 GGACACCGAGGATGACAACT TGGCTACGGGGATGTAAAAG 89 
Dopamine D2 NM_012547.1 CCCAGAGAGGACCCGGTATAG CTGGTTTGGCAGGACTGTCA 110 
Tyrosine 
hydroxylase 
(TH) 
NM_012740.3 GCTTCAATGACGCCAAGGAC CTGGATGGTGTGAGGGCTGT 122 
5-hydroxy 
tryptamine 
2A (5HT2A) 
NM_017254.1 GCGATCTGGATTTACCTGGA CACACGGCAATGATTTTCAG 155 
Catechol-O-
methyl-
transferase 
(COMT) 
NM_012531.2 ATCTTCACGGGGTTTCAGTG GAGCTGCTGGGGACAGTAAG 145 
Monoamine 
oxidase-A 
(MAO-A) 
NM_033653.1 GTGTGGAACCCCTTGGCATA GTCCCATTCCTGAGCGTGTC 117 
Monoamine 
oxidase-B 
(MAO-B) 
NM_013198.1 GATTCCCAGTGATGCTCCAT ATGGGTCTCCGCAGTTACAC 151 
Glutamic acid 
decarboxylase 
65 (GAD65) 
NM_012563.1 TGAGGGAAATCATTGGCTGGC TCTGACGTGAATGCGATGAGC 166 
Appendix B 
 
 
Appendix B – MRI image segmentation  
MRI Regions of interest and their identification landmarks 
Region of 
interest 
Anatomical 
boundaries and 
criteria 
Reference to 
Rat Brain Atlas 
No of 
slices of 
analyzed 
Example ROI 
Whole brain 
(WB) 
Rostral start from 
the base of olfactory 
bulb (at the 
demarcation of the 
olfactory bulb and 
frontal association 
cortex)  
Caudal end at the 
last slice containing 
cerebral cortex 
Approximately 
+5.62 mm to -
9.36 from 
bregma) 
16-17 
(every 
second 
slice) 
 
Striatum  Rostral start at the 
slice containing 
caudate putamen 
surrounded by 
forceps minor of 
corpus callosum 
Caudal end at the 
slice when the 
lateral border of 
hippocampus is 
lower than the 
medial 
Anatomical borders 
– corpus callosum 
superiorly, external 
capsule laterally, 
lateral ventricles 
medially  
Approximately 
+2.52 mm to -
3.6 mm from 
bregma 
11-13 
continuous 
slices 
 
Prefrontal 
Cortex (PFC, 
Prelimbic and 
Infralimbic 
Cortex) 
Rostral start at the 
slice where forceps 
minor of corpus 
callosum starts to 
form clearly 
Caudal end at the 
slice immediately 
before decussation 
of corpus callosum 
Anatomical borders 
– superiorly the line 
Approximately 
from +4.2 mm 
to +2.52 mm 
from Bregma 
4-5 
continuous 
slices 
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joining the genu of 
corpus callosum and 
the most medial 
ventral point of 
cortex (at about 45 
degree); inferiorly 
the horizontal line 
joining the tail of 
the corpus callosum; 
laterally the corpus 
callosum.  
Cerebral 
Cortex (CCx) 
Rostral start from 
the base of olfactory 
bulb (at the 
demarcation of the 
olfactory bulb and 
frontal association 
cortex)  
Caudal end at the 
last slice containing 
cerebral cortex 
Approximately 
+5.62 mm to -
9.36 from 
bregma 
16-17 
(every 
alternate 
slice) 
 
Hippocampus Rostral start - when 
the CA and dentate 
gyrus coincide with 
dorsal hippocampal 
commissure 
Caudal end at the 
loss of contrast 
between the corpus 
callosum and the 
subiculum, the 
absence of the 
dentate gyrus, and 
the clear separation 
of the two cerebral 
hemispheres 
Approximately 
-1.92 mm to -
8.04 mm from 
bregma 
14-15 
continuous 
slices 
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Appendix C – Pilot 1H MRS experiment  
 
Pilot experiment: Examination of accumbal metabolites with acute risperidone administration 
Introduction 
In this pilot experiment, acute effects of single dose administration of risperidone on accumbal 
metabolites were examined in adolescents and adults. N-acetylasparte (NAA), glutamate and 
GABA were of interest in this experiment, given reported changes in these metabolites with APD 
treatment.  
The aims of this pilot experiment are as follows:  
(1) to establish the feasibility of 1H MRS examination of time course of risperidone-induced 
metabolite changes  
(2) to examine whether acute administration of risperidone can differentially affect accumbal 
metabolites in adolescents and adults   
Materials and methods  
Subjects 
Male adolescent and adult (PND33-35 and PND100-103 respectively at the time of examination) 
rats were used (n = 8, 4, 7 and 6 respectively for adolescent risperidone, adolescent vehicle, adult 
risperidone and adult vehicle groups). Rats assigned to risperidone and control groups arrived at 
different time points with an interval of approximately 1 month.   
1H MRS scans with administration of risperidone 
After induction of anaesthesia with 5% isoflurane, each rat received a subcutaneous (SC) 
catheterization using 30G cannula and PE50 tubing (Fisher Scientific). After mounting of the rat on 
the animal bed of 9.4T MRI scanner, anaesthesia was maintained at 1.5-1.7% isoflurane and O2 
flow rate of 1.2 L/min. Axial and sagittal anatomical scans were obtained for localization of voxel 
bilaterally over the NAc (6 x 2 x 2 mm3 for adults and 5.5 x 1.8 x 2 mm3 for adolescents). A smaller 
voxel size was used in adolescent cohorts to accommodate smaller NAc.  
After minimizing magnetic field inhomogeneity with B0 map acquisition, first, second and third 
order shimming was carried out with MAPSHIM. Following acquisition of a reference non-
suppressed water spectrum, a baseline water-suppressed 1H MRS spectrum was obtained from the 
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voxel placed bilaterally on the NAc using PRESS sequence (TE = 9.9 ms; TR = 2500 ms; averages 
= 356; repetition = 1, time taken = ~ 14.5 min). Immediately after the baseline scan, a single time 
course 1H MRS scan with either 1.3 mg/kg risperidone or vehicle challenge was performed on the 
same voxel using the following PRESS sequence: TE = 9.9 ms; TR = 2500 ms; averages = 96; 
repetition = 15, time taken = 60 min. As shown in Figure 1, a vehicle injection was remotely 
administered SC immediately after completion of the first repetition and risperidone or another 
vehicle injection after fourth repetition. Changes in accumbal metabolites were examined for the 
next 11 repetitions i.e. approximately for another 44 min.  
All 1H MRS data were processed on TOPSPIN and analysed in LCModel (version 6.3-1J) software 
(Provencher 1993), using the reference basis sets with the same data acquisition parameter. 
Metabolites with Cramer-Rao Lower bound (CRLB) or %SD > 20 were rejected from the analysis 
unless otherwise stated. The concentration of individual metabolites was expressed as a ratio to total 
creatine (Cr + PCr) following the guidelines in the LCModel manual. 
 
Figure 1 Timeline of 1H MRS data acquisition with acute administration of 1.3 mg/kg risperidone 
or vehicle in adolescents and adults.  
 
Statistical analysis  
Baseline levels of metabolites were analysed with two-way ANOVA. Levels of metabolites from 
time course scan were transformed as %change from pre-drug levels (from the average level of 
repetitions 1-4) and analysed with repeated measures two-way ANOVA, followed by Dunnett’s 
tests. Statistical significance was defined as p < 0.05.  
Results  
Examination of baseline levels showed that control groups (vehicle-vehicle) had significant higher 
NAA and glutamate levels than risperidone groups: two-way ANOVA for NAA: significant main 
effect of drug (F1,21 = 15.077, p = 0.001), age (F1,21 = 4.512, p = 0.046) but no age x drug 
interaction (F < 1, p > 0.8); two-way ANOVA for glutamate: significant main effect of drug (F1,21 
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= 9.062, p = 0.007 but no main effect of age or age x drug interaction (both F < 2.9, both p > 0.1). 
Given CRLB was > 25%, GABA data were not further analysed.   
Given the observed baseline differences, data from time course 1H MRS scan were analysed as 
%change from the mean level of repetitions 1 to 4, that is, pre-drug levels. As shown in Figure 2, 
following the injection of risperidone, a progressive increase in NAA levels was observed and this 
was selective to adolescent risperidone group (repeated measures two-way ANOVA: a significant 
main effect of repetition x drug x age (F14,266 = 3.013, p < 0.001) but no main effects of repetition, 
age, drug, repetition x drug, repetition x age or age x drug (all F < 3.2, p > 0.07). Further 
examination at individual repetitions showed that risperidone-treated adolescents had significantly 
higher NAA levels than risperidone-treated adults at repetitions 10, 12, 13 and 14 (all p < 0.05) and 
vehicle-treated controls at repetition 13 (p < 0.01).   
  
Figure 2 Change in NAA levels in the nucleus accumbens with acute administration of risperidone 
in adolescents and adults. * p < 0.05 for Adoles RIS vs Adoles VEH at repetition 13 and for Adoles 
RIS vs Adult RIS at repetition 10, 12, 13, 14. Data are expressed as mean ±SEM. Adoles – 
adolescent; RIS – risperidone; VEH – vehicle; Data from two risperidone-treated rats were 
discarded given CRLB > 20%.  
 
Repeated measures two-way ANOVA of changes in glutamate also showed a significant main 
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0.003) without a significant main effect of age, drug, age x drug, repetition x age, repetition x drug 
(all F < 1.7, p > 0.05). Further examination at individual time points however did not reveal any 
significant difference among the four groups (Figure 3).    
 
Figure 3 Change in glutamate levels in the nucleus accumbens with acute administration of 
risperidone in adolescents and adults. Data are expressed as mean ±SEM. Adoles – adolescent; RIS 
– risperidone; VEH – vehicle;   
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Appendix D – 1H MRS findings of Chapter 5  
Levels of neural metabolites in the NAc at baseline and after administration of risperidone/vehicle 
at Day 1 and Day 22 of chronic treatment in Chapter 5 are shown in the following tables
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Table 1 Levels of accumbal metabolites at baseline and after administration of risperidone or vehicle at Day 1 of chronic treatment in adolescence or adulthood 
M
et
ab
o
li
te
 
Metabolite concentration (/tCr) ( mean ± SEM) at Day 1 
Time 
block 
BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
G
lu
ta
m
in
e 
Adoles 
CON 
0.62 ± 
0.02 
0.67 ± 
0.02 
0.65 ± 
0.02 
0.67 ± 
0.02 
0.65 ± 
0.03 
0.63 ± 
0.02 
0.66 ± 
0.02 
0.64 ± 
0.03 
0.66 ± 
0.02 
0.62 ± 
0.02 
0.64 ± 
0.03 
0.67 ± 
0.02 
0.66 ± 
0.02 
0.66 ± 
0.03 
0.61 ± 
0.02 
0.60± 
0.02 
Adoles 
RIS 
0.64 ± 
0.02 
0.68 ± 
0.02 
0.67 ± 
0.02 
0.65 ± 
0.02 
0.63 ± 
0.03 
0.62 ± 
0.02 
0.65 ± 
0.02 
0.67 ± 
0.03 
0.72 ± 
0.02 
0.65 ± 
0.02 
0.66 ± 
0.03 
0.67 ± 
0.02 
0.69 ± 
0.02 
0.66 ± 
0.03 
0.68 ± 
0.02 
0.66 ± 
0.02 
Adult 
CON 
0.60 ± 
0.02 
0.65 ± 
0.02 
0.67 ± 
0.02 
0.69 ± 
0.02 
0.65 ± 
0.03 
0.66 ± 
0.02 
0.64 ± 
0.02 
0.63 ± 
0.03 
0.66 ± 
0.02 
0.62 ± 
0.02 
0.63 ± 
0.03 
0.63 ± 
0.02 
0.63 ± 
0.02 
0.62 ± 
0.03 
0.60 ± 
0.02 
0.61 ± 
0.02 
Adult 
RIS 
0.59 ± 
0.02 
0.63 ± 
0.02 
0.66 
0.02 
0.66 ± 
0.03 
0.67 ± 
0.03 
0.64 ± 
0.03 
0.66 ± 
0.02 
0.65 ± 
0.03 
0.68 ± 
0.03 
0.63 ± 
0.02 
0.65 ± 
0.03 
0.61 ± 
0.03 
0.66 ± 
0.02 
0.67 ± 
0.03 
0.63 ± 
0.02 
0.61 ± 
0.02 
Stats  
Time - F15,660 = 3.396, p < 0.001***; Time x Age - F15,660 = 1.123, p = 0.331;  Time x Drug - F15, 660 = 0.991, p = 0.463; Time x Age x 
Drug - F15,660 = 0.624, p = 0.856; Age - F1,44 = 0.830, p = 0.367; Drug - F1,44 = 0.810, p = 0.373; Age x Drug - F1,44 = 0.187, p = 0.668 
G
lu
ta
th
io
n
e 
Adoles 
CON 
0.29 ± 
0.01 
0.27 ± 
0.01 
0.32 ± 
0.01 
0.32 ± 
0.01 
0.31 ± 
0.02 
0.28 ± 
0.02 
0.32 ± 
0.02 
0.32 ± 
0.01 
0.29 ± 
0.01 
0.31 ± 
0.02 
0.28 ± 
0.01 
0.33 ± 
0.02 
0.31 ± 
0.02 
0.33 ± 
0.02 
0.31 ± 
0.02 
0.31 ± 
0.01 
Adoles 
RIS 
0.30 ± 
0.01 
0.29 ± 
0.01 
0.29 ± 
0.01 
0.32 ± 
0.01 
0.32 ± 
0.02 
0.31 ± 
0.02 
0.31 ± 
0.02 
0.29 ± 
0.01 
0.31 ± 
0.01 
0.32 ± 
0.02 
0.30 ± 
0.01 
0.33 ± 
0.02 
0.32 ± 
0.02 
0.34 ± 
0.02 
0.34 ± 
0.02 
0.33 ± 
0.01 
Adult 
CON 
0.30 ± 
0.01 
0.32 ± 
0.01 
0.30 ± 
0.01 
0.31 ± 
0.01 
0.32 ± 
0.01 
0.34 ± 
0.02 
0.31 ± 
0.02 
0.32 ± 
0.01 
0.31 ± 
0.01 
0.32 ± 
0.01 
0.33 ± 
0.01 
0.32 ± 
0.02 
0.32 ± 
0.02 
0.31 ± 
0.02 
0.32 ± 
0.02 
0.31 ± 
0.01 
Adult 
RIS 
0.31 ± 
0.01 
0.31 ± 
0.01 
0.30 ± 
0.01 
0.33 ± 
0.01 
0.32 ± 
0.01 
0.30 ± 
0.02 
0.34 ± 
0.02 
0.32 ± 
0.01 
0.32 ± 
0.01 
0.32 ± 
0.01 
0.30 ± 
0.01 
0.31 ± 
0.02 
0.31 ± 
0.02 
0.34 ± 
0.02 
0.32 ± 
0.02 
0.32 ± 
0.01 
Stats 
Time - F15,615 = 1.901, p = 0.021*; Time x Age - F15,615 = 0.886, p = 0.581; Time x Drug - F15, 615 = 0.691, p = 0.795; Time x Age x Drug - 
F15,615 = 1.242, p = 0.235; Age - F1,41 = 1.009, p = 0.321; Drug - F1,41 = 0.275, p = 0.603; Age x Drug - F1,41 = 0.234, p = 0.634 
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M
y
o
-I
n
o
si
to
l 
Adoles 
CON 
0.67 ± 
0.02 
0.59 ± 
0.03 
0.60 ± 
0.03 
0.59 ± 
0.02 
0.58 ± 
0.02 
0.54 ± 
0.03 
0.57 ± 
0.03 
0.57 ± 
0.03 
0.55 ± 
0.02 
0.57 ± 
0.03 
0.57 ± 
0.03 
0.56 ± 
0.03 
0.56 ± 
0.03 
0.59 ± 
0.03 
0.55 ± 
0.02 
0.58 ± 
0.02 
Adoles 
RIS 
0.70 ± 
0.02 
0.59 ± 
0.03 
0.62 ± 
0.03 
0.60 ± 
0.02 
0.60 ± 
0.02 
0.61 ± 
0.03 
0.64 ± 
0.03 
0.61 ± 
0.03 
0.62 ± 
0.02 
0.61 ± 
0.03 
0.60 ± 
0.03 
0.61 ± 
0.03 
0.59 ± 
0.03 
0.64 ± 
0.03 
0.64 ± 
0.02 
0.63 ± 
0.02 
Adult 
CON 
0.73 ± 
0.02 
0.70 ± 
0.03 
0.70 ± 
0.03 
0.72 ± 
0.02 
0.68 ± 
0.02 
0.68 ± 
0.03 
0.69 ± 
0.03 
0.69 ± 
0.03 
0.72 ± 
0.03 
0.65 ± 
0.03 
0.71 ± 
0.03 
0.69 ± 
0.03 
0.68 ± 
0.03 
0.67 ± 
0.03 
0.69 ± 
0.02 
0.72 ± 
0.02 
Adult 
RIS 
0.77 ± 
0.02 
0.71 ± 
0.03 
0.68 ± 
0.03 
0.73 ± 
0.02 
0.69 ± 
0.02 
0.68 ± 
0.03 
0.71 ± 
0.03 
0.70 ± 
0.03 
0.71 ± 
0.02 
0.68 ± 
0.03 
0.69 ± 
0.03 
0.72 ± 
0.03 
0.69 ± 
0.03 
0.70 ± 
0.03 
0.72 ± 
0.02 
0.69 ± 
0.02 
Stats 
Time - F15,660 = 5.413, p <0.001***; Time x Age - F15,660 = 1.358, p = 0.162; Time x Drug - F15, 660 = 0.962, p = 0.494; Time x Age x Drug 
- F15,660 = 0.655, p = 0.829; Age - F1,44 = 32.863, p < 0.001***; Drug - F1,44 =  2.125, p = 0.152; Age x Drug - F1,44 =  0.768, p = 0.385 
T
au
ri
n
e 
Adoles 
CON 
0.84 ± 
0.02 
0.80 ± 
0.03 
0.81 ± 
0.03 
0.79 ± 
0.02 
0.75 ± 
0.03 
0.77 ± 
0.02 
0.807 
± 0.03 
0.75 ± 
0.03 
0.79 ± 
0.02 
0.78 ± 
0.03 
0.75 ± 
0.02 
0.78 ± 
0.03 
0.73 ± 
0.03 
0.78 ± 
0.03 
0.80 ± 
0.02 
0.73 ± 
0.03 
Adoles 
RIS 
0.87 ± 
0.03 
0.80 ± 
0.03 
0.78 ± 
0.03 
0.76 ± 
0.02 
0.77 ± 
0.03 
0.77 ± 
0.02 
0.77 ± 
0.03 
0.77 ± 
0.03 
0.76 ± 
0.02 
0.80 ± 
0.03 
0.79 ± 
0.02 
0.77 ± 
0.03 
0.81 ± 
0.03 
0.79 ± 
0.03 
0.81 ± 
0.02 
0.79 ± 
0.03 
Adult 
CON 
0.78 ± 
0.02 
0.74 ± 
0.03 
0.73 ± 
0.03 
0.71 ± 
0.02 
0.72 ± 
0.03 
0.74 ± 
0.02 
0.72 ± 
0.03 
0.72 ± 
0.03 
0.72 ± 
0.02 
0.71 ± 
0.03 
0.73 ± 
0.02 
0.74 ± 
0.03 
0.72 ± 
0.03 
0.71 ± 
0.03 
0.74 ± 
0.02 
0.72 ± 
0.03 
Adult 
RIS 
0.82 ± 
0.02 
0.77 ± 
0.03 
0.75 ± 
0.03 
0.75 ± 
0.02 
0.73 ± 
0.03 
0.72 ± 
0.02 
0.74 ± 
0.03 
0.72 ± 
0.03 
0.74 ± 
0.02 
0.73 ± 
0.03 
0.72 ± 
0.02 
0.75 ± 
0.03 
0.74 ± 
0.03 
0.73 ± 
0.03 
0.74 ± 
0.02 
0.75 ± 
0.03 
Stats 
Time - F15,660 = 4.598, p < 0.001***; Time x Age - F15,660 = 0.476, p = 0.953; Time x Drug - F15,660 = 0.912, p = 0.551; Time x Age x Drug 
- F15,660 = 0.803, p = 0.675; Age - F1,44 = 6.444, p = 0.015*; Drug - F1,44 =  0.420, p = 0.521; Age x Drug - F1,44 =  0.025, p = 0.876 
G
A
B
A
 
Adoles 
CON 
0.35 ± 
0.02 
0.30 ± 
0.02 
0.34 ± 
0.02 
0.29 ± 
0.02 
0.33 ± 
0.02 
0.30 ± 
0.02 
0.33 ± 
0.03 
0.31 ± 
0.03 
0.34 ± 
0.03 
0.30 ± 
0.02 
0.30 ± 
0.02 
0.32 ± 
0.02 
0.31 ± 
0.03 
0.36 ± 
0.02 
0.30 ± 
0.02 
0.26 ± 
0.03 
Adoles 
RIS 
0.40 ± 
0.02 
0.36 ± 
0.02 
0.35 ± 
0.02 
0.32 ± 
0.02 
0.33 ± 
0.02 
0.3 ± 
0.02 
0.35 ± 
0.03 
0.35 ± 
0.03 
0.34 ± 
0.03 
0.32 ± 
0.02 
0.34 ± 
0.02 
0.35 ± 
0.02 
0.32 ± 
0.03 
0.31 ± 
0.02 
0.36 ± 
0.02 
0.34 ± 
0.03 
Adult 
CON 
0.38 ± 
0.02 
0.34 ± 
0.02 
0.30 ± 
0.02 
0.35 ± 
0.02 
0.29 ± 
0.02 
0.30 ± 
0.02 
0.32 ± 
0.02 
0.30 ± 
0.02 
0.33 ± 
0.03 
0.29 ± 
0.02 
0.27 ± 
0.02 
0.33 ± 
0.02 
0.32 ± 
0.03 
0.30 ± 
0.02 
0.33 ± 
0.02 
0.32 ± 
0.03 
Adult 
RIS 
0.36 ± 
0.02 
0.32 ± 
0.02 
0.31 ± 
0.02 
0.33 ± 
0.02 
0.33 ± 
0.02 
0.36 ± 
0.02 
0.33 ± 
0.02 
0.32 ± 
0.02 
0.32 ± 
0.03 
0.34 ± 
0.02 
0.33 ± 
0.02 
0.31 ± 
0.02 
0.32 ± 
0.03 
0.33 ± 
0.02 
0.32 ± 
0.02 
0.29 ± 
0.03 
Stats 
Time - F15,270 = 3.305, p < 0.001***; Time x Age - F15,270 = 1.063, p = 0.391; Time x Drug - F15,270 = 0.823, p = 0.652; Time x Age x Drug 
- F15,270 = 2.242, p = 0.006**; Age - F1,18 = 0.131, p = 0.722; Drug - F1,18 =   1.248, p = 0.279; Age x Drug - F1,18 =  0.299, p = 0.591 
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GABA signals from time course 1H MRS scans of some animals were rejected from analysis given CRLB was >25%. Adoles – adolescent cohort; BL – 
baseline; CON – vehicle-treated controls; GABA – gamma-aminobutyric acid; RIS – risperidone-treated rats; Stats – statistical analysis results from 
repeated measure two-way ANOVA   
 
 
 
 
 
 
Table 2 Levels of accumbal metabolites at baseline and after administration of risperidone or vehicle at Day 22 of chronic treatment in adolescence or adulthood 
M
et
ab
o
li
te
 
 
Metabolite concentration (/tCr) ( mean ± SEM) at Day 22 
Time 
block 
BL 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
G
lu
ta
m
in
e 
Adoles 
CON 
0.59 ± 
0.01 
0.63 ± 
0.03 
0.57 ± 
0.03 
0.60 ± 
0.03 
0.60 ± 
0.02 
0.63 ± 
0.03 
0.62 ± 
0.03 
0.64 ± 
0.03 
0.59 ± 
0.03 
0.61 ± 
0.03 
0.63 ± 
0.03 
0.59 ± 
0.02 
0.59 ± 
0.02 
0.62 ± 
0.03 
0.60 ± 
0.02 
0.58 ± 
0.03 
Adoles 
RIS 
0.60 ± 
0.01 
0.60 ± 
0.03 
0.62 ± 
0.03 
0.62 ± 
0.03 
0.63 ± 
0.02 
0.63 ± 
0.03 
0.61 ± 
0.03 
0.61 ±  
0.03 
0.57  
± 0.03 
0.56 ± 
0.03 
0.58 ± 
0.03 
0.60 ± 
0.02 
0.60 ± 
0.02 
0.61 ± 
0.03 
0.60 ± 
0.02 
0.59 ± 
0.03 
Adult 
CON 
0.59 ± 
0.01 
0.62 ± 
0.03 
0.62 ± 
0.03 
0.62 ± 
0.03 
0.64 ± 
0.02 
0.61 ± 
0.03 
0.65 ± 
0.03 
0.64 ± 
0.03 
0.62 ± 
0.03 
0.62 ± 
0.03 
0.60 ± 
0.03 
0.59 ± 
0.02 
0.63 ± 
0.02 
0.63 ± 
0.03 
0.60 ± 
0.02 
0.63 ± 
0.03 
Adult 
RIS 
0.62 ± 
0.01 
0.63 ± 
0.03 
0.68 ± 
0.03 
0.65 ± 
0.03 
0.67 ± 
0.02 
0.63 ± 
0.03 
0.64 ± 
0.03 
0.65 ± 
0.03 
0.66 ± 
0.03 
0.67 ± 
0.03 
0.64 ± 
0.03 
0.64 ± 
0.02 
0.65 ± 
0.02 
0.63 ± 
0.03 
0.61 ± 
0.02 
0.64 ± 
0.03 
Stats 
Time - F15,660 = 1.099, p = 0.353; Time x Age - F15,660 = 1.068, p = 0.383;  Time x Drug - F15,660 = 0.805, p = 0.673; Time x Age x Drug - 
F15,660 = 0.603, p = 0.873; Age - F1,44 = 3.437, p = 0.70; Drug - F1,44 = 0.453, p = 0.505; Age x Drug - F1,44 = 0.847, p = 0.362 
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G
lu
ta
th
io
n
e 
Adoles 
CON 
0.31 ± 
0.01 
0.31 ± 
0.01 
0.31 ± 
0.01 
0.32 ± 
0.01 
0.31 ± 
0.01 
0.29 ± 
0.01 
0.28 ± 
0.01 
0.30 ± 
0.01 
0.32 ± 
0.01 
0.28 ± 
0.01 
0.29 ± 
0.01 
0.30 ± 
0.01 
0.30 ± 
0.01 
0.33 ± 
0.01 
0.31 ± 
0.01 
0.32 ± 
0.01 
Adoles 
RIS 
0.3 ± 
0.01 
0.29 ± 
0.01 
0.29 ± 
0.01 
0.29 ± 
0.01 
0.28 ± 
0.01 
0.30 ± 
0.01 
0.28 ± 
0.01 
0.28 ± 
0.01 
0.32 ± 
0.01 
0.30 ± 
0.01 
0.30 ± 
0.01 
0.30 ± 
0.01 
0.31 ± 
0.01 
0.3 ± 
0.01 
0.33 ± 
0.01 
0.30 ± 
0.01 
Adult 
CON 
0.30 ± 
0.01 
0.29 ± 
0.01 
0.30 ± 
0.01 
0.29 ± 
0.01 
0.29 ± 
0.01 
0.31 ± 
0.01 
0.30 ± 
0.01 
0.29 ± 
0.01 
0.30 ± 
0.02 
0.31 ± 
0.01 
0.33 ± 
0.01 
0.32 ± 
0.01 
0.31 ± 
0.01 
0.27 ± 
0.02 
0.32 ± 
0.01 
0.32 ± 
0.01 
Adult 
RIS 
0.29 ± 
0.01 
0.31 ± 
0.01 
0.30 ± 
0.01 
0.27 ± 
0.01 
0.29 ± 
0.01 
0.28 ± 
0.01 
0.30 ± 
0.01 
0.31 ± 
0.01 
0.32 ± 
0.01 
0.30 ± 
0.01 
0.30 ± 
0.01 
0.30 ± 
0.01 
0.28 ± 
0.01 
0.30 ± 
0.01 
0.30 ± 
0.01 
0.29 ± 
0.01 
Stats 
Time - F15,630 = 2.214, p = 0.008**; Time x Age - F15,630 = 1.539, p = 0.086; Time x Drug - F15,630 = 0.837, p = 0.636; Time x Age x Drug 
- F15,630 = 2.165, p = 0.006**; Age - F1,42 = 0.09, p = 0.766; Drug - F1,42 = 1.213, p = 0.277; Age x Drug - F1,41 = 0.0001, p = 0.997 
M
y
o
-I
n
o
si
to
l 
Adoles 
CON 
0.74 ± 
0.01 
0.66 ± 
0.02 
0.65 ± 
0.02 
0.67 ± 
0.02 
0.66 ± 
0.02 
0.67 ± 
0.02 
0.64 ± 
0.02 
0.66 ± 
0.02 
0.64 ± 
0.02 
0.67 ± 
0.02 
0.67 ± 
0.02 
0.63 ± 
0.02 
0.65 ± 
0.02 
0.68 ± 
0.02 
0.66 ± 
0.02 
0.65 ± 
0.02 
Adoles 
RIS 
0.73 ± 
0.01 
0.65 ± 
0.02 
0.66 ± 
0.02 
0.66 ± 
0.02 
0.62 ± 
0.02 
0.65 ± 
0.02 
0.62 ± 
0.02 
0.62 ± 
0.02 
0.62 ± 
0.02 
0.63 ± 
0.02 
0.64 ± 
0.02 
0.63 ± 
0.02 
0.65 ± 
0.02 
0.67 ± 
0.02 
0.65 ± 
0.02 
0.64 ± 
0.02 
Adult 
CON 
0.72 ± 
0.01 
0.70 ± 
0.02 
0.70 ± 
0.02 
0.72 ± 
0.02 
0.69 ± 
0.02 
0.68 ± 
0.02 
0.67 ± 
0.02 
0.66 ± 
0.02 
0.69 ± 
0.02 
0.68 ± 
0.02 
0.71 ± 
0.02 
0.72 ± 
0.02 
0.67 ± 
0.02 
0.68 ± 
0.02 
0.68 ± 
0.02 
0.68 ± 
0.02 
Adult 
RIS 
0.77 ± 
0.01 
0.71 ± 
0.02 
0.70 ± 
0.02 
0.70 ± 
0.02 
0.68 ± 
0.02 
0.71 ± 
0.02 
0.68 ± 
0.02 
0.69 ± 
0.02 
0.68 ± 
0.02 
0.73 ± 
0.02 
0.69± 
0.02 
0.69 ± 
0.02 
0.67 ± 
0.02 
0.71 ± 
0.02 
0.73 ± 
0.02 
0.68± 
0.02 
Stats 
Time - F15,660 = 5.513, p  <  0.001***; Time x Age - F15,660 =  0.883, p = 0.583; Time x Drug - F15,660 = 0.648, p = 0.836; Time x Age x 
Drug - F15,660 = 0.815, p = 0.661; Age - F1,44 = 16.113, p < 0.001***; Drug - F1,44 =  0.064, p = 0.801; Age x Drug - F1,44 = 1.586, p = 
0.215 
T
au
ri
n
e 
Adoles 
CON 
0.80 ± 
0.02 
0.75 ± 
0.02 
0.74 ± 
0.03 
0.76 ± 
0.02 
0.75 ± 
0.03 
0.76 ± 
0.03 
0.73 ± 
0.02 
0.75 ± 
0.02 
0.77 ± 
0.03 
0.72 ± 
0.03 
0.76 ± 
0.02 
0.75 ± 
0.02 
0.78 ± 
0.02 
0.74 ± 
0.02 
0.74 ± 
0.03 
0.72 ± 
0.02 
Adoles 
RIS 
0.84 ± 
0.02 
0.78 ± 
0.02 
0.76 ± 
0.03 
0.74± 
0.02 
0.73 ± 
0.03 
0.75 ± 
0.03 
0.76 ± 
0.02 
0.78 ± 
0.02 
0.78 ± 
0.03 
0.76 ± 
0.03 
0.74 ± 
0.02 
0.74 ± 
0.02 
0.77 
0.02 
0.78 ± 
0.02 
0.73 ± 
0.03 
0.75 ± 
0.02 
Adult 
CON 
0.83 ± 
0.02 
0.71 ± 
0.02 
0.78 ± 
0.03 
0.78 ± 
0.02 
0.74 ± 
0.03 
0.73 ± 
0.03 
0.76 ± 
0.02 
0.78 ± 
0.02 
0.76 ± 
0.03 
0.76 ± 
0.03 
0.74 ± 
0.02 
0.76 ± 
0.02 
0.74 ± 
0.02 
0.73 ± 
0.02 
0.72 ± 
0.03 
0.74 ± 
0.02 
Adult 
RIS 
0.82 ± 
0.02 
0.75 ± 
0.02 
0.73 ± 
0.03 
0.71 ± 
0.02 
0.72 ± 
0.03 
0.74 ± 
0.03 
0.70 ± 
0.02 
0.72 ± 
0.02 
0.74 ± 
0.03 
0.78 ± 
0.03 
0.71 ± 
0.02 
0.73 ± 
0.02 
0.75 ± 
0.02 
0.72 ± 
0.02 
0.73 ± 
0.03 
0.75 ± 
0.02 
Stats 
Time - F15,660 = 5.491, p < 0.001***; Time x Age - F15,660 = 0.963, p = 0.493; Time x Drug - F15, 660 = 1.413, p = 0.135; Time x Age x 
Drug - F15,660 = 1.070, p = 0.381; Age - F1,44 = 0.408, p = 0.526; Drug - F1,44 = 0.031, p = 0.862;  Age x Drug - F1,44 = 0.557, p = 0.460; 
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G
A
B
A
 
Adoles 
CON 
0.38 ± 
0.02 
0.34 ± 
0.04 
0.36 ± 
0.02 
0.33 ± 
0.03 
0.37 ± 
0.02 
0.34 ± 
0.03 
0.31 ± 
0.03 
0.31 ± 
0.03 
0.32 ± 
0.03 
0.33 ± 
0.02 
0.36 ± 
0.03 
0.33 ± 
0.02 
0.36 ± 
0.03 
0.33 ± 
0.03 
0.34 ± 
0.03 
0.30 ± 
0.02 
Adoles 
RIS 
0.39 ± 
0.01 
0.35 ± 
0.03 
0.33 ± 
0.02 
0.33 ± 
0.02 
0.31 ± 
0.02 
0.33 ± 
0.02 
0.32 ± 
0.02 
0.30 ± 
0.02 
0.32 ± 
0.02 
0.32 ± 
0.01 
0.30 ± 
0.02 
0.32 ± 
0.01 
0.31 ± 
0.02 
0.33 ± 
0.02 
0.31 ± 
0.02 
0.28 ± 
0.02 
Adult 
CON 
0.38 ± 
0.02 
0.35 ± 
0.04 
0.31 ± 
0.02 
0.31 ± 
0.03 
0.31 ± 
0.02 
0.34 ± 
0.03 
0.31 ± 
0.03 
0.35 ± 
0.03 
0.34 ± 
0.03 
0.31 ± 
0.02 
0.37  
0.03 
0.32 ± 
0.02 
0.34 ± 
0.03 
0.29 ± 
0.03 
0.37 ± 
0.03 
0.32 ± 
0.02 
Adult 
RIS 
0.35 ± 
0.02 
0.34 ± 
0.05 
0.31 ± 
0.03 
0.31 ± 
0.04 
0.31 ± 
0.03 
0.39 ± 
0.03 
0.35 ± 
0.03 
0.36 ± 
0.04 
0.36 ± 
0.03 
0.44 ± 
0.02 
0.35 ± 
0.04 
0.33 ± 
0.02 
0.30 ± 
0.04 
0.33 ± 
0.04 
0.33 ± 
0.03 
0.36 ± 
0.03 
Stats 
Time - F15,150 = 1.529, p = 0.102; Time x Age - F15,150 = 1.525, p = 0.103; Time x Drug - F15,150 = 1.184, p = 0.290; Time x Age x Drug - 
F15,150 = 0.668, p = 0.812; Age - F1,10 = 0.636, p = 0.444; Drug - F1,10 = 0.00001, p = 0.997; Age x Drug - F1,10 = 1.752, p = 0.215;  
GABA signals from time course 1H MRS scans of some animals were rejected from analysis given CRLB was >25%. Adoles – adolescent cohort; BL – 
baseline; CON – vehicle-treated controls; GABA – gamma-aminobutyric acid; RIS – risperidone-treated rats; Stats – statistical analysis results from 
repeated measure two-way ANOVA;   
